[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftjKSKRJAH6Eu-d1efVjTGWDEm2QemWBuinPpMoV0sTw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Rigshospitalet, Denmark",[4],1036,false,207,43,1961739,79,796,[14,17,19,22,24,27,29,32],{"name":15,"count":16},"Breast Cancer",17,{"name":18,"count":16},"Healthy",{"name":20,"count":21},"Cancer",15,{"name":23,"count":21},"Pain",{"name":25,"count":26},"Surgery",13,{"name":28,"count":26},"Coronary Artery Disease",{"name":30,"count":31},"Type 2 Diabetes",12,{"name":33,"count":34},"Cardiovascular Diseases",10,[36,41,46,51,56,61,66,70,75,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04088292","Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism","2024-06-05","Alteplase 20 Mg Powder for Solution for Injection Vial",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT02673931","GLP-1 and Hyperoxia for Organ Protection in Heart Surgery","2024-09","Byetta",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05819229","Oral Antibiotics Alone in Children Aged 4 Weeks to 2 Months With a Urinary Tract Infection","2025-04-01","Oral antibiotic therapy",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03833089","Targeted Potassium Levels for Prevention of ICD Therapy","2025-05-09","Targeted serum potassium level",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05350592","Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock","2025-06-30","Tocilizumab",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06805448","Intraglandular Treatment With Adipose-derived Mesenchymal Stem Cells in Patients With Xerostomia Due to Sjögren's Disease","2025-12","MSC",{"nctId":67,"briefTitle":68,"date":64,"intervention":69},"NCT06894017","Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections","Ozurdex",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05942222","A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps","2026-04-01","dupilumab",{"nctId":76,"briefTitle":77,"date":73,"intervention":78},"NCT06449469","The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","Rivaroxaban",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT04688788","Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis","2026-05-05","Rituximab",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,144,184,209,236,263,281,305,323,341,359,377,395,413,431,449,467,485,512,539,557,584,610,628,655,673,702,720,738,775,872,978,1012,1030,1048,1066,1084,1110,1128,1150,1181,1222,1252,1270,1288,1312,1336,1354,1380,1462,1510,1534,1585,1642,1681,1719,1755,1797,1819,1852,1870,1899,1927,1949,1976,1994,2012,2030,2048,2072,2090,2108,2126,2144,2162,2180,2198,2216,2234,2256,2300,2332,2372,2411,2433,2460,2497,2519,2542,2566,2584,2610,2635,2653,2680,2698,2720,2745,2766,2784,2810,2828,2851,2883,2901,2919,2937,2955,2973,2991,3009,3034,3057,3075,3099,3117,3142,3160,3185,3203,3229,3254,3280,3308,3326,3344,3371,3389,3407,3425,3450,3468,3493,3511,3534,3559,3577,3601,3626,3644,3667,3685,3710,3735,3753,3777,3795,3820,3846,3869,3893,3917,3942,3960,3985,4003,4021,4045,4070,4093,4118,4136,4160,4184,4211,4229,4254,4279,4297,4319,4337,4364,4382,4406,4430,4448,4496,4527,4571,4603,4629,4664,4699,4730,4752,4774,4806,4828,4861,4885,4911,4936,4954,4984,5007,5030,5048,5066,5084,5109,5127,5145,5169,5191,5209,5227,5252,5277,5301,5325,5349,5374,5392,5410,5428,5450,5473,5496,5520,5543,5568,5586,5609,5632,5650,5673,5691,5709,5733,5756,5774,5798,5816,5840,5863,5887,5911,5933,5959,5986,6008,6026,6048,6066,6088,6111,6134,6152,6179,6216,6252,6288,6325,6356,6386,6419,6451,6477,6499,6525,6543,6567,6588,6611,6634,6657,6675,6700,6728,6751,6777,6800,6824,6848,6866,6888,6911,6934,6952,6978,6999,7022,7044,7068,7090,7113,7143,7168,7186,7208,7226,7253,7271,7296,7317,7347],{"intervention":93,"totalTrials":94,"cells":95},"Fluconazole",2,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":142},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":112},[107,131],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":121},"NCT06709196","Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","RECRUITING",[89],"2027-01","2025-01-07",248,[116,117,118,119,120],"Cystectomy","Bladder Cancer Requiring Cystectomy","Postoperative Infections","Antibiotic Prophylaxis","Ileal Conduit",[122,122,123,124,125,126,127,128,129,130,93],"Pivmecillinam","Amoxicillin clavulanic acid","Amoxicillin","Cefuroxime","Ciprofloxacin","Linezolid","Nitrofurantoin","Trimethoprim","Sulfamethoxazole trimethoprim",{"nctId":132,"briefTitle":133,"status":110,"phases":134,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":140},"NCT06770530","Introduction of Mycotic Prophylaxis At Cystectomy Trial.",[89],"2027-06","2027-09","2024-06-24",484,[116],[93,141],"Isotonic saline solution",{"trials":143,"activeCount":98},[],{"intervention":145,"totalTrials":94,"cells":146},"Escitalopram",{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":182},{"trials":148,"activeCount":98},[],{"trials":150,"activeCount":98},[151],{"nctId":152,"briefTitle":153,"status":154,"phases":155,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":161},"NCT02869035","Treatment Outcome in Major Depressive Disorder","COMPLETED",[86],"2019-07","2016-08",100,[160],"Major Depressive Disorder",[145,162],"Duloxetine",{"trials":164,"activeCount":98},[],{"trials":166,"activeCount":98},[],{"trials":168,"activeCount":181,"soonestReadout":174},[169],{"nctId":170,"briefTitle":171,"status":172,"phases":173,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":180},"NCT04336228","The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms","ACTIVE_NOT_RECRUITING",[89],"2027-12-31","2020-04-01",46,[178,179],"Obsessive-Compulsive Disorder\u002FHigh Compulsive Individuals","Healthy Individuals",[145],1,{"trials":183,"activeCount":98},[],{"intervention":185,"totalTrials":181,"cells":186},"increased dosing interval of biological therapy",{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":207},{"trials":188,"activeCount":98},[],{"trials":190,"activeCount":98},[],{"trials":192,"activeCount":98},[],{"trials":194,"activeCount":98},[],{"trials":196,"activeCount":181,"soonestReadout":201},[197],{"nctId":198,"briefTitle":199,"status":110,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT07187583","Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps",[89],"2028-03-01","2025-06-05",135,[205],"Chronic Rhinosinusitis With Nasal Polyps",[185],{"trials":208,"activeCount":98},[],{"intervention":55,"totalTrials":181,"cells":210},{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":234},{"trials":212,"activeCount":98},[],{"trials":214,"activeCount":98},[],{"trials":216,"activeCount":98},[],{"trials":218,"activeCount":98},[],{"trials":220,"activeCount":181,"soonestReadout":54},[221],{"nctId":52,"briefTitle":53,"status":172,"phases":222,"primaryCompletion":54,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":233},[89],"2035-04-01","2019-03-01",1200,[227,228,229,230,231,232],"Ventricular Arrhythmias and Cardiac Arrest","Implantable Defibrillator User","Hypokalemia","Hyperkalemia","Ventricular Tachycardia","Atrial Fibrillation",[55],{"trials":235,"activeCount":98},[],{"intervention":237,"totalTrials":181,"cells":238},"Xalatan",{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":261},{"trials":240,"activeCount":98},[],{"trials":242,"activeCount":98},[],{"trials":244,"activeCount":98},[],{"trials":246,"activeCount":98},[],{"trials":248,"activeCount":181,"soonestReadout":253},[249],{"nctId":250,"briefTitle":251,"status":110,"phases":252,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":259},"NCT04957329","Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells",[89],"2026-12-31","2021-09-01",28,[257,258],"Glaucoma","Ocular Hypertension",[237,260],"Monoprost",{"trials":262,"activeCount":98},[],{"intervention":260,"totalTrials":181,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":279},{"trials":266,"activeCount":98},[],{"trials":268,"activeCount":98},[],{"trials":270,"activeCount":98},[],{"trials":272,"activeCount":98},[],{"trials":274,"activeCount":181,"soonestReadout":253},[275],{"nctId":250,"briefTitle":251,"status":110,"phases":276,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":277,"interventions":278},[89],[257,258],[237,260],{"trials":280,"activeCount":98},[],{"intervention":74,"totalTrials":181,"cells":282},{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":291,"NA":303},{"trials":284,"activeCount":98},[],{"trials":286,"activeCount":98},[],{"trials":288,"activeCount":98},[],{"trials":290,"activeCount":98},[],{"trials":292,"activeCount":181,"soonestReadout":73},[293],{"nctId":71,"briefTitle":72,"status":172,"phases":294,"primaryCompletion":73,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":301},[89],"2026-05-01","2023-04-27",220,[205,299,300],"Asthma; Eosinophilic","Eosinophilia",[74,302],"mepolizumab",{"trials":304,"activeCount":98},[],{"intervention":302,"totalTrials":181,"cells":306},{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":315,"NA":321},{"trials":308,"activeCount":98},[],{"trials":310,"activeCount":98},[],{"trials":312,"activeCount":98},[],{"trials":314,"activeCount":98},[],{"trials":316,"activeCount":181,"soonestReadout":73},[317],{"nctId":71,"briefTitle":72,"status":172,"phases":318,"primaryCompletion":73,"completion":295,"start":296,"enrollment":297,"conditions":319,"interventions":320},[89],[205,299,300],[74,302],{"trials":322,"activeCount":98},[],{"intervention":122,"totalTrials":181,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":339},{"trials":326,"activeCount":98},[],{"trials":328,"activeCount":98},[],{"trials":330,"activeCount":98},[],{"trials":332,"activeCount":98},[],{"trials":334,"activeCount":181,"soonestReadout":112},[335],{"nctId":108,"briefTitle":109,"status":110,"phases":336,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":337,"interventions":338},[89],[116,117,118,119,120],[122,122,123,124,125,126,127,128,129,130,93],{"trials":340,"activeCount":98},[],{"intervention":123,"totalTrials":181,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":357},{"trials":344,"activeCount":98},[],{"trials":346,"activeCount":98},[],{"trials":348,"activeCount":98},[],{"trials":350,"activeCount":98},[],{"trials":352,"activeCount":181,"soonestReadout":112},[353],{"nctId":108,"briefTitle":109,"status":110,"phases":354,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":355,"interventions":356},[89],[116,117,118,119,120],[122,122,123,124,125,126,127,128,129,130,93],{"trials":358,"activeCount":98},[],{"intervention":124,"totalTrials":181,"cells":360},{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":367,"PHASE4":369,"NA":375},{"trials":362,"activeCount":98},[],{"trials":364,"activeCount":98},[],{"trials":366,"activeCount":98},[],{"trials":368,"activeCount":98},[],{"trials":370,"activeCount":181,"soonestReadout":112},[371],{"nctId":108,"briefTitle":109,"status":110,"phases":372,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":373,"interventions":374},[89],[116,117,118,119,120],[122,122,123,124,125,126,127,128,129,130,93],{"trials":376,"activeCount":98},[],{"intervention":125,"totalTrials":181,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":393},{"trials":380,"activeCount":98},[],{"trials":382,"activeCount":98},[],{"trials":384,"activeCount":98},[],{"trials":386,"activeCount":98},[],{"trials":388,"activeCount":181,"soonestReadout":112},[389],{"nctId":108,"briefTitle":109,"status":110,"phases":390,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":391,"interventions":392},[89],[116,117,118,119,120],[122,122,123,124,125,126,127,128,129,130,93],{"trials":394,"activeCount":98},[],{"intervention":126,"totalTrials":181,"cells":396},{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":405,"NA":411},{"trials":398,"activeCount":98},[],{"trials":400,"activeCount":98},[],{"trials":402,"activeCount":98},[],{"trials":404,"activeCount":98},[],{"trials":406,"activeCount":181,"soonestReadout":112},[407],{"nctId":108,"briefTitle":109,"status":110,"phases":408,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":409,"interventions":410},[89],[116,117,118,119,120],[122,122,123,124,125,126,127,128,129,130,93],{"trials":412,"activeCount":98},[],{"intervention":127,"totalTrials":181,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":429},{"trials":416,"activeCount":98},[],{"trials":418,"activeCount":98},[],{"trials":420,"activeCount":98},[],{"trials":422,"activeCount":98},[],{"trials":424,"activeCount":181,"soonestReadout":112},[425],{"nctId":108,"briefTitle":109,"status":110,"phases":426,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":427,"interventions":428},[89],[116,117,118,119,120],[122,122,123,124,125,126,127,128,129,130,93],{"trials":430,"activeCount":98},[],{"intervention":128,"totalTrials":181,"cells":432},{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":441,"NA":447},{"trials":434,"activeCount":98},[],{"trials":436,"activeCount":98},[],{"trials":438,"activeCount":98},[],{"trials":440,"activeCount":98},[],{"trials":442,"activeCount":181,"soonestReadout":112},[443],{"nctId":108,"briefTitle":109,"status":110,"phases":444,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":445,"interventions":446},[89],[116,117,118,119,120],[122,122,123,124,125,126,127,128,129,130,93],{"trials":448,"activeCount":98},[],{"intervention":129,"totalTrials":181,"cells":450},{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":465},{"trials":452,"activeCount":98},[],{"trials":454,"activeCount":98},[],{"trials":456,"activeCount":98},[],{"trials":458,"activeCount":98},[],{"trials":460,"activeCount":181,"soonestReadout":112},[461],{"nctId":108,"briefTitle":109,"status":110,"phases":462,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":463,"interventions":464},[89],[116,117,118,119,120],[122,122,123,124,125,126,127,128,129,130,93],{"trials":466,"activeCount":98},[],{"intervention":130,"totalTrials":181,"cells":468},{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":477,"NA":483},{"trials":470,"activeCount":98},[],{"trials":472,"activeCount":98},[],{"trials":474,"activeCount":98},[],{"trials":476,"activeCount":98},[],{"trials":478,"activeCount":181,"soonestReadout":112},[479],{"nctId":108,"briefTitle":109,"status":110,"phases":480,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":481,"interventions":482},[89],[116,117,118,119,120],[122,122,123,124,125,126,127,128,129,130,93],{"trials":484,"activeCount":98},[],{"intervention":486,"totalTrials":181,"cells":487},"Semaglutide 14 MG [Rybelsus]",{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":494,"PHASE4":496,"NA":510},{"trials":489,"activeCount":98},[],{"trials":491,"activeCount":98},[],{"trials":493,"activeCount":98},[],{"trials":495,"activeCount":98},[],{"trials":497,"activeCount":181,"soonestReadout":502},[498],{"nctId":499,"briefTitle":500,"status":110,"phases":501,"primaryCompletion":502,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":509},"NCT05702931","Semaglutide Treatment for Hyperglycaemia After Renal Transplantation",[89],"2027-12","2024-09-19",104,[506,507,508],"Hyperglycemia","Renal Transplant Complication Primary Non-Function","Diabetes",[486],{"trials":511,"activeCount":98},[],{"intervention":513,"totalTrials":181,"cells":514},"Discontinuation of 2nd generation combined oral contraceptive use",{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":523,"NA":537},{"trials":516,"activeCount":98},[],{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":98},[],{"trials":522,"activeCount":98},[],{"trials":524,"activeCount":181,"soonestReadout":530},[525],{"nctId":526,"briefTitle":527,"status":528,"phases":529,"primaryCompletion":530,"completion":530,"start":73,"enrollment":531,"conditions":532,"interventions":535},"NCT07511439","Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission","NOT_YET_RECRUITING",[89],"2030-12-31",60,[533,534],"The Focus of the Study is to Investigate Reversible Effects of Combined Oral Contraceptive Use on Serotonergic Neurotransmission","Healthy Adult Females",[513,536],"Continuation of 2nd generation combined oral contraceptive use",{"trials":538,"activeCount":98},[],{"intervention":536,"totalTrials":181,"cells":540},{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":547,"PHASE4":549,"NA":555},{"trials":542,"activeCount":98},[],{"trials":544,"activeCount":98},[],{"trials":546,"activeCount":98},[],{"trials":548,"activeCount":98},[],{"trials":550,"activeCount":181,"soonestReadout":530},[551],{"nctId":526,"briefTitle":527,"status":528,"phases":552,"primaryCompletion":530,"completion":530,"start":73,"enrollment":531,"conditions":553,"interventions":554},[89],[533,534],[513,536],{"trials":556,"activeCount":98},[],{"intervention":558,"totalTrials":181,"cells":559},"S-ketamine",{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":582},{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":98},[],{"trials":565,"activeCount":98},[],{"trials":567,"activeCount":98},[],{"trials":569,"activeCount":181,"soonestReadout":574},[570],{"nctId":571,"briefTitle":572,"status":110,"phases":573,"primaryCompletion":574,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":581},"NCT05095857","The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury",[89],"2028-09-15","2023-09-15",400,[578,579,580],"Subarachnoid Hemorrhage, Aneurysmal","Intracerebral Hemorrhage","Traumatic Brain Injury",[558],{"trials":583,"activeCount":98},[],{"intervention":585,"totalTrials":181,"cells":586},"DUPIXENT®",{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":595,"NA":608},{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":98},[],{"trials":592,"activeCount":98},[],{"trials":594,"activeCount":98},[],{"trials":596,"activeCount":181,"soonestReadout":601},[597],{"nctId":598,"briefTitle":599,"status":110,"phases":600,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":606},"NCT07268313","Complete Remission After Treatment With Biologics for Nasal Polyps",[89],"2027-06-01","2025-04-03",66,[605],"Nasal Polyps",[585,607],"NUCALA®",{"trials":609,"activeCount":98},[],{"intervention":607,"totalTrials":181,"cells":611},{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":620,"NA":626},{"trials":613,"activeCount":98},[],{"trials":615,"activeCount":98},[],{"trials":617,"activeCount":98},[],{"trials":619,"activeCount":98},[],{"trials":621,"activeCount":181,"soonestReadout":601},[622],{"nctId":598,"briefTitle":599,"status":110,"phases":623,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":624,"interventions":625},[89],[605],[585,607],{"trials":627,"activeCount":98},[],{"intervention":629,"totalTrials":181,"cells":630},"Adjunctive anemia therapy",{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":637,"PHASE4":639,"NA":653},{"trials":632,"activeCount":98},[],{"trials":634,"activeCount":98},[],{"trials":636,"activeCount":98},[],{"trials":638,"activeCount":98},[],{"trials":640,"activeCount":181,"soonestReadout":645},[641],{"nctId":642,"briefTitle":643,"status":110,"phases":644,"primaryCompletion":645,"completion":646,"start":647,"enrollment":648,"conditions":649,"interventions":652},"NCT07523646","Anemia Therapy in Patients With Infective Endocarditis",[89],"2028-04","2028-08","2026-05-15",74,[650,651],"Infective Endocarditis (IE)","Severe Anemia",[629],{"trials":654,"activeCount":98},[],{"intervention":141,"totalTrials":181,"cells":656},{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":663,"PHASE4":665,"NA":671},{"trials":658,"activeCount":98},[],{"trials":660,"activeCount":98},[],{"trials":662,"activeCount":98},[],{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":181,"soonestReadout":135},[667],{"nctId":132,"briefTitle":133,"status":110,"phases":668,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":669,"interventions":670},[89],[116],[93,141],{"trials":672,"activeCount":98},[],{"intervention":674,"totalTrials":181,"cells":675},"Furosemide",{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":684,"NA":700},{"trials":677,"activeCount":98},[],{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":98},[],{"trials":685,"activeCount":181,"soonestReadout":690},[686],{"nctId":687,"briefTitle":688,"status":110,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":697},"NCT05276219","Optimized Treatment of Pulmonary Edema or Congestion",[89],"2027-05-31","2023-09-14",1104,[694,695,696],"Pulmonary Edema","Congestive Heart Failure","Acute Heart Failure",[674,698,699],"Isosorbide Dinitrate","Furosemide and isosorbide dinitrate",{"trials":701,"activeCount":98},[],{"intervention":698,"totalTrials":181,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":712,"NA":718},{"trials":705,"activeCount":98},[],{"trials":707,"activeCount":98},[],{"trials":709,"activeCount":98},[],{"trials":711,"activeCount":98},[],{"trials":713,"activeCount":181,"soonestReadout":690},[714],{"nctId":687,"briefTitle":688,"status":110,"phases":715,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":716,"interventions":717},[89],[694,695,696],[674,698,699],{"trials":719,"activeCount":98},[],{"intervention":699,"totalTrials":181,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":730,"NA":736},{"trials":723,"activeCount":98},[],{"trials":725,"activeCount":98},[],{"trials":727,"activeCount":98},[],{"trials":729,"activeCount":98},[],{"trials":731,"activeCount":181,"soonestReadout":690},[732],{"nctId":687,"briefTitle":688,"status":110,"phases":733,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":734,"interventions":735},[89],[694,695,696],[674,698,699],{"trials":737,"activeCount":98},[],{"intervention":739,"totalTrials":94,"cells":740},"Venetoclax",{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":757,"PHASE4":771,"NA":773},{"trials":742,"activeCount":98},[],{"trials":744,"activeCount":98},[],{"trials":746,"activeCount":181,"soonestReadout":751},[747],{"nctId":748,"briefTitle":749,"status":110,"phases":750,"primaryCompletion":751,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":756},"NCT05431257","Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling",[87],"2031-09-01","2022-05-24",117,[755],"Acute Myeloid Leukemia",[739],{"trials":758,"activeCount":181,"soonestReadout":763},[759],{"nctId":760,"briefTitle":761,"status":110,"phases":762,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":769},"NCT03868722","Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment",[87,88],"2029-07-31","2030-07-31","2019-10-11",212,[768],"CLL",[770,739],"Acalabrutinib",{"trials":772,"activeCount":98},[],{"trials":774,"activeCount":98},[],{"intervention":776,"totalTrials":777,"cells":778},"Methylprednisolone",9,{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":796,"PHASE4":856,"NA":870},{"trials":780,"activeCount":98},[],{"trials":782,"activeCount":98},[],{"trials":784,"activeCount":98},[785],{"nctId":786,"briefTitle":787,"status":154,"phases":788,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":792,"interventions":794},"NCT01305837","Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis",[87],"2013-07","2011-04",30,[793],"Progressive Multiple Sclerosis",[795],"methylprednisolone",{"trials":797,"activeCount":181,"soonestReadout":82},[798,811,822,830,836,844,850],{"nctId":80,"briefTitle":81,"status":172,"phases":799,"primaryCompletion":82,"completion":800,"start":801,"enrollment":802,"conditions":803,"interventions":807},[88],"2029-05-05","2021-04-28",600,[804,805,806],"Relapsing Remitting Multiple Sclerosis","Secondary Progressive Multiple Sclerosis","Primary Progressive Multiple Sclerosis",[83,808,809,810,776],"Ocrelizumab","Fexofenadine","Paracetamol",{"nctId":812,"briefTitle":813,"status":154,"phases":814,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":820},"NCT02332603","Effect of Methylprednisolone on Glucose Homeostasis in Patients Undergoing Total Hip- and Knee-arthroplasty",[88],"2017-01","2015-01",134,[819],"Osteoarthrosis",[776,821],"Isotonic Sodium Chloride",{"nctId":823,"briefTitle":824,"status":154,"phases":825,"primaryCompletion":826,"completion":826,"start":816,"enrollment":827,"conditions":828,"interventions":829},"NCT02319343","Effect of Methylprednisolone on Quadriceps Muscle Function in Patients Undergoing Total Knee-arthroplasty",[88],"2016-04",70,[819],[776,821],{"nctId":831,"briefTitle":832,"status":154,"phases":833,"primaryCompletion":826,"completion":826,"start":816,"enrollment":827,"conditions":834,"interventions":835},"NCT02332629","Effect of Methylprednisolone on Endothelial Function in Patients Undergoing Total Knee-arthroplasty",[88],[819],[776,821],{"nctId":837,"briefTitle":838,"status":154,"phases":839,"primaryCompletion":815,"completion":815,"start":840,"enrollment":841,"conditions":842,"interventions":843},"NCT02445898","Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients",[87,88],"2015-09",64,[819],[776,821],{"nctId":845,"briefTitle":846,"status":154,"phases":847,"primaryCompletion":826,"completion":826,"start":816,"enrollment":827,"conditions":848,"interventions":849},"NCT02332616","Effect of Methylprednisolone on Complement Activation in Patients Undergoing Total Knee-arthroplasty",[88],[819],[776,821],{"nctId":851,"briefTitle":852,"status":154,"phases":853,"primaryCompletion":815,"completion":815,"start":840,"enrollment":841,"conditions":854,"interventions":855},"NCT02542592","Effect of Methylprednisolone on Immune Signaling in Hip-arthroplasty Patients",[87,88],[819],[776,821],{"trials":857,"activeCount":98},[858],{"nctId":859,"briefTitle":860,"status":154,"phases":861,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":866,"interventions":868},"NCT03403517","Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period",[89],"2020-08-28","2020-09-28","2017-12-11",174,[867],"Complication, Postoperative",[776,869],"Dexamethasone",{"trials":871,"activeCount":98},[],{"intervention":869,"totalTrials":873,"cells":874},8,{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":881,"PHASE4":912,"NA":976},{"trials":876,"activeCount":98},[],{"trials":878,"activeCount":98},[],{"trials":880,"activeCount":98},[],{"trials":882,"activeCount":181,"soonestReadout":902},[883,898],{"nctId":884,"briefTitle":885,"status":154,"phases":886,"primaryCompletion":887,"completion":887,"start":888,"enrollment":889,"conditions":890,"interventions":897},"NCT04189107","Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS",[88],"2022-11-09","2020-08-18",18,[891,25,892,893,894,895,896],"Analgesia","Cancer of Head and Neck","Oropharyngeal Cancer","Carcinoma of Unknown Primary","Pain, Postoperative","Postoperative Pain",[869],{"nctId":899,"briefTitle":900,"status":110,"phases":901,"primaryCompletion":902,"completion":903,"start":904,"enrollment":905,"conditions":906,"interventions":911},"NCT07213375","High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy \u002FSegmentectomy",[87,88],"2026-10","2026-11","2025-09-01",80,[907,908,909,910],"Analgetic","Lung Cancer (NSCLC)","Video Assisted Thoracic Surgery (VATS)","Glucocorticoid",[869],{"trials":913,"activeCount":98},[914,918,933,944,956,964],{"nctId":859,"briefTitle":860,"status":154,"phases":915,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":916,"interventions":917},[89],[867],[776,869],{"nctId":919,"briefTitle":920,"status":154,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":932},"NCT03125941","High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy",[89],"2018-04-22","2017-03-27",130,[869,926,927,15,895,928,929,930,931],"Glucocorticoids","Mastectomy","Nausea and Vomiting, Postoperative","Steroid","Systemic Inflammatory Response Syndrome","Postoperative Complications",[869],{"nctId":934,"briefTitle":935,"status":936,"phases":937,"primaryCompletion":938,"completion":938,"start":939,"enrollment":940,"conditions":941,"interventions":943},"NCT03160729","High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Nephrectomy","TERMINATED",[89],"2018-11-23","2017-04-24",45,[942,931],"Kidney Diseases",[869],{"nctId":945,"briefTitle":946,"status":154,"phases":947,"primaryCompletion":948,"completion":840,"start":949,"enrollment":950,"conditions":951,"interventions":952},"NCT01953978","The Effect of Dexamethasone in Combination With Paracetamol and Ibuprofen on Postoperative Pain After Spine Surgery",[89],"2014-08","2012-12",160,[23],[869,953,954,810,955],"Morphine","Zofran","Ibuprofen",{"nctId":957,"briefTitle":958,"status":154,"phases":959,"primaryCompletion":960,"completion":960,"start":939,"enrollment":841,"conditions":961,"interventions":963},"NCT03161938","High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase",[89],"2019-08-20",[962,931],"Hip Dysplasia",[869],{"nctId":965,"briefTitle":966,"status":967,"phases":968,"primaryCompletion":969,"completion":970,"start":971,"enrollment":531,"conditions":972,"interventions":974},"NCT04588857","Efficacy of a Single Dose Dexamethasone in Reducing the Postembolization Syndrome in Men Undergoing Prostatic Artery Embolization for Benign Prostatic Hyperplasia","UNKNOWN",[89],"2022-12-01","2023-06-01","2021-03-01",[973],"Prostatic Hyperplasia",[869,975],"Saline",{"trials":977,"activeCount":98},[],{"intervention":810,"totalTrials":979,"cells":980},3,{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":987,"PHASE4":993,"NA":1010},{"trials":982,"activeCount":98},[],{"trials":984,"activeCount":98},[],{"trials":986,"activeCount":98},[],{"trials":988,"activeCount":181,"soonestReadout":82},[989],{"nctId":80,"briefTitle":81,"status":172,"phases":990,"primaryCompletion":82,"completion":800,"start":801,"enrollment":802,"conditions":991,"interventions":992},[88],[804,805,806],[83,808,809,810,776],{"trials":994,"activeCount":98},[995,1006],{"nctId":996,"briefTitle":997,"status":154,"phases":998,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1004},"NCT01966172","Multimodal Analgesic Treatment Versus Traditional Morphine Analgesia After Cardiac Surgery",[89],"2009-08","2009-12","2007-03",180,[891,896],[955,1005,953,810],"Gabapentin",{"nctId":945,"briefTitle":946,"status":154,"phases":1007,"primaryCompletion":948,"completion":840,"start":949,"enrollment":950,"conditions":1008,"interventions":1009},[89],[23],[869,953,954,810,955],{"trials":1011,"activeCount":98},[],{"intervention":83,"totalTrials":181,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1026,"NA":1028},{"trials":1015,"activeCount":98},[],{"trials":1017,"activeCount":98},[],{"trials":1019,"activeCount":98},[],{"trials":1021,"activeCount":181,"soonestReadout":82},[1022],{"nctId":80,"briefTitle":81,"status":172,"phases":1023,"primaryCompletion":82,"completion":800,"start":801,"enrollment":802,"conditions":1024,"interventions":1025},[88],[804,805,806],[83,808,809,810,776],{"trials":1027,"activeCount":98},[],{"trials":1029,"activeCount":98},[],{"intervention":808,"totalTrials":181,"cells":1031},{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1044,"NA":1046},{"trials":1033,"activeCount":98},[],{"trials":1035,"activeCount":98},[],{"trials":1037,"activeCount":98},[],{"trials":1039,"activeCount":181,"soonestReadout":82},[1040],{"nctId":80,"briefTitle":81,"status":172,"phases":1041,"primaryCompletion":82,"completion":800,"start":801,"enrollment":802,"conditions":1042,"interventions":1043},[88],[804,805,806],[83,808,809,810,776],{"trials":1045,"activeCount":98},[],{"trials":1047,"activeCount":98},[],{"intervention":809,"totalTrials":181,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1056,"PHASE4":1062,"NA":1064},{"trials":1051,"activeCount":98},[],{"trials":1053,"activeCount":98},[],{"trials":1055,"activeCount":98},[],{"trials":1057,"activeCount":181,"soonestReadout":82},[1058],{"nctId":80,"briefTitle":81,"status":172,"phases":1059,"primaryCompletion":82,"completion":800,"start":801,"enrollment":802,"conditions":1060,"interventions":1061},[88],[804,805,806],[83,808,809,810,776],{"trials":1063,"activeCount":98},[],{"trials":1065,"activeCount":98},[],{"intervention":770,"totalTrials":181,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1074,"PHASE4":1080,"NA":1082},{"trials":1069,"activeCount":98},[],{"trials":1071,"activeCount":98},[],{"trials":1073,"activeCount":98},[],{"trials":1075,"activeCount":181,"soonestReadout":763},[1076],{"nctId":760,"briefTitle":761,"status":110,"phases":1077,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":1078,"interventions":1079},[87,88],[768],[770,739],{"trials":1081,"activeCount":98},[],{"trials":1083,"activeCount":98},[],{"intervention":1085,"totalTrials":181,"cells":1086},"Melatonin",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1093,"PHASE4":1106,"NA":1108},{"trials":1088,"activeCount":98},[],{"trials":1090,"activeCount":98},[],{"trials":1092,"activeCount":98},[],{"trials":1094,"activeCount":181,"soonestReadout":1099},[1095],{"nctId":1096,"briefTitle":1097,"status":110,"phases":1098,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":576,"conditions":1102,"interventions":1104},"NCT05541276","MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in Children",[88],"2026-12-01","2027-01-01","2025-01-21",[1103],"Emergence Delirium",[1085,1105],"Isotonic sodium chloride solution",{"trials":1107,"activeCount":98},[],{"trials":1109,"activeCount":98},[],{"intervention":1105,"totalTrials":181,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1124,"NA":1126},{"trials":1113,"activeCount":98},[],{"trials":1115,"activeCount":98},[],{"trials":1117,"activeCount":98},[],{"trials":1119,"activeCount":181,"soonestReadout":1099},[1120],{"nctId":1096,"briefTitle":1097,"status":110,"phases":1121,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":576,"conditions":1122,"interventions":1123},[88],[1103],[1085,1105],{"trials":1125,"activeCount":98},[],{"trials":1127,"activeCount":98},[],{"intervention":40,"totalTrials":181,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1136,"PHASE4":1146,"NA":1148},{"trials":1131,"activeCount":98},[],{"trials":1133,"activeCount":98},[],{"trials":1135,"activeCount":98},[],{"trials":1137,"activeCount":181,"soonestReadout":39},[1138],{"nctId":37,"briefTitle":38,"status":172,"phases":1139,"primaryCompletion":39,"completion":1140,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1145},[88],"2024-11-30","2019-06-06",210,[1144],"Pulmonary Embolism",[40],{"trials":1147,"activeCount":98},[],{"trials":1149,"activeCount":98},[],{"intervention":1151,"totalTrials":181,"cells":1152},"Azithromycin 40 MG\u002FML",{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1159,"PHASE4":1177,"NA":1179},{"trials":1154,"activeCount":98},[],{"trials":1156,"activeCount":98},[],{"trials":1158,"activeCount":98},[],{"trials":1160,"activeCount":181,"soonestReadout":1165},[1161],{"nctId":1162,"briefTitle":1163,"status":528,"phases":1164,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":1168,"conditions":1169,"interventions":1176},"NCT06409299","Enhancing Lung Health in Kids With Structural Lung Damage and Malformations: Azithromycin (AZI) for Airway Infection Prevention",[88],"2027-03-31","2027-08-31","2024-09-01",150,[1170,1171,1172,1173,1174,1175],"Tracheomalacia","Bronchopulmonary Dysplasia (BPD)","Vascular Ring","Cystic Lung Disease","Bronchiectasis","Chronic Atelectasis",[1151],{"trials":1178,"activeCount":98},[],{"trials":1180,"activeCount":98},[],{"intervention":1182,"totalTrials":94,"cells":1183},"Docetaxel",{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1185,"activeCount":98},[],{"trials":1187,"activeCount":98},[],{"trials":1189,"activeCount":181,"soonestReadout":1099},[1190,1200],{"nctId":1191,"briefTitle":1192,"status":110,"phases":1193,"primaryCompletion":1099,"completion":1194,"start":1195,"enrollment":791,"conditions":1196,"interventions":1198},"NCT06480110","Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer",[86,87],"2027-12-01","2024-06-20",[1197],"Metastatic Castration-resistant Prostate Cancer",[1199,1182],"Docetaxel + Ebastine",{"nctId":1201,"briefTitle":1202,"status":967,"phases":1203,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":1208,"interventions":1211},"NCT02177552","Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma",[87],"2019-08","2019-11","2014-06",98,[1209,1210],"Esophageal Neoplasms","Stomach Neoplasms",[1212,1182,1213,1214,1215],"Carboplatin","Capecitabine","Epirubicin","Oxaliplatin",{"trials":1217,"activeCount":98},[],{"trials":1219,"activeCount":98},[],{"trials":1221,"activeCount":98},[],{"intervention":65,"totalTrials":94,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1225,"activeCount":98},[],{"trials":1227,"activeCount":98},[],{"trials":1229,"activeCount":181,"soonestReadout":64},[1230,1237],{"nctId":62,"briefTitle":63,"status":110,"phases":1231,"primaryCompletion":64,"completion":64,"start":1101,"enrollment":1232,"conditions":1233,"interventions":1235},[86,87],40,[1234],"Sjorgren's Syndrome",[65,1236],"Saline Water",{"nctId":1238,"briefTitle":1239,"status":154,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":531,"conditions":1243,"interventions":1245},"NCT01449032","MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)",[87],"2014-01","2010-04",[1244],"Chronic Ischemic Heart Disease",[65,975],{"trials":1247,"activeCount":98},[],{"trials":1249,"activeCount":98},[],{"trials":1251,"activeCount":98},[],{"intervention":1199,"totalTrials":181,"cells":1253},{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1258,"PHASE3":1264,"PHASE4":1266,"NA":1268},{"trials":1255,"activeCount":98},[],{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":181,"soonestReadout":1099},[1260],{"nctId":1191,"briefTitle":1192,"status":110,"phases":1261,"primaryCompletion":1099,"completion":1194,"start":1195,"enrollment":791,"conditions":1262,"interventions":1263},[86,87],[1197],[1199,1182],{"trials":1265,"activeCount":98},[],{"trials":1267,"activeCount":98},[],{"trials":1269,"activeCount":98},[],{"intervention":1236,"totalTrials":181,"cells":1271},{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1276,"PHASE3":1282,"PHASE4":1284,"NA":1286},{"trials":1273,"activeCount":98},[],{"trials":1275,"activeCount":98},[],{"trials":1277,"activeCount":181,"soonestReadout":64},[1278],{"nctId":62,"briefTitle":63,"status":110,"phases":1279,"primaryCompletion":64,"completion":64,"start":1101,"enrollment":1232,"conditions":1280,"interventions":1281},[86,87],[1234],[65,1236],{"trials":1283,"activeCount":98},[],{"trials":1285,"activeCount":98},[],{"trials":1287,"activeCount":98},[],{"intervention":1289,"totalTrials":181,"cells":1290},"Incobotulinumtoxin-A 100 UNIT",{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1292,"activeCount":98},[],{"trials":1294,"activeCount":98},[],{"trials":1296,"activeCount":181,"soonestReadout":1301},[1297],{"nctId":1298,"briefTitle":1299,"status":110,"phases":1300,"primaryCompletion":1301,"completion":1194,"start":1302,"enrollment":905,"conditions":1303,"interventions":1305},"NCT05623111","Perineural Injections of Incobotulinumtoxin-A for Diabetic Neuropathic Pain of the Lower Extremities",[87],"2027-05-01","2023-08-01",[1304],"Diabetic Neuropathy, Painful",[1289,975],{"trials":1307,"activeCount":98},[],{"trials":1309,"activeCount":98},[],{"trials":1311,"activeCount":98},[],{"intervention":1313,"totalTrials":181,"cells":1314},"Dobutamine",{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1330,"PHASE4":1332,"NA":1334},{"trials":1316,"activeCount":98},[],{"trials":1318,"activeCount":98},[],{"trials":1320,"activeCount":181,"soonestReadout":59},[1321],{"nctId":57,"briefTitle":58,"status":172,"phases":1322,"primaryCompletion":59,"completion":1323,"start":1324,"enrollment":158,"conditions":1325,"interventions":1328},[87],"2025-09-30","2022-03-13",[1326,1327],"Acute Myocardial Infarction","Cardiogenic Shock",[60,1313,1329],"NaCl 0.9%",{"trials":1331,"activeCount":98},[],{"trials":1333,"activeCount":98},[],{"trials":1335,"activeCount":98},[],{"intervention":1329,"totalTrials":181,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1348,"PHASE4":1350,"NA":1352},{"trials":1339,"activeCount":98},[],{"trials":1341,"activeCount":98},[],{"trials":1343,"activeCount":181,"soonestReadout":59},[1344],{"nctId":57,"briefTitle":58,"status":172,"phases":1345,"primaryCompletion":59,"completion":1323,"start":1324,"enrollment":158,"conditions":1346,"interventions":1347},[87],[1326,1327],[60,1313,1329],{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[],{"trials":1353,"activeCount":98},[],{"intervention":1355,"totalTrials":181,"cells":1356},"FG001 prior to surgery",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[],{"trials":1362,"activeCount":181,"soonestReadout":1367},[1363],{"nctId":1364,"briefTitle":1365,"status":110,"phases":1366,"primaryCompletion":1367,"completion":1367,"start":1368,"enrollment":1232,"conditions":1369,"interventions":1373},"NCT06684795","FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery",[87],"2026-06-01","2024-05-01",[1370,1371,1372],"Low-grade Glioma","Meningioma","Glioma",[1355],{"trials":1375,"activeCount":98},[],{"trials":1377,"activeCount":98},[],{"trials":1379,"activeCount":98},[],{"intervention":975,"totalTrials":873,"cells":1381},{"EARLY_PHASE1":1382,"PHASE1":1396,"PHASE2":1398,"PHASE3":1428,"PHASE4":1430,"NA":1446},{"trials":1383,"activeCount":98},[1384],{"nctId":1385,"briefTitle":1386,"status":154,"phases":1387,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1394},"NCT05683444","Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial",[85],"2021-03-26","2020-07-01",16,[1392,1393],"Lymphatic Diseases","Chylothorax",[1395,975],"Octreotide",{"trials":1397,"activeCount":98},[],{"trials":1399,"activeCount":181,"soonestReadout":1301},[1400,1404,1414,1424],{"nctId":1298,"briefTitle":1299,"status":110,"phases":1401,"primaryCompletion":1301,"completion":1194,"start":1302,"enrollment":905,"conditions":1402,"interventions":1403},[87],[1304],[1289,975],{"nctId":1405,"briefTitle":1406,"status":154,"phases":1407,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":1411,"interventions":1412},"NCT00644410","Autologous Mesenchymal Stromal Cell Therapy in Heart Failure",[86,87],"2015-03","2008-09",59,[695],[1413,975],"Mesenchymal stromal cell",{"nctId":1415,"briefTitle":1416,"status":967,"phases":1417,"primaryCompletion":1418,"completion":1140,"start":1419,"enrollment":791,"conditions":1420,"interventions":1422},"NCT04714801","Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation",[86,87],"2023-11-30","2020-10-01",[1421],"Lung Transplant Rejection",[1423,975],"adipose derived mesenchymal stromal cells",{"nctId":1238,"briefTitle":1239,"status":154,"phases":1425,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":531,"conditions":1426,"interventions":1427},[87],[1244],[65,975],{"trials":1429,"activeCount":98},[],{"trials":1431,"activeCount":98},[1432,1442],{"nctId":1433,"briefTitle":1434,"status":154,"phases":1435,"primaryCompletion":1000,"completion":1436,"start":1437,"enrollment":158,"conditions":1438,"interventions":1440},"NCT00835848","Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI",[89],"2015-05","2009-01",[1439],"Myocardial Infarction",[1441,975],"Exenatide",{"nctId":965,"briefTitle":966,"status":967,"phases":1443,"primaryCompletion":969,"completion":970,"start":971,"enrollment":531,"conditions":1444,"interventions":1445},[89],[973],[869,975],{"trials":1447,"activeCount":98},[1448],{"nctId":1449,"briefTitle":1450,"status":154,"phases":1451,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1456,"interventions":1459},"NCT01749163","Hyperglycemia and the Extra-pancreatic Effect of Incretins",[90],"2013-12","2014-03","2012-09",20,[1457,1458],"Extra-pancreatic Incretin Effect","Glucose Effectiveness",[975,1460,1461],"GIP","GLP-1",{"intervention":60,"totalTrials":1463,"cells":1464},4,{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1475,"PHASE4":1477,"NA":1479},{"trials":1466,"activeCount":98},[],{"trials":1468,"activeCount":98},[],{"trials":1470,"activeCount":181,"soonestReadout":59},[1471],{"nctId":57,"briefTitle":58,"status":172,"phases":1472,"primaryCompletion":59,"completion":1323,"start":1324,"enrollment":158,"conditions":1473,"interventions":1474},[87],[1326,1327],[60,1313,1329],{"trials":1476,"activeCount":98},[],{"trials":1478,"activeCount":98},[],{"trials":1480,"activeCount":98},[1481,1492,1501],{"nctId":1482,"briefTitle":1483,"status":154,"phases":1484,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":1487,"conditions":1488,"interventions":1490},"NCT03967691","IL-6 Regulation of Substrate Metabolism and Influence of Obesity",[90],"2020-04-03","2019-06-12",22,[1489,18],"Obesity",[60,1491],"Saline 0.9%",{"nctId":1493,"briefTitle":1494,"status":154,"phases":1495,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":1498,"conditions":1499,"interventions":1500},"NCT04687540","Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6",[90],"2021-08-01","2021-04-09",25,[1489,18],[60,1491],{"nctId":1502,"briefTitle":1503,"status":154,"phases":1504,"primaryCompletion":1505,"completion":1505,"start":157,"enrollment":1506,"conditions":1507,"interventions":1509},"NCT02901496","Ectopic Adipose Tissue, Exercise Training and IL-6",[90],"2018-04",83,[1508],"Adiposity",[60],{"intervention":1511,"totalTrials":181,"cells":1512},"Lysergic Acid Diethylamide Tartrate",{"EARLY_PHASE1":1513,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1530,"NA":1532},{"trials":1514,"activeCount":181,"soonestReadout":1519},[1515],{"nctId":1516,"briefTitle":1517,"status":172,"phases":1518,"primaryCompletion":1519,"completion":174,"start":1520,"enrollment":1232,"conditions":1521,"interventions":1523},"NCT05953038","LSD Occupancy of the Serotonin 2A Receptor in the Human Brain",[85],"2027-12-18","2023-11-08",[1522],"Basic Science",[1511],{"trials":1525,"activeCount":98},[],{"trials":1527,"activeCount":98},[],{"trials":1529,"activeCount":98},[],{"trials":1531,"activeCount":98},[],{"trials":1533,"activeCount":98},[],{"intervention":821,"totalTrials":1535,"cells":1536},7,{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1569,"NA":1571},{"trials":1538,"activeCount":98},[],{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":98},[],{"trials":1544,"activeCount":98},[1545,1549,1553,1557,1561,1565],{"nctId":812,"briefTitle":813,"status":154,"phases":1546,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":1547,"interventions":1548},[88],[819],[776,821],{"nctId":823,"briefTitle":824,"status":154,"phases":1550,"primaryCompletion":826,"completion":826,"start":816,"enrollment":827,"conditions":1551,"interventions":1552},[88],[819],[776,821],{"nctId":831,"briefTitle":832,"status":154,"phases":1554,"primaryCompletion":826,"completion":826,"start":816,"enrollment":827,"conditions":1555,"interventions":1556},[88],[819],[776,821],{"nctId":837,"briefTitle":838,"status":154,"phases":1558,"primaryCompletion":815,"completion":815,"start":840,"enrollment":841,"conditions":1559,"interventions":1560},[87,88],[819],[776,821],{"nctId":845,"briefTitle":846,"status":154,"phases":1562,"primaryCompletion":826,"completion":826,"start":816,"enrollment":827,"conditions":1563,"interventions":1564},[88],[819],[776,821],{"nctId":851,"briefTitle":852,"status":154,"phases":1566,"primaryCompletion":815,"completion":815,"start":840,"enrollment":841,"conditions":1567,"interventions":1568},[87,88],[819],[776,821],{"trials":1570,"activeCount":98},[],{"trials":1572,"activeCount":181,"soonestReadout":502},[1573],{"nctId":1574,"briefTitle":1575,"status":110,"phases":1576,"primaryCompletion":502,"completion":1577,"start":1578,"enrollment":225,"conditions":1579,"interventions":1581},"NCT05635227","Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery",[90],"2028-02","2022-11-10",[28,1580],"Aortic Valve Disease",[1582,1583,1584],"Dexamethasone phosphate","Isotonic sodium chloride","Olanzapine 10 MG",{"intervention":1586,"totalTrials":979,"cells":1587},"18F-FDG",{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1589,"activeCount":98},[],{"trials":1591,"activeCount":98},[],{"trials":1593,"activeCount":98},[1594,1609],{"nctId":1595,"briefTitle":1596,"status":967,"phases":1597,"primaryCompletion":1598,"completion":1599,"start":1600,"enrollment":1601,"conditions":1602,"interventions":1607},"NCT05709171","Dual 64Cu-DOTATATE and 18F-FDG PET\u002FCT Imaging of Patients With Neuroendocrine Neoplasms",[87],"2025-01-01","2026-01-01","2023-01-17",200,[1603,1604,1605,1606],"GEP-NET","Neuroendocrine Tumors","Neuroendocrine Carcinoma","Neuroendocrine Carcinoma Metastatic",[1586,1608],"64Cu-Dotatate",{"nctId":1610,"briefTitle":1611,"status":967,"phases":1612,"primaryCompletion":1613,"completion":1614,"start":1615,"enrollment":21,"conditions":1616,"interventions":1619},"NCT05396118","Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET\u002FMRS in Cancer Patients",[87],"2024-08","2024-12","2022-05-18",[15,1604,1605,1606,1617,1618],"Lymphoma","Sarcoma",[1586,1620],"Injection of hyperpolarized [1-13C]Pyruvate",{"trials":1622,"activeCount":98},[],{"trials":1624,"activeCount":98},[],{"trials":1626,"activeCount":181,"soonestReadout":1631},[1627],{"nctId":1628,"briefTitle":1629,"status":172,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1637},"NCT07366710","Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET",[90],"2027-10","2024-11-05",36,[1635,1636],"Glucose Metabolism","NAFLD (Nonalcoholic Fatty Liver Disease)",[1586,1586,1638,1638,1639,1640,1641],"18F-FET","Glucagon","Somatostatin","Sodium chloride",{"intervention":1641,"totalTrials":979,"cells":1643},{"EARLY_PHASE1":1644,"PHASE1":1646,"PHASE2":1648,"PHASE3":1650,"PHASE4":1662,"NA":1664},{"trials":1645,"activeCount":98},[],{"trials":1647,"activeCount":98},[],{"trials":1649,"activeCount":98},[],{"trials":1651,"activeCount":98},[1652],{"nctId":1653,"briefTitle":1654,"status":967,"phases":1655,"primaryCompletion":1656,"completion":1656,"start":1657,"enrollment":1658,"conditions":1659,"interventions":1660},"NCT05091242","The PREVENT AGITATION Trial II - Children ≤1 Year",[87,88],"2026-01-31","2021-10-25",336,[1103],[1661,1641],"Clonidine",{"trials":1663,"activeCount":98},[],{"trials":1665,"activeCount":181,"soonestReadout":1631},[1666,1677],{"nctId":1667,"briefTitle":1668,"status":154,"phases":1669,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":1672,"conditions":1673,"interventions":1676},"NCT03371199","The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy.",[90],"2018-12-31","2017-12-01",21,[1674,1675],"Hyponatremia","Metabolic Bone Disease",[1641],{"nctId":1628,"briefTitle":1629,"status":172,"phases":1678,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1679,"interventions":1680},[90],[1635,1636],[1586,1586,1638,1638,1639,1640,1641],{"intervention":1461,"totalTrials":979,"cells":1682},{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1689,"PHASE4":1691,"NA":1693},{"trials":1684,"activeCount":98},[],{"trials":1686,"activeCount":98},[],{"trials":1688,"activeCount":98},[],{"trials":1690,"activeCount":98},[],{"trials":1692,"activeCount":98},[],{"trials":1694,"activeCount":181,"soonestReadout":1699},[1695,1705,1715],{"nctId":1696,"briefTitle":1697,"status":110,"phases":1698,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":1633,"conditions":1702,"interventions":1704},"NCT07398300","Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion",[90],"2027-03-12","2027-05","2026-03-12",[30,1703],"Healhty",[1460,1461],{"nctId":1706,"briefTitle":1707,"status":154,"phases":1708,"primaryCompletion":1709,"completion":1709,"start":1710,"enrollment":1232,"conditions":1711,"interventions":1713},"NCT01347801","Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1",[90],"2014-09","2011-03",[1712],"Hypoglycaemia",[1461,1714],"TNF-alfa",{"nctId":1449,"briefTitle":1450,"status":154,"phases":1716,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1717,"interventions":1718},[90],[1457,1458],[975,1460,1461],{"intervention":1720,"totalTrials":94,"cells":1721},"Isotonic saline",{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1735,"PHASE3":1737,"PHASE4":1739,"NA":1741},{"trials":1723,"activeCount":98},[],{"trials":1725,"activeCount":98},[1726],{"nctId":1727,"briefTitle":1728,"status":154,"phases":1729,"primaryCompletion":1730,"completion":1241,"start":1731,"enrollment":1232,"conditions":1732,"interventions":1733},"NCT01528943","Effect of Prostacyclin on Haemostasis in Abdominal Surgery",[86],"2013-03","2012-03",[25],[1734,1720],"Prostacycline",{"trials":1736,"activeCount":98},[],{"trials":1738,"activeCount":98},[],{"trials":1740,"activeCount":98},[],{"trials":1742,"activeCount":181,"soonestReadout":1747},[1743],{"nctId":1744,"briefTitle":1745,"status":110,"phases":1746,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":1751,"interventions":1753},"NCT05609877","The NONA-LISA Trial",[90],"2028-05-31","2029-05-31","2024-06-01",324,[1752],"Respiratory Distress Syndrome in Premature Infant",[1720,1754],"Fentanyl",{"intervention":1756,"totalTrials":94,"cells":1757},"Warfarin",{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1762,"PHASE3":1764,"PHASE4":1766,"NA":1779},{"trials":1759,"activeCount":98},[],{"trials":1761,"activeCount":98},[],{"trials":1763,"activeCount":98},[],{"trials":1765,"activeCount":98},[],{"trials":1767,"activeCount":98},[1768],{"nctId":1769,"briefTitle":1770,"status":154,"phases":1771,"primaryCompletion":1731,"completion":1731,"start":1772,"enrollment":1773,"conditions":1774,"interventions":1777},"NCT01452568","Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin",[89],"2005-06",370,[1775,1776],"Thromboembolism","Bleeding",[1778,1756],"Aspirin",{"trials":1780,"activeCount":181,"soonestReadout":73},[1781],{"nctId":76,"briefTitle":77,"status":172,"phases":1782,"primaryCompletion":73,"completion":1783,"start":1784,"enrollment":1785,"conditions":1786,"interventions":1791},[90],"2030-04-01","2021-05-01",352,[1787,33,1788,1789,1790],"Aortic Valve Stenosis","Heart Diseases","Heart Valve Diseases","Valve Disease, Aortic",[78,1792,1793,1794,1795,1796,1756],"Acetylsalicylic acid","Clopidogrel","Edoxaban","Dabigatran","Apixaban",{"intervention":1460,"totalTrials":94,"cells":1798},{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1803,"PHASE3":1805,"PHASE4":1807,"NA":1809},{"trials":1800,"activeCount":98},[],{"trials":1802,"activeCount":98},[],{"trials":1804,"activeCount":98},[],{"trials":1806,"activeCount":98},[],{"trials":1808,"activeCount":98},[],{"trials":1810,"activeCount":181,"soonestReadout":1699},[1811,1815],{"nctId":1696,"briefTitle":1697,"status":110,"phases":1812,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":1633,"conditions":1813,"interventions":1814},[90],[30,1703],[1460,1461],{"nctId":1449,"briefTitle":1450,"status":154,"phases":1816,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1817,"interventions":1818},[90],[1457,1458],[975,1460,1461],{"intervention":1792,"totalTrials":94,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1827,"PHASE4":1844,"NA":1846},{"trials":1822,"activeCount":98},[],{"trials":1824,"activeCount":98},[],{"trials":1826,"activeCount":98},[],{"trials":1828,"activeCount":98},[1829],{"nctId":1830,"briefTitle":1831,"status":967,"phases":1832,"primaryCompletion":1833,"completion":1709,"start":1834,"enrollment":1835,"conditions":1836,"interventions":1841},"NCT01046942","ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery",[88],"2014-05","2008-11",250,[1837,1838,1839,1840],"Graft Patency","Coronary Artery Bypass Grafting Surgery","Hypercoagulability","Thrombosis",[1842,1843],"Clopidogrel+acetylsalicylic acid","acetylsalicylic acid",{"trials":1845,"activeCount":98},[],{"trials":1847,"activeCount":181,"soonestReadout":73},[1848],{"nctId":76,"briefTitle":77,"status":172,"phases":1849,"primaryCompletion":73,"completion":1783,"start":1784,"enrollment":1785,"conditions":1850,"interventions":1851},[90],[1787,33,1788,1789,1790],[78,1792,1793,1794,1795,1796,1756],{"intervention":1754,"totalTrials":181,"cells":1853},{"EARLY_PHASE1":1854,"PHASE1":1856,"PHASE2":1858,"PHASE3":1860,"PHASE4":1862,"NA":1864},{"trials":1855,"activeCount":98},[],{"trials":1857,"activeCount":98},[],{"trials":1859,"activeCount":98},[],{"trials":1861,"activeCount":98},[],{"trials":1863,"activeCount":98},[],{"trials":1865,"activeCount":181,"soonestReadout":1747},[1866],{"nctId":1744,"briefTitle":1745,"status":110,"phases":1867,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":1868,"interventions":1869},[90],[1752],[1720,1754],{"intervention":1871,"totalTrials":181,"cells":1872},"Treatment Package for First-Episode Depression",{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1874,"activeCount":98},[],{"trials":1876,"activeCount":98},[],{"trials":1878,"activeCount":98},[],{"trials":1880,"activeCount":98},[],{"trials":1882,"activeCount":98},[],{"trials":1884,"activeCount":181,"soonestReadout":1889},[1885],{"nctId":1886,"briefTitle":1887,"status":110,"phases":1888,"primaryCompletion":1889,"completion":1889,"start":1890,"enrollment":1891,"conditions":1892,"interventions":1898},"NCT05616559","Precision Medicine in the Depression Treatment",[],"2026-12","2021-06-15",800,[1893,1894,1895,1896,1897],"Depressive Disorder, Major","Treatment Outcome","Cognitive Dysfunction","Cognitive Behavioral Therapy","Antidepressive Agents",[1871],{"intervention":1900,"totalTrials":181,"cells":1901},"Oral antibiotic treatment",{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1906,"PHASE3":1908,"PHASE4":1910,"NA":1912},{"trials":1903,"activeCount":98},[],{"trials":1905,"activeCount":98},[],{"trials":1907,"activeCount":98},[],{"trials":1909,"activeCount":98},[],{"trials":1911,"activeCount":98},[],{"trials":1913,"activeCount":181,"soonestReadout":1918},[1914],{"nctId":1915,"briefTitle":1916,"status":110,"phases":1917,"primaryCompletion":1918,"completion":1700,"start":1919,"enrollment":158,"conditions":1920,"interventions":1926},"NCT06827496","Initial Oral Antibiotics for Bone and Joint Infections in Children",[],"2026-11-15","2024-11-15",[1921,1922,1923,1924,1925],"Osteomyelitis Acute","Septic Arthritis","Bone Infection","Joint Infection","Bone and Joint Infection",[1900],{"intervention":69,"totalTrials":181,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1935,"PHASE4":1937,"NA":1939},{"trials":1930,"activeCount":98},[],{"trials":1932,"activeCount":98},[],{"trials":1934,"activeCount":98},[],{"trials":1936,"activeCount":98},[],{"trials":1938,"activeCount":98},[],{"trials":1940,"activeCount":181,"soonestReadout":64},[1941],{"nctId":67,"briefTitle":68,"status":110,"phases":1942,"primaryCompletion":64,"completion":1943,"start":1944,"enrollment":1601,"conditions":1945,"interventions":1948},[],"2026-01","2025-01-13",[1946,1947],"Informed Consent","Preference, Patient",[69],{"intervention":45,"totalTrials":181,"cells":1950},{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":98},[],{"trials":1956,"activeCount":98},[],{"trials":1958,"activeCount":98},[],{"trials":1960,"activeCount":98},[],{"trials":1962,"activeCount":181,"soonestReadout":44},[1963],{"nctId":42,"briefTitle":43,"status":172,"phases":1964,"primaryCompletion":44,"completion":44,"start":1965,"enrollment":1966,"conditions":1967,"interventions":1973},[90],"2016-02",1400,[1968,1969,1970,1971,1972,1580],"Coronary Disease","Shock, Cardiogenic","Renal Failure","Stroke","Brain Injury",[45,1974,1975],"Conoxia","20% Human Albumin",{"intervention":1974,"totalTrials":181,"cells":1977},{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1984,"PHASE4":1986,"NA":1988},{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[],{"trials":1983,"activeCount":98},[],{"trials":1985,"activeCount":98},[],{"trials":1987,"activeCount":98},[],{"trials":1989,"activeCount":181,"soonestReadout":44},[1990],{"nctId":42,"briefTitle":43,"status":172,"phases":1991,"primaryCompletion":44,"completion":44,"start":1965,"enrollment":1966,"conditions":1992,"interventions":1993},[90],[1968,1969,1970,1971,1972,1580],[45,1974,1975],{"intervention":1975,"totalTrials":181,"cells":1995},{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2004,"NA":2006},{"trials":1997,"activeCount":98},[],{"trials":1999,"activeCount":98},[],{"trials":2001,"activeCount":98},[],{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[],{"trials":2007,"activeCount":181,"soonestReadout":44},[2008],{"nctId":42,"briefTitle":43,"status":172,"phases":2009,"primaryCompletion":44,"completion":44,"start":1965,"enrollment":1966,"conditions":2010,"interventions":2011},[90],[1968,1969,1970,1971,1972,1580],[45,1974,1975],{"intervention":1582,"totalTrials":181,"cells":2013},{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2015,"activeCount":98},[],{"trials":2017,"activeCount":98},[],{"trials":2019,"activeCount":98},[],{"trials":2021,"activeCount":98},[],{"trials":2023,"activeCount":98},[],{"trials":2025,"activeCount":181,"soonestReadout":502},[2026],{"nctId":1574,"briefTitle":1575,"status":110,"phases":2027,"primaryCompletion":502,"completion":1577,"start":1578,"enrollment":225,"conditions":2028,"interventions":2029},[90],[28,1580],[1582,1583,1584],{"intervention":1584,"totalTrials":181,"cells":2031},{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2036,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2033,"activeCount":98},[],{"trials":2035,"activeCount":98},[],{"trials":2037,"activeCount":98},[],{"trials":2039,"activeCount":98},[],{"trials":2041,"activeCount":98},[],{"trials":2043,"activeCount":181,"soonestReadout":502},[2044],{"nctId":1574,"briefTitle":1575,"status":110,"phases":2045,"primaryCompletion":502,"completion":1577,"start":1578,"enrollment":225,"conditions":2046,"interventions":2047},[90],[28,1580],[1582,1583,1584],{"intervention":2049,"totalTrials":181,"cells":2050},"Beta-lactam antibiotic with spectrum for Enterococcus faecalis",{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2052,"activeCount":98},[],{"trials":2054,"activeCount":98},[],{"trials":2056,"activeCount":98},[],{"trials":2058,"activeCount":98},[],{"trials":2060,"activeCount":98},[],{"trials":2062,"activeCount":181,"soonestReadout":2067},[2063],{"nctId":2064,"briefTitle":2065,"status":528,"phases":2066,"primaryCompletion":2067,"completion":2067,"start":1367,"enrollment":2068,"conditions":2069,"interventions":2070},"NCT07442357","The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial",[90],"2029-06-01",1986,[1787],[2049,2071],"Cephalosporin",{"intervention":2071,"totalTrials":181,"cells":2073},{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2078,"PHASE3":2080,"PHASE4":2082,"NA":2084},{"trials":2075,"activeCount":98},[],{"trials":2077,"activeCount":98},[],{"trials":2079,"activeCount":98},[],{"trials":2081,"activeCount":98},[],{"trials":2083,"activeCount":98},[],{"trials":2085,"activeCount":181,"soonestReadout":2067},[2086],{"nctId":2064,"briefTitle":2065,"status":528,"phases":2087,"primaryCompletion":2067,"completion":2067,"start":1367,"enrollment":2068,"conditions":2088,"interventions":2089},[90],[1787],[2049,2071],{"intervention":1638,"totalTrials":181,"cells":2091},{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2096,"PHASE3":2098,"PHASE4":2100,"NA":2102},{"trials":2093,"activeCount":98},[],{"trials":2095,"activeCount":98},[],{"trials":2097,"activeCount":98},[],{"trials":2099,"activeCount":98},[],{"trials":2101,"activeCount":98},[],{"trials":2103,"activeCount":181,"soonestReadout":1631},[2104],{"nctId":1628,"briefTitle":1629,"status":172,"phases":2105,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":2106,"interventions":2107},[90],[1635,1636],[1586,1586,1638,1638,1639,1640,1641],{"intervention":1639,"totalTrials":181,"cells":2109},{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2116,"PHASE4":2118,"NA":2120},{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[],{"trials":2115,"activeCount":98},[],{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":181,"soonestReadout":1631},[2122],{"nctId":1628,"briefTitle":1629,"status":172,"phases":2123,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":2124,"interventions":2125},[90],[1635,1636],[1586,1586,1638,1638,1639,1640,1641],{"intervention":1640,"totalTrials":181,"cells":2127},{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2132,"PHASE3":2134,"PHASE4":2136,"NA":2138},{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[],{"trials":2133,"activeCount":98},[],{"trials":2135,"activeCount":98},[],{"trials":2137,"activeCount":98},[],{"trials":2139,"activeCount":181,"soonestReadout":1631},[2140],{"nctId":1628,"briefTitle":1629,"status":172,"phases":2141,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":2142,"interventions":2143},[90],[1635,1636],[1586,1586,1638,1638,1639,1640,1641],{"intervention":78,"totalTrials":181,"cells":2145},{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2152,"PHASE4":2154,"NA":2156},{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"trials":2151,"activeCount":98},[],{"trials":2153,"activeCount":98},[],{"trials":2155,"activeCount":98},[],{"trials":2157,"activeCount":181,"soonestReadout":73},[2158],{"nctId":76,"briefTitle":77,"status":172,"phases":2159,"primaryCompletion":73,"completion":1783,"start":1784,"enrollment":1785,"conditions":2160,"interventions":2161},[90],[1787,33,1788,1789,1790],[78,1792,1793,1794,1795,1796,1756],{"intervention":1793,"totalTrials":181,"cells":2163},{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2170,"PHASE4":2172,"NA":2174},{"trials":2165,"activeCount":98},[],{"trials":2167,"activeCount":98},[],{"trials":2169,"activeCount":98},[],{"trials":2171,"activeCount":98},[],{"trials":2173,"activeCount":98},[],{"trials":2175,"activeCount":181,"soonestReadout":73},[2176],{"nctId":76,"briefTitle":77,"status":172,"phases":2177,"primaryCompletion":73,"completion":1783,"start":1784,"enrollment":1785,"conditions":2178,"interventions":2179},[90],[1787,33,1788,1789,1790],[78,1792,1793,1794,1795,1796,1756],{"intervention":1794,"totalTrials":181,"cells":2181},{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2188,"PHASE4":2190,"NA":2192},{"trials":2183,"activeCount":98},[],{"trials":2185,"activeCount":98},[],{"trials":2187,"activeCount":98},[],{"trials":2189,"activeCount":98},[],{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":181,"soonestReadout":73},[2194],{"nctId":76,"briefTitle":77,"status":172,"phases":2195,"primaryCompletion":73,"completion":1783,"start":1784,"enrollment":1785,"conditions":2196,"interventions":2197},[90],[1787,33,1788,1789,1790],[78,1792,1793,1794,1795,1796,1756],{"intervention":1795,"totalTrials":181,"cells":2199},{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2208,"NA":2210},{"trials":2201,"activeCount":98},[],{"trials":2203,"activeCount":98},[],{"trials":2205,"activeCount":98},[],{"trials":2207,"activeCount":98},[],{"trials":2209,"activeCount":98},[],{"trials":2211,"activeCount":181,"soonestReadout":73},[2212],{"nctId":76,"briefTitle":77,"status":172,"phases":2213,"primaryCompletion":73,"completion":1783,"start":1784,"enrollment":1785,"conditions":2214,"interventions":2215},[90],[1787,33,1788,1789,1790],[78,1792,1793,1794,1795,1796,1756],{"intervention":1796,"totalTrials":181,"cells":2217},{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2226,"NA":2228},{"trials":2219,"activeCount":98},[],{"trials":2221,"activeCount":98},[],{"trials":2223,"activeCount":98},[],{"trials":2225,"activeCount":98},[],{"trials":2227,"activeCount":98},[],{"trials":2229,"activeCount":181,"soonestReadout":73},[2230],{"nctId":76,"briefTitle":77,"status":172,"phases":2231,"primaryCompletion":73,"completion":1783,"start":1784,"enrollment":1785,"conditions":2232,"interventions":2233},[90],[1787,33,1788,1789,1790],[78,1792,1793,1794,1795,1796,1756],{"intervention":50,"totalTrials":181,"cells":2235},{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2242,"PHASE4":2244,"NA":2246},{"trials":2237,"activeCount":98},[],{"trials":2239,"activeCount":98},[],{"trials":2241,"activeCount":98},[],{"trials":2243,"activeCount":98},[],{"trials":2245,"activeCount":98},[],{"trials":2247,"activeCount":181,"soonestReadout":49},[2248],{"nctId":47,"briefTitle":48,"status":110,"phases":2249,"primaryCompletion":49,"completion":2250,"start":2251,"enrollment":2252,"conditions":2253,"interventions":2255},[],"2025-05-01","2023-02-27",125,[2254],"Urinary Tract Infections in Children",[50],{"intervention":2257,"totalTrials":979,"cells":2258},"Lidocaine",{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2285,"PHASE4":2287,"NA":2298},{"trials":2260,"activeCount":98},[],{"trials":2262,"activeCount":98},[],{"trials":2264,"activeCount":98},[2265,2278],{"nctId":2266,"briefTitle":2267,"status":154,"phases":2268,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":2271,"conditions":2272,"interventions":2276},"NCT02253966","Preoperative Intraarticular Injection of Methylprednisolone in Patients Scheduled for Total Knee-arthroplasty",[87],"2016-03","2014-10",48,[2273,2274,2275],"Knee Joint Osteoarthrosis","Hyperalgesia","Severe Movement Related Pain",[2277,2257],"Methylprednisoloneacetate",{"nctId":2279,"briefTitle":2280,"status":154,"phases":2281,"primaryCompletion":2282,"completion":2282,"start":1241,"enrollment":1232,"conditions":2283,"interventions":2284},"NCT02033356","ED95 of Lidocaine 1.0% for Filling the Adductor Canal",[87],"2014-02",[18],[2257],{"trials":2286,"activeCount":98},[],{"trials":2288,"activeCount":98},[2289],{"nctId":2290,"briefTitle":2291,"status":936,"phases":2292,"primaryCompletion":2293,"completion":2293,"start":2294,"enrollment":31,"conditions":2295,"interventions":2296},"NCT01373593","Ultrasound Guided Blocks of the Iliohypogastric and Ilioinguinal Nerves in Persistent Postherniorrhaphy Pain Patients",[89],"2011-07","2011-01",[23],[2297],"lidocaine",{"trials":2299,"activeCount":98},[],{"intervention":953,"totalTrials":979,"cells":2301},{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2306,"PHASE3":2308,"PHASE4":2310,"NA":2330},{"trials":2303,"activeCount":98},[],{"trials":2305,"activeCount":98},[],{"trials":2307,"activeCount":98},[],{"trials":2309,"activeCount":98},[],{"trials":2311,"activeCount":98},[2312,2316,2326],{"nctId":996,"briefTitle":997,"status":154,"phases":2313,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":2314,"interventions":2315},[89],[891,896],[955,1005,953,810],{"nctId":2317,"briefTitle":2318,"status":154,"phases":2319,"primaryCompletion":2320,"completion":2320,"start":2321,"enrollment":2322,"conditions":2323,"interventions":2325},"NCT01933542","The Effect of Chlorzoxazone on Moderate to Severe Postoperative Pain After Spine Surgery",[89],"2015-08","2013-08",110,[2324,896],"Chlorzoxazone",[2324,953,954],{"nctId":945,"briefTitle":946,"status":154,"phases":2327,"primaryCompletion":948,"completion":840,"start":949,"enrollment":950,"conditions":2328,"interventions":2329},[89],[23],[869,953,954,810,955],{"trials":2331,"activeCount":98},[],{"intervention":2333,"totalTrials":94,"cells":2334},"Liberal oxygen",{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2341,"PHASE4":2343,"NA":2370},{"trials":2336,"activeCount":98},[],{"trials":2338,"activeCount":98},[],{"trials":2340,"activeCount":98},[],{"trials":2342,"activeCount":98},[],{"trials":2344,"activeCount":98},[2345,2359],{"nctId":2346,"briefTitle":2347,"status":154,"phases":2348,"primaryCompletion":2349,"completion":2350,"start":2351,"enrollment":2352,"conditions":2353,"interventions":2357},"NCT05146700","Restrictive Vs. Liberal Oxygen in Trauma",[89],"2023-10-12","2024-10-12","2021-12-10",1508,[2354,2355,2356],"Trauma","Oxygen Toxicity","Wounds and Injuries",[2358,2333],"Restrictive oxygen",{"nctId":2360,"briefTitle":2361,"status":154,"phases":2362,"primaryCompletion":2363,"completion":2363,"start":2364,"enrollment":2365,"conditions":2366,"interventions":2367},"NCT03491644","Restrictive vs. Liberal Oxygen Therapy for Trauma Patients",[89],"2018-07-02","2018-04-03",41,[2354,2356],[2368,2369],"Titrated Oxygen","Liberal Oxygen",{"trials":2371,"activeCount":98},[],{"intervention":2373,"totalTrials":94,"cells":2374},"OctaplasLG®",{"EARLY_PHASE1":2375,"PHASE1":2377,"PHASE2":2379,"PHASE3":2381,"PHASE4":2383,"NA":2409},{"trials":2376,"activeCount":98},[],{"trials":2378,"activeCount":98},[],{"trials":2380,"activeCount":98},[],{"trials":2382,"activeCount":98},[],{"trials":2384,"activeCount":98},[2385,2398],{"nctId":2386,"briefTitle":2387,"status":154,"phases":2388,"primaryCompletion":2389,"completion":2390,"start":2391,"enrollment":2392,"conditions":2393,"interventions":2396},"NCT02253082","Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)",[89],"2016-09","2016-12","2014-11",44,[2394,2395],"Aortic Aneurysm, Thoracic","Endothelial Dysfunction",[2373,2397],"Fresh frozen plasma",{"nctId":2399,"briefTitle":2400,"status":936,"phases":2401,"primaryCompletion":2402,"completion":2402,"start":2403,"enrollment":2404,"conditions":2405,"interventions":2407},"NCT02875236","Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81)",[89],"2016-11-08","2016-09-01",5,[2406],"Septic Shock",[2373,2408],"Ringer-acetat",{"trials":2410,"activeCount":98},[],{"intervention":955,"totalTrials":94,"cells":2412},{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2417,"PHASE3":2419,"PHASE4":2421,"NA":2431},{"trials":2414,"activeCount":98},[],{"trials":2416,"activeCount":98},[],{"trials":2418,"activeCount":98},[],{"trials":2420,"activeCount":98},[],{"trials":2422,"activeCount":98},[2423,2427],{"nctId":996,"briefTitle":997,"status":154,"phases":2424,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":2425,"interventions":2426},[89],[891,896],[955,1005,953,810],{"nctId":945,"briefTitle":946,"status":154,"phases":2428,"primaryCompletion":948,"completion":840,"start":949,"enrollment":950,"conditions":2429,"interventions":2430},[89],[23],[869,953,954,810,955],{"trials":2432,"activeCount":98},[],{"intervention":1661,"totalTrials":94,"cells":2434},{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2439,"PHASE3":2441,"PHASE4":2447,"NA":2458},{"trials":2436,"activeCount":98},[],{"trials":2438,"activeCount":98},[],{"trials":2440,"activeCount":98},[],{"trials":2442,"activeCount":98},[2443],{"nctId":1653,"briefTitle":1654,"status":967,"phases":2444,"primaryCompletion":1656,"completion":1656,"start":1657,"enrollment":1658,"conditions":2445,"interventions":2446},[87,88],[1103],[1661,1641],{"trials":2448,"activeCount":98},[2449],{"nctId":2450,"briefTitle":2451,"status":154,"phases":2452,"primaryCompletion":2453,"completion":2453,"start":816,"enrollment":2454,"conditions":2455,"interventions":2457},"NCT02361476","Does Intraoperative Clonidine Reduce Post Operative Agitation in Children?",[89],"2015-12",379,[2456],"Psychomotor Agitation",[1661],{"trials":2459,"activeCount":98},[],{"intervention":2461,"totalTrials":94,"cells":2462},"Propofol",{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2467,"PHASE3":2469,"PHASE4":2471,"NA":2495},{"trials":2464,"activeCount":98},[],{"trials":2466,"activeCount":98},[],{"trials":2468,"activeCount":98},[],{"trials":2470,"activeCount":98},[],{"trials":2472,"activeCount":98},[2473,2485],{"nctId":2474,"briefTitle":2475,"status":154,"phases":2476,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":2479,"conditions":2480,"interventions":2483},"NCT00965107","Onset Time of Thiopental Versus Propofol in the Elderly",[89],"2010-03","2009-09",78,[2481,2482],"Induction of Anaesthesia","Age",[2484,2461],"Thiopental",{"nctId":2486,"briefTitle":2487,"status":154,"phases":2488,"primaryCompletion":2489,"completion":2489,"start":2490,"enrollment":2491,"conditions":2492,"interventions":2494},"NCT00270335","Optimizing Propofol in Obese Patients",[89],"2007-08","2006-01",38,[2493],"Hysterectomy",[2461],{"trials":2496,"activeCount":98},[],{"intervention":954,"totalTrials":94,"cells":2498},{"EARLY_PHASE1":2499,"PHASE1":2501,"PHASE2":2503,"PHASE3":2505,"PHASE4":2507,"NA":2517},{"trials":2500,"activeCount":98},[],{"trials":2502,"activeCount":98},[],{"trials":2504,"activeCount":98},[],{"trials":2506,"activeCount":98},[],{"trials":2508,"activeCount":98},[2509,2513],{"nctId":2317,"briefTitle":2318,"status":154,"phases":2510,"primaryCompletion":2320,"completion":2320,"start":2321,"enrollment":2322,"conditions":2511,"interventions":2512},[89],[2324,896],[2324,953,954],{"nctId":945,"briefTitle":946,"status":154,"phases":2514,"primaryCompletion":948,"completion":840,"start":949,"enrollment":950,"conditions":2515,"interventions":2516},[89],[23],[869,953,954,810,955],{"trials":2518,"activeCount":98},[],{"intervention":2520,"totalTrials":181,"cells":2521},"Escitalopram 20 mg",{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2530,"NA":2540},{"trials":2523,"activeCount":98},[],{"trials":2525,"activeCount":98},[],{"trials":2527,"activeCount":98},[],{"trials":2529,"activeCount":98},[],{"trials":2531,"activeCount":98},[2532],{"nctId":2533,"briefTitle":2534,"status":154,"phases":2535,"primaryCompletion":2536,"completion":2536,"start":2537,"enrollment":603,"conditions":2538,"interventions":2539},"NCT04239339","Serotonergic Modulation of Cognition, Emotion and Brain Activation in Healthy Volunteers",[89],"2022-10-30","2020-04-28",[18],[2520],{"trials":2541,"activeCount":98},[],{"intervention":2543,"totalTrials":181,"cells":2544},"Oral treatment with antibiotics for endocarditis",{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2549,"PHASE3":2551,"PHASE4":2553,"NA":2564},{"trials":2546,"activeCount":98},[],{"trials":2548,"activeCount":98},[],{"trials":2550,"activeCount":98},[],{"trials":2552,"activeCount":98},[],{"trials":2554,"activeCount":98},[2555],{"nctId":2556,"briefTitle":2557,"status":154,"phases":2558,"primaryCompletion":2559,"completion":2559,"start":2293,"enrollment":576,"conditions":2560,"interventions":2562},"NCT01375257","Partial Oral Treatment of Endocarditis",[89],"2017-08-30",[2561],"Endocarditis",[2543,2563],"Guideline treatment with parenteral antibiotics",{"trials":2565,"activeCount":98},[],{"intervention":2563,"totalTrials":181,"cells":2567},{"EARLY_PHASE1":2568,"PHASE1":2570,"PHASE2":2572,"PHASE3":2574,"PHASE4":2576,"NA":2582},{"trials":2569,"activeCount":98},[],{"trials":2571,"activeCount":98},[],{"trials":2573,"activeCount":98},[],{"trials":2575,"activeCount":98},[],{"trials":2577,"activeCount":98},[2578],{"nctId":2556,"briefTitle":2557,"status":154,"phases":2579,"primaryCompletion":2559,"completion":2559,"start":2293,"enrollment":576,"conditions":2580,"interventions":2581},[89],[2561],[2543,2563],{"trials":2583,"activeCount":98},[],{"intervention":2585,"totalTrials":181,"cells":2586},"Indocyanine green",{"EARLY_PHASE1":2587,"PHASE1":2589,"PHASE2":2591,"PHASE3":2593,"PHASE4":2595,"NA":2608},{"trials":2588,"activeCount":98},[],{"trials":2590,"activeCount":98},[],{"trials":2592,"activeCount":98},[],{"trials":2594,"activeCount":98},[],{"trials":2596,"activeCount":98},[2597],{"nctId":2598,"briefTitle":2599,"status":936,"phases":2600,"primaryCompletion":2601,"completion":2602,"start":2603,"enrollment":2604,"conditions":2605,"interventions":2607},"NCT05354856","The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.",[89],"2023-12-29","2023-12-30","2022-03-11",11,[2606],"Gastric Cancer",[2585],{"trials":2609,"activeCount":98},[],{"intervention":2611,"totalTrials":181,"cells":2612},"Botulinum toxin",{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2617,"PHASE3":2619,"PHASE4":2621,"NA":2633},{"trials":2614,"activeCount":98},[],{"trials":2616,"activeCount":98},[],{"trials":2618,"activeCount":98},[],{"trials":2620,"activeCount":98},[],{"trials":2622,"activeCount":98},[2623],{"nctId":2624,"briefTitle":2625,"status":967,"phases":2626,"completion":2627,"start":2628,"enrollment":841,"conditions":2629,"interventions":2632},"NCT00119886","Botox on Vulvar Vestibulitis",[89],"2008-06","2005-04",[2630,2631],"Vulvar Vestibulitis","Vulvar Diseases",[2611],{"trials":2634,"activeCount":98},[],{"intervention":2358,"totalTrials":181,"cells":2636},{"EARLY_PHASE1":2637,"PHASE1":2639,"PHASE2":2641,"PHASE3":2643,"PHASE4":2645,"NA":2651},{"trials":2638,"activeCount":98},[],{"trials":2640,"activeCount":98},[],{"trials":2642,"activeCount":98},[],{"trials":2644,"activeCount":98},[],{"trials":2646,"activeCount":98},[2647],{"nctId":2346,"briefTitle":2347,"status":154,"phases":2648,"primaryCompletion":2349,"completion":2350,"start":2351,"enrollment":2352,"conditions":2649,"interventions":2650},[89],[2354,2355,2356],[2358,2333],{"trials":2652,"activeCount":98},[],{"intervention":2654,"totalTrials":181,"cells":2655},"recombinant luteinizing hormone",{"EARLY_PHASE1":2656,"PHASE1":2658,"PHASE2":2660,"PHASE3":2662,"PHASE4":2664,"NA":2678},{"trials":2657,"activeCount":98},[],{"trials":2659,"activeCount":98},[],{"trials":2661,"activeCount":98},[],{"trials":2663,"activeCount":98},[],{"trials":2665,"activeCount":98},[2666],{"nctId":2667,"briefTitle":2668,"status":154,"phases":2669,"completion":2670,"start":2671,"enrollment":2672,"conditions":2673,"interventions":2676},"NCT00553293","Nordic Luveris Study",[89],"2004-11","2003-08",526,[2674,2675],"Infertility","In Vitro Fertilization",[2654,2677],"recombinant follicle stimulating hormone",{"trials":2679,"activeCount":98},[],{"intervention":2677,"totalTrials":181,"cells":2681},{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2688,"PHASE4":2690,"NA":2696},{"trials":2683,"activeCount":98},[],{"trials":2685,"activeCount":98},[],{"trials":2687,"activeCount":98},[],{"trials":2689,"activeCount":98},[],{"trials":2691,"activeCount":98},[2692],{"nctId":2667,"briefTitle":2668,"status":154,"phases":2693,"completion":2670,"start":2671,"enrollment":2672,"conditions":2694,"interventions":2695},[89],[2674,2675],[2654,2677],{"trials":2697,"activeCount":98},[],{"intervention":2699,"totalTrials":181,"cells":2700},"Metoprolole",{"EARLY_PHASE1":2701,"PHASE1":2703,"PHASE2":2705,"PHASE3":2707,"PHASE4":2709,"NA":2718},{"trials":2702,"activeCount":98},[],{"trials":2704,"activeCount":98},[],{"trials":2706,"activeCount":98},[],{"trials":2708,"activeCount":98},[],{"trials":2710,"activeCount":98},[2711],{"nctId":2712,"briefTitle":2713,"status":967,"phases":2714,"primaryCompletion":999,"completion":1000,"start":1409,"enrollment":791,"conditions":2715,"interventions":2717},"NCT00885651","Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines",[89],[2716],"Heart Failure",[2699],{"trials":2719,"activeCount":98},[],{"intervention":2721,"totalTrials":181,"cells":2722},"Enzyme replacement",{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2729,"PHASE4":2731,"NA":2743},{"trials":2724,"activeCount":98},[],{"trials":2726,"activeCount":98},[],{"trials":2728,"activeCount":98},[],{"trials":2730,"activeCount":98},[],{"trials":2732,"activeCount":98},[2733],{"nctId":2734,"briefTitle":2735,"status":154,"phases":2736,"primaryCompletion":2737,"completion":2270,"start":2738,"enrollment":2739,"conditions":2740,"interventions":2742},"NCT01997489","Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.",[89],"2013-09","2001-09",39,[2741],"Fabry Disease",[2721],{"trials":2744,"activeCount":98},[],{"intervention":2746,"totalTrials":181,"cells":2747},"Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH",{"EARLY_PHASE1":2748,"PHASE1":2750,"PHASE2":2752,"PHASE3":2754,"PHASE4":2756,"NA":2764},{"trials":2749,"activeCount":98},[],{"trials":2751,"activeCount":98},[],{"trials":2753,"activeCount":98},[],{"trials":2755,"activeCount":98},[],{"trials":2757,"activeCount":98},[2758],{"nctId":2759,"briefTitle":2760,"status":154,"phases":2761,"conditions":2762,"interventions":2763},"NCT00286364","Short-Term Androgen Priming Before COS Using Aromatase Inhibitor and hCG During Early-Follicular-Phase GnRH Antagonist Administration - a Randomized Controlled Trial",[89],[2674],[2746],{"trials":2765,"activeCount":98},[],{"intervention":2397,"totalTrials":181,"cells":2767},{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2772,"PHASE3":2774,"PHASE4":2776,"NA":2782},{"trials":2769,"activeCount":98},[],{"trials":2771,"activeCount":98},[],{"trials":2773,"activeCount":98},[],{"trials":2775,"activeCount":98},[],{"trials":2777,"activeCount":98},[2778],{"nctId":2386,"briefTitle":2387,"status":154,"phases":2779,"primaryCompletion":2389,"completion":2390,"start":2391,"enrollment":2392,"conditions":2780,"interventions":2781},[89],[2394,2395],[2373,2397],{"trials":2783,"activeCount":98},[],{"intervention":2785,"totalTrials":181,"cells":2786},"Oral co-amoxiclav or oral dicloxacillin only",{"EARLY_PHASE1":2787,"PHASE1":2789,"PHASE2":2791,"PHASE3":2793,"PHASE4":2795,"NA":2808},{"trials":2788,"activeCount":98},[],{"trials":2790,"activeCount":98},[],{"trials":2792,"activeCount":98},[],{"trials":2794,"activeCount":98},[],{"trials":2796,"activeCount":98},[2797],{"nctId":2798,"briefTitle":2799,"status":154,"phases":2800,"primaryCompletion":2801,"completion":2802,"start":2803,"enrollment":1002,"conditions":2804,"interventions":2806},"NCT04563325","Oral-only Antibiotics for Bone and Joint Infections in Children",[89],"2024-01-01","2024-08-05","2020-09-15",[2805,1922,1923,1924,1925],"Osteomyelitis",[2785,2807],"IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin",{"trials":2809,"activeCount":98},[],{"intervention":2807,"totalTrials":181,"cells":2811},{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2816,"PHASE3":2818,"PHASE4":2820,"NA":2826},{"trials":2813,"activeCount":98},[],{"trials":2815,"activeCount":98},[],{"trials":2817,"activeCount":98},[],{"trials":2819,"activeCount":98},[],{"trials":2821,"activeCount":98},[2822],{"nctId":2798,"briefTitle":2799,"status":154,"phases":2823,"primaryCompletion":2801,"completion":2802,"start":2803,"enrollment":1002,"conditions":2824,"interventions":2825},[89],[2805,1922,1923,1924,1925],[2785,2807],{"trials":2827,"activeCount":98},[],{"intervention":2829,"totalTrials":181,"cells":2830},"Combined treatment with Arimidex and Zoladex before IVF",{"EARLY_PHASE1":2831,"PHASE1":2833,"PHASE2":2835,"PHASE3":2837,"PHASE4":2839,"NA":2849},{"trials":2832,"activeCount":98},[],{"trials":2834,"activeCount":98},[],{"trials":2836,"activeCount":98},[],{"trials":2838,"activeCount":98},[],{"trials":2840,"activeCount":98},[2841],{"nctId":2842,"briefTitle":2843,"status":154,"phases":2844,"start":2845,"enrollment":1455,"conditions":2846,"interventions":2848},"NCT00286351","Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis",[89],"2005-01",[2847],"Endometriosis",[2829],{"trials":2850,"activeCount":98},[],{"intervention":2852,"totalTrials":181,"cells":2853},"(S)-(+)-Ketamine Hydrochloride Solution 25 mg\u002Fml",{"EARLY_PHASE1":2854,"PHASE1":2856,"PHASE2":2858,"PHASE3":2860,"PHASE4":2862,"NA":2881},{"trials":2855,"activeCount":98},[],{"trials":2857,"activeCount":98},[],{"trials":2859,"activeCount":98},[],{"trials":2861,"activeCount":98},[],{"trials":2863,"activeCount":98},[2864],{"nctId":2865,"briefTitle":2866,"status":154,"phases":2867,"primaryCompletion":2868,"completion":2869,"start":1833,"enrollment":2870,"conditions":2871,"interventions":2874},"NCT02085577","The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients",[89],"2015-10","2016-11-01",147,[896,2872,2873],"Chronic Pain","Analgesics",[2852,2875,2876,2877,2877,2878,2879,2877,2880],"Isotonic sodium chloride 0.9 percent","Paracetamol 1 g","Morphine Sulphate 1 mg\u002Fml","Ondansetron 2 mg\u002Fml","Usual daily opioids","Sufentanil 5 microgram\u002Fml",{"trials":2882,"activeCount":98},[],{"intervention":2875,"totalTrials":181,"cells":2884},{"EARLY_PHASE1":2885,"PHASE1":2887,"PHASE2":2889,"PHASE3":2891,"PHASE4":2893,"NA":2899},{"trials":2886,"activeCount":98},[],{"trials":2888,"activeCount":98},[],{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[],{"trials":2894,"activeCount":98},[2895],{"nctId":2865,"briefTitle":2866,"status":154,"phases":2896,"primaryCompletion":2868,"completion":2869,"start":1833,"enrollment":2870,"conditions":2897,"interventions":2898},[89],[896,2872,2873],[2852,2875,2876,2877,2877,2878,2879,2877,2880],{"trials":2900,"activeCount":98},[],{"intervention":2876,"totalTrials":181,"cells":2902},{"EARLY_PHASE1":2903,"PHASE1":2905,"PHASE2":2907,"PHASE3":2909,"PHASE4":2911,"NA":2917},{"trials":2904,"activeCount":98},[],{"trials":2906,"activeCount":98},[],{"trials":2908,"activeCount":98},[],{"trials":2910,"activeCount":98},[],{"trials":2912,"activeCount":98},[2913],{"nctId":2865,"briefTitle":2866,"status":154,"phases":2914,"primaryCompletion":2868,"completion":2869,"start":1833,"enrollment":2870,"conditions":2915,"interventions":2916},[89],[896,2872,2873],[2852,2875,2876,2877,2877,2878,2879,2877,2880],{"trials":2918,"activeCount":98},[],{"intervention":2877,"totalTrials":181,"cells":2920},{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2925,"PHASE3":2927,"PHASE4":2929,"NA":2935},{"trials":2922,"activeCount":98},[],{"trials":2924,"activeCount":98},[],{"trials":2926,"activeCount":98},[],{"trials":2928,"activeCount":98},[],{"trials":2930,"activeCount":98},[2931],{"nctId":2865,"briefTitle":2866,"status":154,"phases":2932,"primaryCompletion":2868,"completion":2869,"start":1833,"enrollment":2870,"conditions":2933,"interventions":2934},[89],[896,2872,2873],[2852,2875,2876,2877,2877,2878,2879,2877,2880],{"trials":2936,"activeCount":98},[],{"intervention":2878,"totalTrials":181,"cells":2938},{"EARLY_PHASE1":2939,"PHASE1":2941,"PHASE2":2943,"PHASE3":2945,"PHASE4":2947,"NA":2953},{"trials":2940,"activeCount":98},[],{"trials":2942,"activeCount":98},[],{"trials":2944,"activeCount":98},[],{"trials":2946,"activeCount":98},[],{"trials":2948,"activeCount":98},[2949],{"nctId":2865,"briefTitle":2866,"status":154,"phases":2950,"primaryCompletion":2868,"completion":2869,"start":1833,"enrollment":2870,"conditions":2951,"interventions":2952},[89],[896,2872,2873],[2852,2875,2876,2877,2877,2878,2879,2877,2880],{"trials":2954,"activeCount":98},[],{"intervention":2879,"totalTrials":181,"cells":2956},{"EARLY_PHASE1":2957,"PHASE1":2959,"PHASE2":2961,"PHASE3":2963,"PHASE4":2965,"NA":2971},{"trials":2958,"activeCount":98},[],{"trials":2960,"activeCount":98},[],{"trials":2962,"activeCount":98},[],{"trials":2964,"activeCount":98},[],{"trials":2966,"activeCount":98},[2967],{"nctId":2865,"briefTitle":2866,"status":154,"phases":2968,"primaryCompletion":2868,"completion":2869,"start":1833,"enrollment":2870,"conditions":2969,"interventions":2970},[89],[896,2872,2873],[2852,2875,2876,2877,2877,2878,2879,2877,2880],{"trials":2972,"activeCount":98},[],{"intervention":2880,"totalTrials":181,"cells":2974},{"EARLY_PHASE1":2975,"PHASE1":2977,"PHASE2":2979,"PHASE3":2981,"PHASE4":2983,"NA":2989},{"trials":2976,"activeCount":98},[],{"trials":2978,"activeCount":98},[],{"trials":2980,"activeCount":98},[],{"trials":2982,"activeCount":98},[],{"trials":2984,"activeCount":98},[2985],{"nctId":2865,"briefTitle":2866,"status":154,"phases":2986,"primaryCompletion":2868,"completion":2869,"start":1833,"enrollment":2870,"conditions":2987,"interventions":2988},[89],[896,2872,2873],[2852,2875,2876,2877,2877,2878,2879,2877,2880],{"trials":2990,"activeCount":98},[],{"intervention":1005,"totalTrials":181,"cells":2992},{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":2997,"PHASE3":2999,"PHASE4":3001,"NA":3007},{"trials":2994,"activeCount":98},[],{"trials":2996,"activeCount":98},[],{"trials":2998,"activeCount":98},[],{"trials":3000,"activeCount":98},[],{"trials":3002,"activeCount":98},[3003],{"nctId":996,"briefTitle":997,"status":154,"phases":3004,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":3005,"interventions":3006},[89],[891,896],[955,1005,953,810],{"trials":3008,"activeCount":98},[],{"intervention":3010,"totalTrials":181,"cells":3011},"Menopur",{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3016,"PHASE3":3018,"PHASE4":3020,"NA":3032},{"trials":3013,"activeCount":98},[],{"trials":3015,"activeCount":98},[],{"trials":3017,"activeCount":98},[],{"trials":3019,"activeCount":98},[],{"trials":3021,"activeCount":98},[3022],{"nctId":3023,"briefTitle":3024,"status":154,"phases":3025,"primaryCompletion":949,"completion":3026,"start":3027,"enrollment":3028,"conditions":3029,"interventions":3031},"NCT01250821","Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility",[89],"2013-04","2010-12",75,[3030,2674],"Anovulation",[3010],{"trials":3033,"activeCount":98},[],{"intervention":3035,"totalTrials":181,"cells":3036},"Adalimumab",{"EARLY_PHASE1":3037,"PHASE1":3039,"PHASE2":3041,"PHASE3":3043,"PHASE4":3045,"NA":3055},{"trials":3038,"activeCount":98},[],{"trials":3040,"activeCount":98},[],{"trials":3042,"activeCount":98},[],{"trials":3044,"activeCount":98},[],{"trials":3046,"activeCount":98},[3047],{"nctId":3048,"briefTitle":3049,"status":154,"phases":3050,"primaryCompletion":1452,"completion":1452,"start":1000,"enrollment":3051,"conditions":3052,"interventions":3054},"NCT01029847","Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis",[89],49,[3053],"Spondyloarthritis",[3035],{"trials":3056,"activeCount":98},[],{"intervention":1778,"totalTrials":181,"cells":3058},{"EARLY_PHASE1":3059,"PHASE1":3061,"PHASE2":3063,"PHASE3":3065,"PHASE4":3067,"NA":3073},{"trials":3060,"activeCount":98},[],{"trials":3062,"activeCount":98},[],{"trials":3064,"activeCount":98},[],{"trials":3066,"activeCount":98},[],{"trials":3068,"activeCount":98},[3069],{"nctId":1769,"briefTitle":1770,"status":154,"phases":3070,"primaryCompletion":1731,"completion":1731,"start":1772,"enrollment":1773,"conditions":3071,"interventions":3072},[89],[1775,1776],[1778,1756],{"trials":3074,"activeCount":98},[],{"intervention":3076,"totalTrials":181,"cells":3077},"rFSH",{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3082,"PHASE3":3084,"PHASE4":3086,"NA":3097},{"trials":3079,"activeCount":98},[],{"trials":3081,"activeCount":98},[],{"trials":3083,"activeCount":98},[],{"trials":3085,"activeCount":98},[],{"trials":3087,"activeCount":98},[3088],{"nctId":3089,"briefTitle":3090,"status":154,"phases":3091,"primaryCompletion":3092,"completion":3092,"start":3093,"enrollment":531,"conditions":3094,"interventions":3095},"NCT00844311","Supplementation With Human Chorionic Gonadotropin (hCG) During Controlled Ovarian Stimulation With Recombinant Follicle-stimulating Hormone (FSH) for In Vitro Fertilisation",[89],"2010-06","2009-02",[2674],[3076,3096,3096,3096],"human chorionic gonadotropin",{"trials":3098,"activeCount":98},[],{"intervention":3096,"totalTrials":181,"cells":3100},{"EARLY_PHASE1":3101,"PHASE1":3103,"PHASE2":3105,"PHASE3":3107,"PHASE4":3109,"NA":3115},{"trials":3102,"activeCount":98},[],{"trials":3104,"activeCount":98},[],{"trials":3106,"activeCount":98},[],{"trials":3108,"activeCount":98},[],{"trials":3110,"activeCount":98},[3111],{"nctId":3089,"briefTitle":3090,"status":154,"phases":3112,"primaryCompletion":3092,"completion":3092,"start":3093,"enrollment":531,"conditions":3113,"interventions":3114},[89],[2674],[3076,3096,3096,3096],{"trials":3116,"activeCount":98},[],{"intervention":3118,"totalTrials":181,"cells":3119},"Rocuronium-Sugammadex",{"EARLY_PHASE1":3120,"PHASE1":3122,"PHASE2":3124,"PHASE3":3126,"PHASE4":3128,"NA":3140},{"trials":3121,"activeCount":98},[],{"trials":3123,"activeCount":98},[],{"trials":3125,"activeCount":98},[],{"trials":3127,"activeCount":98},[],{"trials":3129,"activeCount":98},[3130],{"nctId":3131,"briefTitle":3132,"status":154,"phases":3133,"primaryCompletion":2294,"completion":3134,"start":2478,"enrollment":3135,"conditions":3136,"interventions":3138},"NCT00953550","Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine",[89],"2011-02",61,[3137],"Rapid Sequence Intubation",[3118,3139],"Succinylcholine",{"trials":3141,"activeCount":98},[],{"intervention":3139,"totalTrials":181,"cells":3143},{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3148,"PHASE3":3150,"PHASE4":3152,"NA":3158},{"trials":3145,"activeCount":98},[],{"trials":3147,"activeCount":98},[],{"trials":3149,"activeCount":98},[],{"trials":3151,"activeCount":98},[],{"trials":3153,"activeCount":98},[3154],{"nctId":3131,"briefTitle":3132,"status":154,"phases":3155,"primaryCompletion":2294,"completion":3134,"start":2478,"enrollment":3135,"conditions":3156,"interventions":3157},[89],[3137],[3118,3139],{"trials":3159,"activeCount":98},[],{"intervention":3161,"totalTrials":181,"cells":3162},"Captopril and Trandolapril",{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3169,"PHASE4":3171,"NA":3183},{"trials":3164,"activeCount":98},[],{"trials":3166,"activeCount":98},[],{"trials":3168,"activeCount":98},[],{"trials":3170,"activeCount":98},[],{"trials":3172,"activeCount":98},[3173],{"nctId":3174,"briefTitle":3175,"status":967,"phases":3176,"completion":3177,"start":3178,"enrollment":841,"conditions":3179,"interventions":3181},"NCT00252317","Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis",[89],"2008-10","2005-11",[3180],"Aortic Stenosis",[3161,3182],"Captopril Test Dose and Trandolapril",{"trials":3184,"activeCount":98},[],{"intervention":3182,"totalTrials":181,"cells":3186},{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3193,"PHASE4":3195,"NA":3201},{"trials":3188,"activeCount":98},[],{"trials":3190,"activeCount":98},[],{"trials":3192,"activeCount":98},[],{"trials":3194,"activeCount":98},[],{"trials":3196,"activeCount":98},[3197],{"nctId":3174,"briefTitle":3175,"status":967,"phases":3198,"completion":3177,"start":3178,"enrollment":841,"conditions":3199,"interventions":3200},[89],[3180],[3161,3182],{"trials":3202,"activeCount":98},[],{"intervention":3204,"totalTrials":181,"cells":3205},"Liraglutide",{"EARLY_PHASE1":3206,"PHASE1":3208,"PHASE2":3210,"PHASE3":3212,"PHASE4":3214,"NA":3227},{"trials":3207,"activeCount":98},[],{"trials":3209,"activeCount":98},[],{"trials":3211,"activeCount":98},[],{"trials":3213,"activeCount":98},[],{"trials":3215,"activeCount":98},[3216],{"nctId":3217,"briefTitle":3218,"status":154,"phases":3219,"primaryCompletion":3220,"completion":3220,"start":1965,"enrollment":1232,"conditions":3221,"interventions":3226},"NCT02655770","Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients",[89],"2019-12",[3222,3223,3224,3225],"Diabetes Mellitus Type 2","Diastolic Dysfunction","Cardiac MRI","Myocardial Perfusion",[3204],{"trials":3228,"activeCount":98},[],{"intervention":3230,"totalTrials":181,"cells":3231},"Ovitrelle",{"EARLY_PHASE1":3232,"PHASE1":3234,"PHASE2":3236,"PHASE3":3238,"PHASE4":3240,"NA":3252},{"trials":3233,"activeCount":98},[],{"trials":3235,"activeCount":98},[],{"trials":3237,"activeCount":98},[],{"trials":3239,"activeCount":98},[],{"trials":3241,"activeCount":98},[3242],{"nctId":3243,"briefTitle":3244,"status":154,"phases":3245,"primaryCompletion":3246,"completion":3246,"start":3247,"enrollment":1455,"conditions":3248,"interventions":3251},"NCT04643925","hCG Priming in Women With Low Ovarian Reserve",[89],"2021-08-31","2020-12-27",[3249,3250,2675],"Infertility, Female","Ovarian Reserve",[3230],{"trials":3253,"activeCount":98},[],{"intervention":3255,"totalTrials":181,"cells":3256},"Letrozole 2.5mg, hCG",{"EARLY_PHASE1":3257,"PHASE1":3259,"PHASE2":3261,"PHASE3":3263,"PHASE4":3265,"NA":3278},{"trials":3258,"activeCount":98},[],{"trials":3260,"activeCount":98},[],{"trials":3262,"activeCount":98},[],{"trials":3264,"activeCount":98},[],{"trials":3266,"activeCount":98},[3267],{"nctId":3268,"briefTitle":3269,"status":936,"phases":3270,"primaryCompletion":3271,"completion":3271,"start":3272,"enrollment":873,"conditions":3273,"interventions":3277},"NCT05205837","A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial",[89],"2023-08-15","2021-11-24",[3274,3275,3276],"Hypogonadism","Hypogonadism, Male","Hypogonadotropic Hypogonadism",[3255],{"trials":3279,"activeCount":98},[],{"intervention":3281,"totalTrials":181,"cells":3282},"Rocuronium 0.6 mg\u002Fkg",{"EARLY_PHASE1":3283,"PHASE1":3285,"PHASE2":3287,"PHASE3":3289,"PHASE4":3291,"NA":3306},{"trials":3284,"activeCount":98},[],{"trials":3286,"activeCount":98},[],{"trials":3288,"activeCount":98},[],{"trials":3290,"activeCount":98},[],{"trials":3292,"activeCount":98},[3293],{"nctId":3294,"briefTitle":3295,"status":154,"phases":3296,"primaryCompletion":3297,"completion":3298,"start":3299,"enrollment":2479,"conditions":3300,"interventions":3304},"NCT04287426","A Comparison of Rocuronium 0.6 mg\u002Fkg and Remifentanil 2 µg\u002Fkg in Elderly Patients Over 80 Years",[89],"2020-12-10","2020-12-13","2020-03-11",[3301,3302,3303],"Neuromuscular Blockade","Intubation Complication","Anesthesia",[3281,3305],"Remifentanil 2 µg\u002Fkg",{"trials":3307,"activeCount":98},[],{"intervention":3305,"totalTrials":181,"cells":3309},{"EARLY_PHASE1":3310,"PHASE1":3312,"PHASE2":3314,"PHASE3":3316,"PHASE4":3318,"NA":3324},{"trials":3311,"activeCount":98},[],{"trials":3313,"activeCount":98},[],{"trials":3315,"activeCount":98},[],{"trials":3317,"activeCount":98},[],{"trials":3319,"activeCount":98},[3320],{"nctId":3294,"briefTitle":3295,"status":154,"phases":3321,"primaryCompletion":3297,"completion":3298,"start":3299,"enrollment":2479,"conditions":3322,"interventions":3323},[89],[3301,3302,3303],[3281,3305],{"trials":3325,"activeCount":98},[],{"intervention":2408,"totalTrials":181,"cells":3327},{"EARLY_PHASE1":3328,"PHASE1":3330,"PHASE2":3332,"PHASE3":3334,"PHASE4":3336,"NA":3342},{"trials":3329,"activeCount":98},[],{"trials":3331,"activeCount":98},[],{"trials":3333,"activeCount":98},[],{"trials":3335,"activeCount":98},[],{"trials":3337,"activeCount":98},[3338],{"nctId":2399,"briefTitle":2400,"status":936,"phases":3339,"primaryCompletion":2402,"completion":2402,"start":2403,"enrollment":2404,"conditions":3340,"interventions":3341},[89],[2406],[2373,2408],{"trials":3343,"activeCount":98},[],{"intervention":3345,"totalTrials":181,"cells":3346},"Xylometazoline 0,1%",{"EARLY_PHASE1":3347,"PHASE1":3349,"PHASE2":3351,"PHASE3":3353,"PHASE4":3355,"NA":3369},{"trials":3348,"activeCount":98},[],{"trials":3350,"activeCount":98},[],{"trials":3352,"activeCount":98},[],{"trials":3354,"activeCount":98},[],{"trials":3356,"activeCount":98},[3357],{"nctId":3358,"briefTitle":3359,"status":154,"phases":3360,"primaryCompletion":3361,"completion":3362,"start":3363,"enrollment":3364,"conditions":3365,"interventions":3367},"NCT05334017","Xylometazoline and Cocaine for Nasal Vasoconstriction",[89],"2023-03-21","2023-03-22","2022-09-08",120,[3366],"Epistaxis",[3345,3368],"Cocaine 4%",{"trials":3370,"activeCount":98},[],{"intervention":3368,"totalTrials":181,"cells":3372},{"EARLY_PHASE1":3373,"PHASE1":3375,"PHASE2":3377,"PHASE3":3379,"PHASE4":3381,"NA":3387},{"trials":3374,"activeCount":98},[],{"trials":3376,"activeCount":98},[],{"trials":3378,"activeCount":98},[],{"trials":3380,"activeCount":98},[],{"trials":3382,"activeCount":98},[3383],{"nctId":3358,"briefTitle":3359,"status":154,"phases":3384,"primaryCompletion":3361,"completion":3362,"start":3363,"enrollment":3364,"conditions":3385,"interventions":3386},[89],[3366],[3345,3368],{"trials":3388,"activeCount":98},[],{"intervention":2484,"totalTrials":181,"cells":3390},{"EARLY_PHASE1":3391,"PHASE1":3393,"PHASE2":3395,"PHASE3":3397,"PHASE4":3399,"NA":3405},{"trials":3392,"activeCount":98},[],{"trials":3394,"activeCount":98},[],{"trials":3396,"activeCount":98},[],{"trials":3398,"activeCount":98},[],{"trials":3400,"activeCount":98},[3401],{"nctId":2474,"briefTitle":2475,"status":154,"phases":3402,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":2479,"conditions":3403,"interventions":3404},[89],[2481,2482],[2484,2461],{"trials":3406,"activeCount":98},[],{"intervention":2324,"totalTrials":181,"cells":3408},{"EARLY_PHASE1":3409,"PHASE1":3411,"PHASE2":3413,"PHASE3":3415,"PHASE4":3417,"NA":3423},{"trials":3410,"activeCount":98},[],{"trials":3412,"activeCount":98},[],{"trials":3414,"activeCount":98},[],{"trials":3416,"activeCount":98},[],{"trials":3418,"activeCount":98},[3419],{"nctId":2317,"briefTitle":2318,"status":154,"phases":3420,"primaryCompletion":2320,"completion":2320,"start":2321,"enrollment":2322,"conditions":3421,"interventions":3422},[89],[2324,896],[2324,953,954],{"trials":3424,"activeCount":98},[],{"intervention":3426,"totalTrials":181,"cells":3427},"Insulin Detemir; Insulin Insulatard",{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3432,"PHASE3":3434,"PHASE4":3436,"NA":3448},{"trials":3429,"activeCount":98},[],{"trials":3431,"activeCount":98},[],{"trials":3433,"activeCount":98},[],{"trials":3435,"activeCount":98},[],{"trials":3437,"activeCount":98},[3438],{"nctId":3439,"briefTitle":3440,"status":154,"phases":3441,"primaryCompletion":1000,"completion":1000,"start":2627,"enrollment":3442,"conditions":3443,"interventions":3446},"NCT00742976","Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients",[89],24,[3444,3445],"Diabetes Type 2","Weight Gain",[3426,3447],"Insulin Detemir, Insulin Insulatard",{"trials":3449,"activeCount":98},[],{"intervention":3447,"totalTrials":181,"cells":3451},{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3456,"PHASE3":3458,"PHASE4":3460,"NA":3466},{"trials":3453,"activeCount":98},[],{"trials":3455,"activeCount":98},[],{"trials":3457,"activeCount":98},[],{"trials":3459,"activeCount":98},[],{"trials":3461,"activeCount":98},[3462],{"nctId":3439,"briefTitle":3440,"status":154,"phases":3463,"primaryCompletion":1000,"completion":1000,"start":2627,"enrollment":3442,"conditions":3464,"interventions":3465},[89],[3444,3445],[3426,3447],{"trials":3467,"activeCount":98},[],{"intervention":3469,"totalTrials":181,"cells":3470},"Empagliflozin",{"EARLY_PHASE1":3471,"PHASE1":3473,"PHASE2":3475,"PHASE3":3477,"PHASE4":3479,"NA":3491},{"trials":3472,"activeCount":98},[],{"trials":3474,"activeCount":98},[],{"trials":3476,"activeCount":98},[],{"trials":3478,"activeCount":98},[],{"trials":3480,"activeCount":98},[3481],{"nctId":3482,"briefTitle":3483,"status":154,"phases":3484,"primaryCompletion":3485,"completion":3486,"start":3487,"enrollment":3488,"conditions":3489,"interventions":3490},"NCT06171802","EMPagliflozin After Aortic Valve Replacement",[89],"2026-05-08","2026-05-18","2024-02-14",206,[1787],[3469],{"trials":3492,"activeCount":98},[],{"intervention":1441,"totalTrials":181,"cells":3494},{"EARLY_PHASE1":3495,"PHASE1":3497,"PHASE2":3499,"PHASE3":3501,"PHASE4":3503,"NA":3509},{"trials":3496,"activeCount":98},[],{"trials":3498,"activeCount":98},[],{"trials":3500,"activeCount":98},[],{"trials":3502,"activeCount":98},[],{"trials":3504,"activeCount":98},[3505],{"nctId":1433,"briefTitle":1434,"status":154,"phases":3506,"primaryCompletion":1000,"completion":1436,"start":1437,"enrollment":158,"conditions":3507,"interventions":3508},[89],[1439],[1441,975],{"trials":3510,"activeCount":98},[],{"intervention":3512,"totalTrials":181,"cells":3513},"Adductor canal block with 20 ml lidocaine, single bolus",{"EARLY_PHASE1":3514,"PHASE1":3516,"PHASE2":3518,"PHASE3":3520,"PHASE4":3522,"NA":3532},{"trials":3515,"activeCount":98},[],{"trials":3517,"activeCount":98},[],{"trials":3519,"activeCount":98},[],{"trials":3521,"activeCount":98},[],{"trials":3523,"activeCount":98},[3524],{"nctId":3525,"briefTitle":3526,"status":154,"phases":3527,"primaryCompletion":3528,"completion":3528,"start":1206,"enrollment":3529,"conditions":3530,"interventions":3531},"NCT02172729","The Effect of Different Doses (Mass) of Local Anesthetic on Duration of Adductor Canal Block in Healthy Volunteers - Part 2",[89],"2014-07",14,[18],[3512],{"trials":3533,"activeCount":98},[],{"intervention":3535,"totalTrials":181,"cells":3536},"Evolocumab or Alirocumab",{"EARLY_PHASE1":3537,"PHASE1":3539,"PHASE2":3541,"PHASE3":3543,"PHASE4":3545,"NA":3557},{"trials":3538,"activeCount":98},[],{"trials":3540,"activeCount":98},[],{"trials":3542,"activeCount":98},[],{"trials":3544,"activeCount":98},[],{"trials":3546,"activeCount":98},[3547],{"nctId":3548,"briefTitle":3549,"status":3550,"phases":3551,"primaryCompletion":3552,"completion":1419,"start":3553,"enrollment":98,"conditions":3554,"interventions":3556},"NCT02941016","Vascular Inflammation and Cholesterol Lowering Therapy","WITHDRAWN",[89],"2020-10","2016-10",[3555],"Lipid Lowering, Vascular Inflammation",[3535],{"trials":3558,"activeCount":98},[],{"intervention":2368,"totalTrials":181,"cells":3560},{"EARLY_PHASE1":3561,"PHASE1":3563,"PHASE2":3565,"PHASE3":3567,"PHASE4":3569,"NA":3575},{"trials":3562,"activeCount":98},[],{"trials":3564,"activeCount":98},[],{"trials":3566,"activeCount":98},[],{"trials":3568,"activeCount":98},[],{"trials":3570,"activeCount":98},[3571],{"nctId":2360,"briefTitle":2361,"status":154,"phases":3572,"primaryCompletion":2363,"completion":2363,"start":2364,"enrollment":2365,"conditions":3573,"interventions":3574},[89],[2354,2356],[2368,2369],{"trials":3576,"activeCount":98},[],{"intervention":3578,"totalTrials":181,"cells":3579},"Felodipine",{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3586,"PHASE4":3588,"NA":3599},{"trials":3581,"activeCount":98},[],{"trials":3583,"activeCount":98},[],{"trials":3585,"activeCount":98},[],{"trials":3587,"activeCount":98},[],{"trials":3589,"activeCount":98},[3590],{"nctId":3591,"briefTitle":3592,"status":154,"phases":3593,"primaryCompletion":3594,"completion":3553,"start":2737,"enrollment":3595,"conditions":3596,"interventions":3598},"NCT02744872","Copenhagen Acute Renal Complications After Transplantations Study Group",[89],"2016-07",42,[3597],"Disorder Related to Lung Transplantation",[3578],{"trials":3600,"activeCount":98},[],{"intervention":3602,"totalTrials":181,"cells":3603},"Hydroxyethylstarch 130\u002F0,4",{"EARLY_PHASE1":3604,"PHASE1":3606,"PHASE2":3608,"PHASE3":3610,"PHASE4":3612,"NA":3624},{"trials":3605,"activeCount":98},[],{"trials":3607,"activeCount":98},[],{"trials":3609,"activeCount":98},[],{"trials":3611,"activeCount":98},[],{"trials":3613,"activeCount":98},[3614],{"nctId":3615,"briefTitle":3616,"status":967,"phases":3617,"primaryCompletion":2478,"completion":2478,"start":3618,"enrollment":3619,"conditions":3620,"interventions":3622},"NCT00431743","Fluid Infusion During Breast Surgery",[89],"2009-04",32,[3621],"Breast Surgery",[3602,3623],"Lactated Ringer's solution",{"trials":3625,"activeCount":98},[],{"intervention":3623,"totalTrials":181,"cells":3627},{"EARLY_PHASE1":3628,"PHASE1":3630,"PHASE2":3632,"PHASE3":3634,"PHASE4":3636,"NA":3642},{"trials":3629,"activeCount":98},[],{"trials":3631,"activeCount":98},[],{"trials":3633,"activeCount":98},[],{"trials":3635,"activeCount":98},[],{"trials":3637,"activeCount":98},[3638],{"nctId":3615,"briefTitle":3616,"status":967,"phases":3639,"primaryCompletion":2478,"completion":2478,"start":3618,"enrollment":3619,"conditions":3640,"interventions":3641},[89],[3621],[3602,3623],{"trials":3643,"activeCount":98},[],{"intervention":3645,"totalTrials":181,"cells":3646},"Treatment with mycophenolat mofetil",{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3651,"PHASE3":3653,"PHASE4":3655,"NA":3665},{"trials":3648,"activeCount":98},[],{"trials":3650,"activeCount":98},[],{"trials":3652,"activeCount":98},[],{"trials":3654,"activeCount":98},[],{"trials":3656,"activeCount":98},[3657],{"nctId":3658,"briefTitle":3659,"status":154,"phases":3660,"conditions":3661,"interventions":3663},"NCT00687180","Mycophenolate vs Azathioprin in Autoimmune Hepatitis",[89],[3662],"Autoimmune Hepatitis",[3645,3664],"Treatment with azathioprin",{"trials":3666,"activeCount":98},[],{"intervention":3664,"totalTrials":181,"cells":3668},{"EARLY_PHASE1":3669,"PHASE1":3671,"PHASE2":3673,"PHASE3":3675,"PHASE4":3677,"NA":3683},{"trials":3670,"activeCount":98},[],{"trials":3672,"activeCount":98},[],{"trials":3674,"activeCount":98},[],{"trials":3676,"activeCount":98},[],{"trials":3678,"activeCount":98},[3679],{"nctId":3658,"briefTitle":3659,"status":154,"phases":3680,"conditions":3681,"interventions":3682},[89],[3662],[3645,3664],{"trials":3684,"activeCount":98},[],{"intervention":3686,"totalTrials":181,"cells":3687},"HTK Custodiol",{"EARLY_PHASE1":3688,"PHASE1":3690,"PHASE2":3692,"PHASE3":3694,"PHASE4":3696,"NA":3708},{"trials":3689,"activeCount":98},[],{"trials":3691,"activeCount":98},[],{"trials":3693,"activeCount":98},[],{"trials":3695,"activeCount":98},[],{"trials":3697,"activeCount":98},[3698],{"nctId":3699,"briefTitle":3700,"status":154,"phases":3701,"primaryCompletion":3702,"completion":3702,"start":3703,"enrollment":3704,"conditions":3705,"interventions":3707},"NCT01614951","The Pulmonary Protection Trial",[89],"2013-11","2012-07",90,[3706],"Chronic Obstructive Lung Disease",[3686],{"trials":3709,"activeCount":98},[],{"intervention":3711,"totalTrials":181,"cells":3712},"Voltaren Ophtha 1 mg\u002Fml, GSK",{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3717,"PHASE3":3719,"PHASE4":3721,"NA":3733},{"trials":3714,"activeCount":98},[],{"trials":3716,"activeCount":98},[],{"trials":3718,"activeCount":98},[],{"trials":3720,"activeCount":98},[],{"trials":3722,"activeCount":98},[3723],{"nctId":3724,"briefTitle":3725,"status":967,"phases":3726,"primaryCompletion":3727,"completion":3728,"start":3729,"enrollment":827,"conditions":3730,"interventions":3731},"NCT04054830","Steroids and\u002F or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy.",[89],"2022-06-15","2023-07","2019-08-01",[257],[3711,3732],"Monopex 1 mg\u002Fml, Théa",{"trials":3734,"activeCount":98},[],{"intervention":3732,"totalTrials":181,"cells":3736},{"EARLY_PHASE1":3737,"PHASE1":3739,"PHASE2":3741,"PHASE3":3743,"PHASE4":3745,"NA":3751},{"trials":3738,"activeCount":98},[],{"trials":3740,"activeCount":98},[],{"trials":3742,"activeCount":98},[],{"trials":3744,"activeCount":98},[],{"trials":3746,"activeCount":98},[3747],{"nctId":3724,"briefTitle":3725,"status":967,"phases":3748,"primaryCompletion":3727,"completion":3728,"start":3729,"enrollment":827,"conditions":3749,"interventions":3750},[89],[257],[3711,3732],{"trials":3752,"activeCount":98},[],{"intervention":3754,"totalTrials":181,"cells":3755},"Study medication, azithromycin or placebo",{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3760,"PHASE3":3762,"PHASE4":3764,"NA":3775},{"trials":3757,"activeCount":98},[],{"trials":3759,"activeCount":98},[],{"trials":3761,"activeCount":98},[],{"trials":3763,"activeCount":98},[],{"trials":3765,"activeCount":98},[3766],{"nctId":3767,"briefTitle":3768,"status":154,"phases":3769,"primaryCompletion":1452,"completion":1453,"start":3770,"enrollment":940,"conditions":3771,"interventions":3773},"NCT00411736","Scandinavian Cystic Fibrosis Azithromycin Study",[89],"2008-05",[3772],"Cystic Fibrosis",[3754,3774],"Azithromycin or placebo",{"trials":3776,"activeCount":98},[],{"intervention":3774,"totalTrials":181,"cells":3778},{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3785,"PHASE4":3787,"NA":3793},{"trials":3780,"activeCount":98},[],{"trials":3782,"activeCount":98},[],{"trials":3784,"activeCount":98},[],{"trials":3786,"activeCount":98},[],{"trials":3788,"activeCount":98},[3789],{"nctId":3767,"briefTitle":3768,"status":154,"phases":3790,"primaryCompletion":1452,"completion":1453,"start":3770,"enrollment":940,"conditions":3791,"interventions":3792},[89],[3772],[3754,3774],{"trials":3794,"activeCount":98},[],{"intervention":3796,"totalTrials":181,"cells":3797},"MMRvaxpro",{"EARLY_PHASE1":3798,"PHASE1":3800,"PHASE2":3802,"PHASE3":3804,"PHASE4":3806,"NA":3818},{"trials":3799,"activeCount":98},[],{"trials":3801,"activeCount":98},[],{"trials":3803,"activeCount":98},[],{"trials":3805,"activeCount":98},[],{"trials":3807,"activeCount":98},[3808],{"nctId":3809,"briefTitle":3810,"status":154,"phases":3811,"primaryCompletion":3812,"completion":3812,"start":3813,"enrollment":3814,"conditions":3815,"interventions":3817},"NCT03780179","MMR at 6 Months Trial",[89],"2022-01-07","2019-04-15",6540,[3816],"Meales-mumps-rubella Vaccine",[3796],{"trials":3819,"activeCount":98},[],{"intervention":3821,"totalTrials":181,"cells":3822},"Low dose naltrexone",{"EARLY_PHASE1":3823,"PHASE1":3825,"PHASE2":3827,"PHASE3":3829,"PHASE4":3831,"NA":3844},{"trials":3824,"activeCount":98},[],{"trials":3826,"activeCount":98},[],{"trials":3828,"activeCount":98},[],{"trials":3830,"activeCount":98},[],{"trials":3832,"activeCount":98},[3833],{"nctId":3834,"briefTitle":3835,"status":154,"phases":3836,"primaryCompletion":3837,"completion":3838,"start":3839,"enrollment":3840,"conditions":3841,"interventions":3843},"NCT02806440","Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism?",[89],"2019-12-01","2022-09-01","2016-06",58,[3842],"Fibromyalgia",[3821],{"trials":3845,"activeCount":98},[],{"intervention":3847,"totalTrials":181,"cells":3848},"Cytotec",{"EARLY_PHASE1":3849,"PHASE1":3851,"PHASE2":3853,"PHASE3":3855,"PHASE4":3857,"NA":3867},{"trials":3850,"activeCount":98},[],{"trials":3852,"activeCount":98},[],{"trials":3854,"activeCount":98},[],{"trials":3856,"activeCount":98},[],{"trials":3858,"activeCount":98},[3859],{"nctId":3860,"briefTitle":3861,"status":967,"phases":3862,"completion":1437,"enrollment":1601,"conditions":3863,"interventions":3866},"NCT00256009","Treatment of Late Abortion: Evacuatio Uteri or Conservative Treatment",[89],[3864,3865],"Abortion, Spontaneous","Abortion, Induced",[3847],{"trials":3868,"activeCount":98},[],{"intervention":3870,"totalTrials":181,"cells":3871},"Bosentan and Sildenafil",{"EARLY_PHASE1":3872,"PHASE1":3874,"PHASE2":3876,"PHASE3":3878,"PHASE4":3889,"NA":3891},{"trials":3873,"activeCount":98},[],{"trials":3875,"activeCount":98},[],{"trials":3877,"activeCount":98},[],{"trials":3879,"activeCount":98},[3880],{"nctId":3881,"briefTitle":3882,"status":154,"phases":3883,"primaryCompletion":3884,"completion":3884,"start":3885,"enrollment":1455,"conditions":3886,"interventions":3888},"NCT00303004","Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome",[88],"2008-01","2006-03",[3887],"Eisenmenger Syndrome",[3870],{"trials":3890,"activeCount":98},[],{"trials":3892,"activeCount":98},[],{"intervention":3894,"totalTrials":181,"cells":3895},"Adrenaline",{"EARLY_PHASE1":3896,"PHASE1":3898,"PHASE2":3900,"PHASE3":3902,"PHASE4":3913,"NA":3915},{"trials":3897,"activeCount":98},[],{"trials":3899,"activeCount":98},[],{"trials":3901,"activeCount":98},[],{"trials":3903,"activeCount":98},[3904],{"nctId":3905,"briefTitle":3906,"status":154,"phases":3907,"primaryCompletion":2737,"completion":2737,"start":3908,"enrollment":3909,"conditions":3910,"interventions":3912},"NCT01708642","The Effect of Administration of Low Dose Adrenaline During Surgery on Bleeding During Hip Surgery",[88],"2012-11",106,[3911],"Intraoperative Blood Loss",[3894],{"trials":3914,"activeCount":98},[],{"trials":3916,"activeCount":98},[],{"intervention":3918,"totalTrials":181,"cells":3919},"Intravenous immunoglobulin",{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3926,"PHASE4":3938,"NA":3940},{"trials":3921,"activeCount":98},[],{"trials":3923,"activeCount":98},[],{"trials":3925,"activeCount":98},[],{"trials":3927,"activeCount":98},[3928],{"nctId":3929,"briefTitle":3930,"status":154,"phases":3931,"primaryCompletion":1833,"completion":1833,"start":3932,"enrollment":3933,"conditions":3934,"interventions":3936},"NCT00722475","Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage",[88],"2008-08",82,[3935],"Secondary Recurrent Miscarriage",[3918,3937],"Human albumin",{"trials":3939,"activeCount":98},[],{"trials":3941,"activeCount":98},[],{"intervention":3937,"totalTrials":181,"cells":3943},{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3948,"PHASE3":3950,"PHASE4":3956,"NA":3958},{"trials":3945,"activeCount":98},[],{"trials":3947,"activeCount":98},[],{"trials":3949,"activeCount":98},[],{"trials":3951,"activeCount":98},[3952],{"nctId":3929,"briefTitle":3930,"status":154,"phases":3953,"primaryCompletion":1833,"completion":1833,"start":3932,"enrollment":3933,"conditions":3954,"interventions":3955},[88],[3935],[3918,3937],{"trials":3957,"activeCount":98},[],{"trials":3959,"activeCount":98},[],{"intervention":3961,"totalTrials":181,"cells":3962},"Cociane hydrochloride 4%",{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3967,"PHASE3":3969,"PHASE4":3981,"NA":3983},{"trials":3964,"activeCount":98},[],{"trials":3966,"activeCount":98},[],{"trials":3968,"activeCount":98},[],{"trials":3970,"activeCount":98},[3971],{"nctId":3972,"briefTitle":3973,"status":154,"phases":3974,"primaryCompletion":3975,"completion":3975,"start":3976,"enrollment":1390,"conditions":3977,"interventions":3978},"NCT06443255","Cocaine, Lidocaine\u002Fxylometazoline and Saline for Nasal Analgesia",[88],"2024-08-27","2024-07-01",[891],[3961,3979,3980,1491],"Lidocaine 4%","Xylometazoline 0.1%",{"trials":3982,"activeCount":98},[],{"trials":3984,"activeCount":98},[],{"intervention":3979,"totalTrials":181,"cells":3986},{"EARLY_PHASE1":3987,"PHASE1":3989,"PHASE2":3991,"PHASE3":3993,"PHASE4":3999,"NA":4001},{"trials":3988,"activeCount":98},[],{"trials":3990,"activeCount":98},[],{"trials":3992,"activeCount":98},[],{"trials":3994,"activeCount":98},[3995],{"nctId":3972,"briefTitle":3973,"status":154,"phases":3996,"primaryCompletion":3975,"completion":3975,"start":3976,"enrollment":1390,"conditions":3997,"interventions":3998},[88],[891],[3961,3979,3980,1491],{"trials":4000,"activeCount":98},[],{"trials":4002,"activeCount":98},[],{"intervention":3980,"totalTrials":181,"cells":4004},{"EARLY_PHASE1":4005,"PHASE1":4007,"PHASE2":4009,"PHASE3":4011,"PHASE4":4017,"NA":4019},{"trials":4006,"activeCount":98},[],{"trials":4008,"activeCount":98},[],{"trials":4010,"activeCount":98},[],{"trials":4012,"activeCount":98},[4013],{"nctId":3972,"briefTitle":3973,"status":154,"phases":4014,"primaryCompletion":3975,"completion":3975,"start":3976,"enrollment":1390,"conditions":4015,"interventions":4016},[88],[891],[3961,3979,3980,1491],{"trials":4018,"activeCount":98},[],{"trials":4020,"activeCount":98},[],{"intervention":4022,"totalTrials":181,"cells":4023},"capsaicin patch",{"EARLY_PHASE1":4024,"PHASE1":4026,"PHASE2":4028,"PHASE3":4030,"PHASE4":4041,"NA":4043},{"trials":4025,"activeCount":98},[],{"trials":4027,"activeCount":98},[],{"trials":4029,"activeCount":98},[],{"trials":4031,"activeCount":98},[4032],{"nctId":4033,"briefTitle":4034,"status":936,"phases":4035,"primaryCompletion":2737,"completion":2737,"start":4036,"enrollment":4037,"conditions":4038,"interventions":4040},"NCT01699854","Capsaicin Patch 8 % for the Treatment of Persistent Pain After Inguinal Herniotomy",[88],"2012-08",50,[4039],"Persistent Pain After Inguinal Herniotomy",[4022],{"trials":4042,"activeCount":98},[],{"trials":4044,"activeCount":98},[],{"intervention":4046,"totalTrials":181,"cells":4047},"Cholecalciferol and calcium",{"EARLY_PHASE1":4048,"PHASE1":4050,"PHASE2":4052,"PHASE3":4054,"PHASE4":4066,"NA":4068},{"trials":4049,"activeCount":98},[],{"trials":4051,"activeCount":98},[],{"trials":4053,"activeCount":98},[],{"trials":4055,"activeCount":98},[4056],{"nctId":4057,"briefTitle":4058,"status":154,"phases":4059,"primaryCompletion":4060,"completion":4061,"start":3134,"enrollment":4062,"conditions":4063,"interventions":4065},"NCT01304927","Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical Trial",[87,88],"2014-12","2016-05",307,[4064],"Male Infertility",[4046],{"trials":4067,"activeCount":98},[],{"trials":4069,"activeCount":98},[],{"intervention":4071,"totalTrials":181,"cells":4072},"phleum pratense",{"EARLY_PHASE1":4073,"PHASE1":4075,"PHASE2":4077,"PHASE3":4079,"PHASE4":4089,"NA":4091},{"trials":4074,"activeCount":98},[],{"trials":4076,"activeCount":98},[],{"trials":4078,"activeCount":98},[],{"trials":4080,"activeCount":98},[4081],{"nctId":4082,"briefTitle":4083,"status":154,"phases":4084,"primaryCompletion":3908,"completion":3908,"start":4085,"enrollment":2392,"conditions":4086,"interventions":4088},"NCT01166269","Study to Asses Efficacy of Intralymphatic Immunotherapy",[87,88],"2010-07",[4087],"Allergy",[4071,4071],{"trials":4090,"activeCount":98},[],{"trials":4092,"activeCount":98},[],{"intervention":4094,"totalTrials":181,"cells":4095},"Opioids taper off",{"EARLY_PHASE1":4096,"PHASE1":4098,"PHASE2":4100,"PHASE3":4102,"PHASE4":4114,"NA":4116},{"trials":4097,"activeCount":98},[],{"trials":4099,"activeCount":98},[],{"trials":4101,"activeCount":98},[],{"trials":4103,"activeCount":98},[4104],{"nctId":4105,"briefTitle":4106,"status":154,"phases":4107,"primaryCompletion":4108,"completion":4108,"start":4109,"enrollment":3028,"conditions":4110,"interventions":4112},"NCT03365817","Cognitive Function and Addiction Under Opioid Tapering",[88],"2014-12-01","2009-02-02",[2872,4111],"Opioid Use",[4094,4113],"Opioid stable treatment",{"trials":4115,"activeCount":98},[],{"trials":4117,"activeCount":98},[],{"intervention":4113,"totalTrials":181,"cells":4119},{"EARLY_PHASE1":4120,"PHASE1":4122,"PHASE2":4124,"PHASE3":4126,"PHASE4":4132,"NA":4134},{"trials":4121,"activeCount":98},[],{"trials":4123,"activeCount":98},[],{"trials":4125,"activeCount":98},[],{"trials":4127,"activeCount":98},[4128],{"nctId":4105,"briefTitle":4106,"status":154,"phases":4129,"primaryCompletion":4108,"completion":4108,"start":4109,"enrollment":3028,"conditions":4130,"interventions":4131},[88],[2872,4111],[4094,4113],{"trials":4133,"activeCount":98},[],{"trials":4135,"activeCount":98},[],{"intervention":4137,"totalTrials":181,"cells":4138},"lidocaine patch",{"EARLY_PHASE1":4139,"PHASE1":4141,"PHASE2":4143,"PHASE3":4145,"PHASE4":4156,"NA":4158},{"trials":4140,"activeCount":98},[],{"trials":4142,"activeCount":98},[],{"trials":4144,"activeCount":98},[],{"trials":4146,"activeCount":98},[4147],{"nctId":4148,"briefTitle":4149,"status":154,"phases":4150,"primaryCompletion":4151,"completion":4151,"start":4152,"enrollment":1672,"conditions":4153,"interventions":4155},"NCT01443325","Lidocaine Patch for Treatment of Persistent Inguinal Postherniorrhaphy Pain",[88],"2012-06","2011-09",[4154],"Inguinal Pain",[4137],{"trials":4157,"activeCount":98},[],{"trials":4159,"activeCount":98},[],{"intervention":4161,"totalTrials":181,"cells":4162},"Carboplatin and Paclitaxel",{"EARLY_PHASE1":4163,"PHASE1":4165,"PHASE2":4167,"PHASE3":4169,"PHASE4":4180,"NA":4182},{"trials":4164,"activeCount":98},[],{"trials":4166,"activeCount":98},[],{"trials":4168,"activeCount":98},[],{"trials":4170,"activeCount":98},[4171],{"nctId":4172,"briefTitle":4173,"status":936,"phases":4174,"completion":2490,"start":4175,"enrollment":4176,"conditions":4177,"interventions":4179},"NCT00273507","Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA\u002FT3",[88],"1998-01",270,[4178],"Non-small Cell Lung Cancer",[4161],{"trials":4181,"activeCount":98},[],{"trials":4183,"activeCount":98},[],{"intervention":4185,"totalTrials":181,"cells":4186},"Faster-acting Aspart insulin Fiasp",{"EARLY_PHASE1":4187,"PHASE1":4189,"PHASE2":4191,"PHASE3":4193,"PHASE4":4207,"NA":4209},{"trials":4188,"activeCount":98},[],{"trials":4190,"activeCount":98},[],{"trials":4192,"activeCount":98},[],{"trials":4194,"activeCount":98},[4195],{"nctId":4196,"briefTitle":4197,"status":154,"phases":4198,"primaryCompletion":4199,"completion":4199,"start":4200,"enrollment":4201,"conditions":4202,"interventions":4205},"NCT03770767","Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes",[88],"2023-03-23","2019-11-11",216,[4203,4204],"Diabetes Mellitus","Pregnancy Complications",[4185,4206],"Control",{"trials":4208,"activeCount":98},[],{"trials":4210,"activeCount":98},[],{"intervention":4206,"totalTrials":181,"cells":4212},{"EARLY_PHASE1":4213,"PHASE1":4215,"PHASE2":4217,"PHASE3":4219,"PHASE4":4225,"NA":4227},{"trials":4214,"activeCount":98},[],{"trials":4216,"activeCount":98},[],{"trials":4218,"activeCount":98},[],{"trials":4220,"activeCount":98},[4221],{"nctId":4196,"briefTitle":4197,"status":154,"phases":4222,"primaryCompletion":4199,"completion":4199,"start":4200,"enrollment":4201,"conditions":4223,"interventions":4224},[88],[4203,4204],[4185,4206],{"trials":4226,"activeCount":98},[],{"trials":4228,"activeCount":98},[],{"intervention":4230,"totalTrials":181,"cells":4231},"Xenon vs propofol",{"EARLY_PHASE1":4232,"PHASE1":4234,"PHASE2":4236,"PHASE3":4238,"PHASE4":4250,"NA":4252},{"trials":4233,"activeCount":98},[],{"trials":4235,"activeCount":98},[],{"trials":4237,"activeCount":98},[],{"trials":4239,"activeCount":98},[4240],{"nctId":4241,"briefTitle":4242,"status":154,"phases":4243,"completion":4244,"start":4245,"enrollment":2392,"conditions":4246,"interventions":4249},"NCT00192959","Xenon Inhalation During Orthopaedic Surgery in Elderly Subjects.",[88],"2004-12","2004-03",[4247,4248],"Anaesthesia","Postoperative Cognitive Function",[4230],{"trials":4251,"activeCount":98},[],{"trials":4253,"activeCount":98},[],{"intervention":4255,"totalTrials":181,"cells":4256},"6MPindividualized",{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4261,"PHASE3":4263,"PHASE4":4275,"NA":4277},{"trials":4258,"activeCount":98},[],{"trials":4260,"activeCount":98},[],{"trials":4262,"activeCount":98},[],{"trials":4264,"activeCount":98},[4265],{"nctId":4266,"briefTitle":4267,"status":154,"phases":4268,"primaryCompletion":4269,"completion":4269,"start":1437,"enrollment":4270,"conditions":4271,"interventions":4273},"NCT00816049","ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy",[88],"2016-03-02",775,[4272],"Acute Lymphoblastic Leukemia",[4255,4274],"6MPfixed",{"trials":4276,"activeCount":98},[],{"trials":4278,"activeCount":98},[],{"intervention":4274,"totalTrials":181,"cells":4280},{"EARLY_PHASE1":4281,"PHASE1":4283,"PHASE2":4285,"PHASE3":4287,"PHASE4":4293,"NA":4295},{"trials":4282,"activeCount":98},[],{"trials":4284,"activeCount":98},[],{"trials":4286,"activeCount":98},[],{"trials":4288,"activeCount":98},[4289],{"nctId":4266,"briefTitle":4267,"status":154,"phases":4290,"primaryCompletion":4269,"completion":4269,"start":1437,"enrollment":4270,"conditions":4291,"interventions":4292},[88],[4272],[4255,4274],{"trials":4294,"activeCount":98},[],{"trials":4296,"activeCount":98},[],{"intervention":4298,"totalTrials":181,"cells":4299},"Pirfenidone",{"EARLY_PHASE1":4300,"PHASE1":4302,"PHASE2":4304,"PHASE3":4306,"PHASE4":4315,"NA":4317},{"trials":4301,"activeCount":98},[],{"trials":4303,"activeCount":98},[],{"trials":4305,"activeCount":98},[],{"trials":4307,"activeCount":98},[4308],{"nctId":4309,"briefTitle":4310,"status":154,"phases":4311,"primaryCompletion":3220,"completion":3220,"start":1436,"enrollment":3704,"conditions":4312,"interventions":4314},"NCT02262299","European Trial of Pirfenidone in BOS, A European Multi-center Study",[87,88],[3597,4313],"CLAD, Bronchiolitis Obliterans",[4298],{"trials":4316,"activeCount":98},[],{"trials":4318,"activeCount":98},[],{"intervention":1842,"totalTrials":181,"cells":4320},{"EARLY_PHASE1":4321,"PHASE1":4323,"PHASE2":4325,"PHASE3":4327,"PHASE4":4333,"NA":4335},{"trials":4322,"activeCount":98},[],{"trials":4324,"activeCount":98},[],{"trials":4326,"activeCount":98},[],{"trials":4328,"activeCount":98},[4329],{"nctId":1830,"briefTitle":1831,"status":967,"phases":4330,"primaryCompletion":1833,"completion":1709,"start":1834,"enrollment":1835,"conditions":4331,"interventions":4332},[88],[1837,1838,1839,1840],[1842,1843],{"trials":4334,"activeCount":98},[],{"trials":4336,"activeCount":98},[],{"intervention":4338,"totalTrials":181,"cells":4339},"Hydroxychloroquine",{"EARLY_PHASE1":4340,"PHASE1":4342,"PHASE2":4344,"PHASE3":4346,"PHASE4":4360,"NA":4362},{"trials":4341,"activeCount":98},[],{"trials":4343,"activeCount":98},[],{"trials":4345,"activeCount":98},[],{"trials":4347,"activeCount":98},[4348],{"nctId":4349,"briefTitle":4350,"status":967,"phases":4351,"primaryCompletion":4352,"completion":4353,"start":4354,"enrollment":4355,"conditions":4356,"interventions":4358},"NCT03305263","Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss",[88],"2022-01","2023-01","2018-01-25",186,[4357],"Recurrent Pregnancy Loss",[4338,4359],"Hydroxychloroquine placebo",{"trials":4361,"activeCount":98},[],{"trials":4363,"activeCount":98},[],{"intervention":4359,"totalTrials":181,"cells":4365},{"EARLY_PHASE1":4366,"PHASE1":4368,"PHASE2":4370,"PHASE3":4372,"PHASE4":4378,"NA":4380},{"trials":4367,"activeCount":98},[],{"trials":4369,"activeCount":98},[],{"trials":4371,"activeCount":98},[],{"trials":4373,"activeCount":98},[4374],{"nctId":4349,"briefTitle":4350,"status":967,"phases":4375,"primaryCompletion":4352,"completion":4353,"start":4354,"enrollment":4355,"conditions":4376,"interventions":4377},[88],[4357],[4338,4359],{"trials":4379,"activeCount":98},[],{"trials":4381,"activeCount":98},[],{"intervention":4383,"totalTrials":181,"cells":4384},"Midodrine",{"EARLY_PHASE1":4385,"PHASE1":4387,"PHASE2":4389,"PHASE3":4391,"PHASE4":4402,"NA":4404},{"trials":4386,"activeCount":98},[],{"trials":4388,"activeCount":98},[],{"trials":4390,"activeCount":98},[],{"trials":4392,"activeCount":98},[4393],{"nctId":4394,"briefTitle":4395,"status":154,"phases":4396,"primaryCompletion":2737,"completion":2737,"start":4397,"enrollment":3364,"conditions":4398,"interventions":4401},"NCT01707953","Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty",[88],"2012-10",[4399,4400],"Postoperative Orthostatic Hypotension","Postoperative Orthostatic Intolerance",[4383],{"trials":4403,"activeCount":98},[],{"trials":4405,"activeCount":98},[],{"intervention":4407,"totalTrials":181,"cells":4408},"PEG Asparaginase at six weeks interval",{"EARLY_PHASE1":4409,"PHASE1":4411,"PHASE2":4413,"PHASE3":4415,"PHASE4":4426,"NA":4428},{"trials":4410,"activeCount":98},[],{"trials":4412,"activeCount":98},[],{"trials":4414,"activeCount":98},[],{"trials":4416,"activeCount":98},[4417],{"nctId":4418,"briefTitle":4419,"status":154,"phases":4420,"primaryCompletion":4269,"completion":4269,"start":4421,"enrollment":4422,"conditions":4423,"interventions":4424},"NCT00819351","ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase",[88],"2009-01-01",650,[4272],[4407,4425],"PEG Asparaginase at two weeks interval",{"trials":4427,"activeCount":98},[],{"trials":4429,"activeCount":98},[],{"intervention":4425,"totalTrials":181,"cells":4431},{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4436,"PHASE3":4438,"PHASE4":4444,"NA":4446},{"trials":4433,"activeCount":98},[],{"trials":4435,"activeCount":98},[],{"trials":4437,"activeCount":98},[],{"trials":4439,"activeCount":98},[4440],{"nctId":4418,"briefTitle":4419,"status":154,"phases":4441,"primaryCompletion":4269,"completion":4269,"start":4421,"enrollment":4422,"conditions":4442,"interventions":4443},[88],[4272],[4407,4425],{"trials":4445,"activeCount":98},[],{"trials":4447,"activeCount":98},[],{"intervention":4449,"totalTrials":979,"cells":4450},"Paclitaxel",{"EARLY_PHASE1":4451,"PHASE1":4453,"PHASE2":4455,"PHASE3":4490,"PHASE4":4492,"NA":4494},{"trials":4452,"activeCount":98},[],{"trials":4454,"activeCount":98},[],{"trials":4456,"activeCount":98},[4457,4468,4478],{"nctId":4458,"briefTitle":4459,"status":936,"phases":4460,"primaryCompletion":4461,"completion":3553,"start":4462,"enrollment":873,"conditions":4463,"interventions":4465},"NCT00531687","Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer",[87],"2012-02","2007-09",[4464],"Testicular Cancer",[4449,4466,4467],"Cisplatin","Gemcitabine",{"nctId":4469,"briefTitle":4470,"status":3550,"phases":4471,"primaryCompletion":2489,"completion":4472,"start":4473,"enrollment":98,"conditions":4474,"interventions":4476},"NCT00458315","Cisplatin\u002FPaclitaxel\u002FGemcitabine +\u002F- Avastin in Patients With Unknown Primary Tumor",[87],"2012-05","2007-05",[4475],"Unknown Primary Tumors",[4466,4449,4467,4477],"Avastin",{"nctId":4479,"briefTitle":4480,"status":154,"phases":4481,"completion":4482,"start":4483,"enrollment":905,"conditions":4484,"interventions":4486},"NCT00003732","Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer",[87],"2005-09","1998-09",[4485],"Ovarian Cancer",[4487,4488,4489],"carboplatin","paclitaxel","topotecan hydrochloride",{"trials":4491,"activeCount":98},[],{"trials":4493,"activeCount":98},[],{"trials":4495,"activeCount":98},[],{"intervention":4467,"totalTrials":979,"cells":4497},{"EARLY_PHASE1":4498,"PHASE1":4500,"PHASE2":4502,"PHASE3":4521,"PHASE4":4523,"NA":4525},{"trials":4499,"activeCount":98},[],{"trials":4501,"activeCount":98},[],{"trials":4503,"activeCount":98},[4504,4508,4512],{"nctId":4458,"briefTitle":4459,"status":936,"phases":4505,"primaryCompletion":4461,"completion":3553,"start":4462,"enrollment":873,"conditions":4506,"interventions":4507},[87],[4464],[4449,4466,4467],{"nctId":4469,"briefTitle":4470,"status":3550,"phases":4509,"primaryCompletion":2489,"completion":4472,"start":4473,"enrollment":98,"conditions":4510,"interventions":4511},[87],[4475],[4466,4449,4467,4477],{"nctId":4513,"briefTitle":4514,"status":154,"phases":4515,"completion":4516,"start":4517,"enrollment":2739,"conditions":4518,"interventions":4520},"NCT00350961","Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma",[86,87],"2008-02","2004-06",[4519],"Cholangiocarcinoma",[4467,1215,1213],{"trials":4522,"activeCount":98},[],{"trials":4524,"activeCount":98},[],{"trials":4526,"activeCount":98},[],{"intervention":4528,"totalTrials":979,"cells":4529},"Bevacizumab",{"EARLY_PHASE1":4530,"PHASE1":4532,"PHASE2":4534,"PHASE3":4565,"PHASE4":4567,"NA":4569},{"trials":4531,"activeCount":98},[],{"trials":4533,"activeCount":98},[],{"trials":4535,"activeCount":98},[4536,4545,4555],{"nctId":4537,"briefTitle":4538,"status":154,"phases":4539,"primaryCompletion":4540,"completion":4540,"start":1834,"enrollment":31,"conditions":4541,"interventions":4543},"NCT00800917","A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme",[87],"2010-02",[4542],"Glioblastoma Multiforme",[4544,4528],"Temsirolimus",{"nctId":4546,"briefTitle":4547,"status":154,"phases":4548,"primaryCompletion":1710,"completion":4549,"start":1001,"enrollment":4550,"conditions":4551,"interventions":4553},"NCT00463203","Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy",[87],"2011-06",54,[4552,1372],"Brain Neoplasms",[4528,4554],"Irinotecan",{"nctId":4556,"briefTitle":4557,"status":154,"phases":4558,"primaryCompletion":4559,"completion":4559,"start":4560,"enrollment":3619,"conditions":4561,"interventions":4563},"NCT00463073","Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas",[87],"2008-12","2006-08",[4562],"Malignant Gliomas",[4564,4528,4554],"Cetuximab",{"trials":4566,"activeCount":98},[],{"trials":4568,"activeCount":98},[],{"trials":4570,"activeCount":98},[],{"intervention":1213,"totalTrials":979,"cells":4572},{"EARLY_PHASE1":4573,"PHASE1":4575,"PHASE2":4577,"PHASE3":4597,"PHASE4":4599,"NA":4601},{"trials":4574,"activeCount":98},[],{"trials":4576,"activeCount":98},[],{"trials":4578,"activeCount":98},[4579,4583,4587],{"nctId":1201,"briefTitle":1202,"status":967,"phases":4580,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":4581,"interventions":4582},[87],[1209,1210],[1212,1182,1213,1214,1215],{"nctId":4513,"briefTitle":4514,"status":154,"phases":4584,"completion":4516,"start":4517,"enrollment":2739,"conditions":4585,"interventions":4586},[86,87],[4519],[4467,1215,1213],{"nctId":4588,"briefTitle":4589,"status":936,"phases":4590,"completion":4591,"start":4592,"enrollment":2739,"conditions":4593,"interventions":4595},"NCT00351195","Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)",[87],"2007-04","2006-02",[4594],"Hepatocellular Carcinoma",[4596,1215,1213],"Etoposide",{"trials":4598,"activeCount":98},[],{"trials":4600,"activeCount":98},[],{"trials":4602,"activeCount":98},[],{"intervention":1215,"totalTrials":979,"cells":4604},{"EARLY_PHASE1":4605,"PHASE1":4607,"PHASE2":4609,"PHASE3":4623,"PHASE4":4625,"NA":4627},{"trials":4606,"activeCount":98},[],{"trials":4608,"activeCount":98},[],{"trials":4610,"activeCount":98},[4611,4615,4619],{"nctId":1201,"briefTitle":1202,"status":967,"phases":4612,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":4613,"interventions":4614},[87],[1209,1210],[1212,1182,1213,1214,1215],{"nctId":4513,"briefTitle":4514,"status":154,"phases":4616,"completion":4516,"start":4517,"enrollment":2739,"conditions":4617,"interventions":4618},[86,87],[4519],[4467,1215,1213],{"nctId":4588,"briefTitle":4589,"status":936,"phases":4620,"completion":4591,"start":4592,"enrollment":2739,"conditions":4621,"interventions":4622},[87],[4594],[4596,1215,1213],{"trials":4624,"activeCount":98},[],{"trials":4626,"activeCount":98},[],{"trials":4628,"activeCount":98},[],{"intervention":4630,"totalTrials":94,"cells":4631},"Triheptanoin",{"EARLY_PHASE1":4632,"PHASE1":4634,"PHASE2":4636,"PHASE3":4658,"PHASE4":4660,"NA":4662},{"trials":4633,"activeCount":98},[],{"trials":4635,"activeCount":98},[],{"trials":4637,"activeCount":98},[4638,4647],{"nctId":4639,"briefTitle":4640,"status":154,"phases":4641,"primaryCompletion":1505,"completion":4642,"start":4643,"enrollment":1487,"conditions":4644,"interventions":4646},"NCT02432768","The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V)",[87],"2019-02","2015-04",[4645],"Glycogen Storage Disease Type V",[4630],{"nctId":4648,"briefTitle":4649,"status":154,"phases":4650,"primaryCompletion":4651,"completion":4651,"start":4652,"enrollment":979,"conditions":4653,"interventions":4657},"NCT03642860","The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses",[87],"2019-08-28","2018-08-15",[4654,4655,4656],"Tarui Disease","Debrancher Deficiency","GYG1 DEFICIENCY",[4630],{"trials":4659,"activeCount":98},[],{"trials":4661,"activeCount":98},[],{"trials":4663,"activeCount":98},[],{"intervention":4665,"totalTrials":94,"cells":4666},"68Ga-NOTA-AE105",{"EARLY_PHASE1":4667,"PHASE1":4669,"PHASE2":4671,"PHASE3":4693,"PHASE4":4695,"NA":4697},{"trials":4668,"activeCount":98},[],{"trials":4670,"activeCount":98},[],{"trials":4672,"activeCount":98},[4673,4683],{"nctId":4674,"briefTitle":4675,"status":154,"phases":4676,"primaryCompletion":4677,"completion":4677,"start":4678,"enrollment":4679,"conditions":4680,"interventions":4682},"NCT02965001","Phase II Trial: uPAR-PET\u002FCT for Prognostication in Head- and Neck Cancer",[87],"2021-12","2016-11",57,[4681],"Head and Neck Cancer",[4665],{"nctId":4684,"briefTitle":4685,"status":967,"phases":4686,"primaryCompletion":765,"completion":4687,"start":4688,"enrollment":4689,"conditions":4690,"interventions":4692},"NCT03307460","uPAR-PET\u002FMRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness",[87],"2022-04-01","2017-11-21",52,[4691],"Prostate Cancer",[4665],{"trials":4694,"activeCount":98},[],{"trials":4696,"activeCount":98},[],{"trials":4698,"activeCount":98},[],{"intervention":4700,"totalTrials":94,"cells":4701},"Injection of 68Ga-NOTA-AE105",{"EARLY_PHASE1":4702,"PHASE1":4704,"PHASE2":4713,"PHASE3":4724,"PHASE4":4726,"NA":4728},{"trials":4703,"activeCount":98},[],{"trials":4705,"activeCount":98},[4706],{"nctId":4707,"briefTitle":4708,"status":154,"phases":4709,"primaryCompletion":2320,"completion":2320,"start":1436,"enrollment":34,"conditions":4710,"interventions":4712},"NCT02437539","Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography",[86],[15,4691,4711],"Urinary Bladder Cancer",[4700],{"trials":4714,"activeCount":98},[4715],{"nctId":4716,"briefTitle":4717,"status":967,"phases":4718,"primaryCompletion":4719,"completion":4719,"start":2389,"enrollment":1232,"conditions":4720,"interventions":4722},"NCT02805608","uPAR PET\u002FCT and FDG PET\u002FMRI for Preoperative Staging of Bladder Cancer",[87],"2019-01",[4721],"Urinary Bladder Neoplasms",[4700,4723],"Injection of 18F-FDG",{"trials":4725,"activeCount":98},[],{"trials":4727,"activeCount":98},[],{"trials":4729,"activeCount":98},[],{"intervention":4466,"totalTrials":94,"cells":4731},{"EARLY_PHASE1":4732,"PHASE1":4734,"PHASE2":4736,"PHASE3":4746,"PHASE4":4748,"NA":4750},{"trials":4733,"activeCount":98},[],{"trials":4735,"activeCount":98},[],{"trials":4737,"activeCount":98},[4738,4742],{"nctId":4458,"briefTitle":4459,"status":936,"phases":4739,"primaryCompletion":4461,"completion":3553,"start":4462,"enrollment":873,"conditions":4740,"interventions":4741},[87],[4464],[4449,4466,4467],{"nctId":4469,"briefTitle":4470,"status":3550,"phases":4743,"primaryCompletion":2489,"completion":4472,"start":4473,"enrollment":98,"conditions":4744,"interventions":4745},[87],[4475],[4466,4449,4467,4477],{"trials":4747,"activeCount":98},[],{"trials":4749,"activeCount":98},[],{"trials":4751,"activeCount":98},[],{"intervention":1212,"totalTrials":94,"cells":4753},{"EARLY_PHASE1":4754,"PHASE1":4756,"PHASE2":4758,"PHASE3":4768,"PHASE4":4770,"NA":4772},{"trials":4755,"activeCount":98},[],{"trials":4757,"activeCount":98},[],{"trials":4759,"activeCount":98},[4760,4764],{"nctId":1201,"briefTitle":1202,"status":967,"phases":4761,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":4762,"interventions":4763},[87],[1209,1210],[1212,1182,1213,1214,1215],{"nctId":4479,"briefTitle":4480,"status":154,"phases":4765,"completion":4482,"start":4483,"enrollment":905,"conditions":4766,"interventions":4767},[87],[4485],[4487,4488,4489],{"trials":4769,"activeCount":98},[],{"trials":4771,"activeCount":98},[],{"trials":4773,"activeCount":98},[],{"intervention":4775,"totalTrials":94,"cells":4776},"One injection of 68Ga-NOTA-AE105",{"EARLY_PHASE1":4777,"PHASE1":4779,"PHASE2":4781,"PHASE3":4800,"PHASE4":4802,"NA":4804},{"trials":4778,"activeCount":98},[],{"trials":4780,"activeCount":98},[],{"trials":4782,"activeCount":98},[4783,4792],{"nctId":4784,"briefTitle":4785,"status":154,"phases":4786,"primaryCompletion":4787,"completion":4787,"start":4788,"enrollment":4789,"conditions":4790,"interventions":4791},"NCT03278275","PET\u002FCT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105",[87],"2021-07-08","2017-11-01",116,[1604],[4775],{"nctId":4793,"briefTitle":4794,"status":967,"phases":4795,"primaryCompletion":4796,"completion":4796,"start":815,"enrollment":4797,"conditions":4798,"interventions":4799},"NCT02945826","uPAR-PET\u002FMRI in Glioblastoma Multiforme",[87],"2020-12",35,[4542],[4775],{"trials":4801,"activeCount":98},[],{"trials":4803,"activeCount":98},[],{"trials":4805,"activeCount":98},[],{"intervention":4554,"totalTrials":94,"cells":4807},{"EARLY_PHASE1":4808,"PHASE1":4810,"PHASE2":4812,"PHASE3":4822,"PHASE4":4824,"NA":4826},{"trials":4809,"activeCount":98},[],{"trials":4811,"activeCount":98},[],{"trials":4813,"activeCount":98},[4814,4818],{"nctId":4546,"briefTitle":4547,"status":154,"phases":4815,"primaryCompletion":1710,"completion":4549,"start":1001,"enrollment":4550,"conditions":4816,"interventions":4817},[87],[4552,1372],[4528,4554],{"nctId":4556,"briefTitle":4557,"status":154,"phases":4819,"primaryCompletion":4559,"completion":4559,"start":4560,"enrollment":3619,"conditions":4820,"interventions":4821},[87],[4562],[4564,4528,4554],{"trials":4823,"activeCount":98},[],{"trials":4825,"activeCount":98},[],{"trials":4827,"activeCount":98},[],{"intervention":4829,"totalTrials":94,"cells":4830},"One injection of 68Ga-NODAGA-E[c(RGDyK)]2",{"EARLY_PHASE1":4831,"PHASE1":4833,"PHASE2":4835,"PHASE3":4855,"PHASE4":4857,"NA":4859},{"trials":4832,"activeCount":98},[],{"trials":4834,"activeCount":98},[],{"trials":4836,"activeCount":98},[4837,4846],{"nctId":4838,"briefTitle":4839,"status":967,"phases":4840,"primaryCompletion":4841,"completion":4841,"start":4842,"enrollment":1232,"conditions":4843,"interventions":4845},"NCT03393689","RGD PET\u002FMRI in Sporadic Vestibular Schwannoma",[87],"2021-01-02","2018-01-02",[4844],"Acoustic Neuroma",[4829],{"nctId":4847,"briefTitle":4848,"status":154,"phases":4849,"primaryCompletion":4850,"completion":4850,"start":4851,"enrollment":4852,"conditions":4853,"interventions":4854},"NCT03271281","PET\u002FCT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2",[87],"2021-12-31","2017-12-04",113,[1604],[4829],{"trials":4856,"activeCount":98},[],{"trials":4858,"activeCount":98},[],{"trials":4860,"activeCount":98},[],{"intervention":4862,"totalTrials":181,"cells":4863},"Bezafibrate",{"EARLY_PHASE1":4864,"PHASE1":4866,"PHASE2":4868,"PHASE3":4879,"PHASE4":4881,"NA":4883},{"trials":4865,"activeCount":98},[],{"trials":4867,"activeCount":98},[],{"trials":4869,"activeCount":98},[4870],{"nctId":4871,"briefTitle":4872,"status":154,"phases":4873,"primaryCompletion":4152,"completion":4152,"start":4874,"enrollment":31,"conditions":4875,"interventions":4878},"NCT00983788","Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects",[87],"2009-10",[4876,4877],"Carnitine Palmitoyltransferase II Deficiency","Very Long Chain Acyl Coa Dehydrogenase Deficiency",[4862],{"trials":4880,"activeCount":98},[],{"trials":4882,"activeCount":98},[],{"trials":4884,"activeCount":98},[],{"intervention":4886,"totalTrials":181,"cells":4887},"stem cell",{"EARLY_PHASE1":4888,"PHASE1":4890,"PHASE2":4892,"PHASE3":4905,"PHASE4":4907,"NA":4909},{"trials":4889,"activeCount":98},[],{"trials":4891,"activeCount":98},[],{"trials":4893,"activeCount":98},[4894],{"nctId":4895,"briefTitle":4896,"status":154,"phases":4897,"primaryCompletion":4898,"completion":4898,"start":4899,"enrollment":4900,"conditions":4901,"interventions":4904},"NCT00260338","Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia",[86,87],"2009-07","2005-12",31,[4902,4903],"Myocardial Ischemia","Coronary Heart Disease",[4886],{"trials":4906,"activeCount":98},[],{"trials":4908,"activeCount":98},[],{"trials":4910,"activeCount":98},[],{"intervention":4912,"totalTrials":181,"cells":4913},"Mesenchymal stem cell",{"EARLY_PHASE1":4914,"PHASE1":4916,"PHASE2":4918,"PHASE3":4930,"PHASE4":4932,"NA":4934},{"trials":4915,"activeCount":98},[],{"trials":4917,"activeCount":98},[],{"trials":4919,"activeCount":98},[4920],{"nctId":4921,"briefTitle":4922,"status":154,"phases":4923,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":791,"conditions":4926,"interventions":4928},"NCT02513238","Mesenchymal Stemcells for Radiation Induced Xerostomia",[87],"2017-04-06","2015-08-08",[4927],"Xerostomia",[4912,4929],"Isotonic NaCl",{"trials":4931,"activeCount":98},[],{"trials":4933,"activeCount":98},[],{"trials":4935,"activeCount":98},[],{"intervention":4929,"totalTrials":181,"cells":4937},{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4942,"PHASE3":4948,"PHASE4":4950,"NA":4952},{"trials":4939,"activeCount":98},[],{"trials":4941,"activeCount":98},[],{"trials":4943,"activeCount":98},[4944],{"nctId":4921,"briefTitle":4922,"status":154,"phases":4945,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":791,"conditions":4946,"interventions":4947},[87],[4927],[4912,4929],{"trials":4949,"activeCount":98},[],{"trials":4951,"activeCount":98},[],{"trials":4953,"activeCount":98},[],{"intervention":4955,"totalTrials":181,"cells":4956},"Autologous adipose-derived mesenchymal stem\u002Fstromal cells",{"EARLY_PHASE1":4957,"PHASE1":4959,"PHASE2":4961,"PHASE3":4978,"PHASE4":4980,"NA":4982},{"trials":4958,"activeCount":98},[],{"trials":4960,"activeCount":98},[],{"trials":4962,"activeCount":98},[4963],{"nctId":4964,"briefTitle":4965,"status":967,"phases":4966,"primaryCompletion":969,"completion":4967,"start":4968,"enrollment":791,"conditions":4969,"interventions":4977},"NCT03876197","Mesenchymal Stem Cells for Radiation-induced Xerostomia",[86,87],"2023-12-01","2020-08-01",[4970,4971,4972,4973,4974,4975,4976],"Radiation Toxicity","Xerostomia Due to Radiotherapy","Dry Mouth","Hyposalivation","Mesenchymal Stem Cells","Mesenchymal Stromal Cells","Long Term Adverse Effects",[4955],{"trials":4979,"activeCount":98},[],{"trials":4981,"activeCount":98},[],{"trials":4983,"activeCount":98},[],{"intervention":4985,"totalTrials":181,"cells":4986},"Trichuris suis ova",{"EARLY_PHASE1":4987,"PHASE1":4989,"PHASE2":4991,"PHASE3":5001,"PHASE4":5003,"NA":5005},{"trials":4988,"activeCount":98},[],{"trials":4990,"activeCount":98},[],{"trials":4992,"activeCount":98},[4993],{"nctId":4994,"briefTitle":4995,"status":154,"phases":4996,"primaryCompletion":2294,"completion":4152,"start":4997,"enrollment":34,"conditions":4998,"interventions":5000},"NCT01006941","Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study",[87],"2010-05",[4999],"Relapsing Multiple Sclerosis",[4985],{"trials":5002,"activeCount":98},[],{"trials":5004,"activeCount":98},[],{"trials":5006,"activeCount":98},[],{"intervention":5008,"totalTrials":181,"cells":5009},"Simvastatin",{"EARLY_PHASE1":5010,"PHASE1":5012,"PHASE2":5014,"PHASE3":5024,"PHASE4":5026,"NA":5028},{"trials":5011,"activeCount":98},[],{"trials":5013,"activeCount":98},[],{"trials":5015,"activeCount":98},[5016],{"nctId":5017,"briefTitle":5018,"status":154,"phases":5019,"primaryCompletion":5020,"completion":5020,"start":1709,"enrollment":1232,"conditions":5021,"interventions":5023},"NCT02256254","SIMOX - Induction of Oxidative Stress",[87],"2015-02",[5022],"Oxidative Stress",[5008],{"trials":5025,"activeCount":98},[],{"trials":5027,"activeCount":98},[],{"trials":5029,"activeCount":98},[],{"intervention":2277,"totalTrials":181,"cells":5031},{"EARLY_PHASE1":5032,"PHASE1":5034,"PHASE2":5036,"PHASE3":5042,"PHASE4":5044,"NA":5046},{"trials":5033,"activeCount":98},[],{"trials":5035,"activeCount":98},[],{"trials":5037,"activeCount":98},[5038],{"nctId":2266,"briefTitle":2267,"status":154,"phases":5039,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":2271,"conditions":5040,"interventions":5041},[87],[2273,2274,2275],[2277,2257],{"trials":5043,"activeCount":98},[],{"trials":5045,"activeCount":98},[],{"trials":5047,"activeCount":98},[],{"intervention":1608,"totalTrials":181,"cells":5049},{"EARLY_PHASE1":5050,"PHASE1":5052,"PHASE2":5054,"PHASE3":5060,"PHASE4":5062,"NA":5064},{"trials":5051,"activeCount":98},[],{"trials":5053,"activeCount":98},[],{"trials":5055,"activeCount":98},[5056],{"nctId":1595,"briefTitle":1596,"status":967,"phases":5057,"primaryCompletion":1598,"completion":1599,"start":1600,"enrollment":1601,"conditions":5058,"interventions":5059},[87],[1603,1604,1605,1606],[1586,1608],{"trials":5061,"activeCount":98},[],{"trials":5063,"activeCount":98},[],{"trials":5065,"activeCount":98},[],{"intervention":4723,"totalTrials":181,"cells":5067},{"EARLY_PHASE1":5068,"PHASE1":5070,"PHASE2":5072,"PHASE3":5078,"PHASE4":5080,"NA":5082},{"trials":5069,"activeCount":98},[],{"trials":5071,"activeCount":98},[],{"trials":5073,"activeCount":98},[5074],{"nctId":4716,"briefTitle":4717,"status":967,"phases":5075,"primaryCompletion":4719,"completion":4719,"start":2389,"enrollment":1232,"conditions":5076,"interventions":5077},[87],[4721],[4700,4723],{"trials":5079,"activeCount":98},[],{"trials":5081,"activeCount":98},[],{"trials":5083,"activeCount":98},[],{"intervention":5085,"totalTrials":181,"cells":5086},"ASCs",{"EARLY_PHASE1":5087,"PHASE1":5089,"PHASE2":5091,"PHASE3":5103,"PHASE4":5105,"NA":5107},{"trials":5088,"activeCount":98},[],{"trials":5090,"activeCount":98},[],{"trials":5092,"activeCount":98},[5093],{"nctId":5094,"briefTitle":5095,"status":154,"phases":5096,"primaryCompletion":969,"completion":5097,"start":5098,"enrollment":1232,"conditions":5099,"interventions":5101},"NCT04615455","Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome",[87],"2023-01-01","2020-11-03",[5100],"Keratoconjunctivitis Sicca, in Sjogren's Syndrome",[5085,5102],"Cryostor CS10",{"trials":5104,"activeCount":98},[],{"trials":5106,"activeCount":98},[],{"trials":5108,"activeCount":98},[],{"intervention":5102,"totalTrials":181,"cells":5110},{"EARLY_PHASE1":5111,"PHASE1":5113,"PHASE2":5115,"PHASE3":5121,"PHASE4":5123,"NA":5125},{"trials":5112,"activeCount":98},[],{"trials":5114,"activeCount":98},[],{"trials":5116,"activeCount":98},[5117],{"nctId":5094,"briefTitle":5095,"status":154,"phases":5118,"primaryCompletion":969,"completion":5097,"start":5098,"enrollment":1232,"conditions":5119,"interventions":5120},[87],[5100],[5085,5102],{"trials":5122,"activeCount":98},[],{"trials":5124,"activeCount":98},[],{"trials":5126,"activeCount":98},[],{"intervention":4477,"totalTrials":181,"cells":5128},{"EARLY_PHASE1":5129,"PHASE1":5131,"PHASE2":5133,"PHASE3":5139,"PHASE4":5141,"NA":5143},{"trials":5130,"activeCount":98},[],{"trials":5132,"activeCount":98},[],{"trials":5134,"activeCount":98},[5135],{"nctId":4469,"briefTitle":4470,"status":3550,"phases":5136,"primaryCompletion":2489,"completion":4472,"start":4473,"enrollment":98,"conditions":5137,"interventions":5138},[87],[4475],[4466,4449,4467,4477],{"trials":5140,"activeCount":98},[],{"trials":5142,"activeCount":98},[],{"trials":5144,"activeCount":98},[],{"intervention":5146,"totalTrials":181,"cells":5147},"Stem cells",{"EARLY_PHASE1":5148,"PHASE1":5150,"PHASE2":5152,"PHASE3":5163,"PHASE4":5165,"NA":5167},{"trials":5149,"activeCount":98},[],{"trials":5151,"activeCount":98},[],{"trials":5153,"activeCount":98},[5154],{"nctId":5155,"briefTitle":5156,"status":967,"phases":5157,"primaryCompletion":5158,"completion":5158,"start":5159,"enrollment":3364,"conditions":5160,"interventions":5162},"NCT04776538","Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivation and Xerostomia in Previous Head and Neck Cancer Patients",[87],"2024-03-01","2021-02-09",[5161],"Xerostomia Following Radiotherapy",[5146],{"trials":5164,"activeCount":98},[],{"trials":5166,"activeCount":98},[],{"trials":5168,"activeCount":98},[],{"intervention":5170,"totalTrials":181,"cells":5171},"mCyp c 1",{"EARLY_PHASE1":5172,"PHASE1":5174,"PHASE2":5176,"PHASE3":5185,"PHASE4":5187,"NA":5189},{"trials":5173,"activeCount":98},[],{"trials":5175,"activeCount":98},[],{"trials":5177,"activeCount":98},[5178],{"nctId":5179,"briefTitle":5180,"status":154,"phases":5181,"primaryCompletion":2270,"completion":2270,"start":2321,"enrollment":21,"conditions":5182,"interventions":5184},"NCT02017626","FAST-Fish -Food Allergy Specific Treatment for Fish Allergy.",[86,87],[5183],"Fish Allergy",[5170],{"trials":5186,"activeCount":98},[],{"trials":5188,"activeCount":98},[],{"trials":5190,"activeCount":98},[],{"intervention":4544,"totalTrials":181,"cells":5192},{"EARLY_PHASE1":5193,"PHASE1":5195,"PHASE2":5197,"PHASE3":5203,"PHASE4":5205,"NA":5207},{"trials":5194,"activeCount":98},[],{"trials":5196,"activeCount":98},[],{"trials":5198,"activeCount":98},[5199],{"nctId":4537,"briefTitle":4538,"status":154,"phases":5200,"primaryCompletion":4540,"completion":4540,"start":1834,"enrollment":31,"conditions":5201,"interventions":5202},[87],[4542],[4544,4528],{"trials":5204,"activeCount":98},[],{"trials":5206,"activeCount":98},[],{"trials":5208,"activeCount":98},[],{"intervention":1214,"totalTrials":181,"cells":5210},{"EARLY_PHASE1":5211,"PHASE1":5213,"PHASE2":5215,"PHASE3":5221,"PHASE4":5223,"NA":5225},{"trials":5212,"activeCount":98},[],{"trials":5214,"activeCount":98},[],{"trials":5216,"activeCount":98},[5217],{"nctId":1201,"briefTitle":1202,"status":967,"phases":5218,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":5219,"interventions":5220},[87],[1209,1210],[1212,1182,1213,1214,1215],{"trials":5222,"activeCount":98},[],{"trials":5224,"activeCount":98},[],{"trials":5226,"activeCount":98},[],{"intervention":5228,"totalTrials":181,"cells":5229},"Progesterone",{"EARLY_PHASE1":5230,"PHASE1":5232,"PHASE2":5234,"PHASE3":5246,"PHASE4":5248,"NA":5250},{"trials":5231,"activeCount":98},[],{"trials":5233,"activeCount":98},[],{"trials":5235,"activeCount":98},[5236],{"nctId":5237,"briefTitle":5238,"status":154,"phases":5239,"primaryCompletion":3093,"completion":5240,"start":5241,"enrollment":5242,"conditions":5243,"interventions":5245},"NCT00329914","Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies?",[87],"2010-09","2006-06",677,[5244],"Preterm Delivery",[5228],{"trials":5247,"activeCount":98},[],{"trials":5249,"activeCount":98},[],{"trials":5251,"activeCount":98},[],{"intervention":5253,"totalTrials":181,"cells":5254},"Stem Cell Product",{"EARLY_PHASE1":5255,"PHASE1":5257,"PHASE2":5259,"PHASE3":5271,"PHASE4":5273,"NA":5275},{"trials":5256,"activeCount":98},[],{"trials":5258,"activeCount":98},[],{"trials":5260,"activeCount":98},[5261],{"nctId":5262,"briefTitle":5263,"status":3550,"phases":5264,"primaryCompletion":5265,"completion":5266,"start":5267,"enrollment":98,"conditions":5268,"interventions":5270},"NCT04341610","ASC Therapy for Patients With Severe Respiratory COVID-19",[86,87],"2021-01-30","2021-04-30","2020-04-20",[5269],"Respiratory Tract Diseases",[5253],{"trials":5272,"activeCount":98},[],{"trials":5274,"activeCount":98},[],{"trials":5276,"activeCount":98},[],{"intervention":5278,"totalTrials":181,"cells":5279},"Hyperbaric oxygen",{"EARLY_PHASE1":5280,"PHASE1":5282,"PHASE2":5284,"PHASE3":5295,"PHASE4":5297,"NA":5299},{"trials":5281,"activeCount":98},[],{"trials":5283,"activeCount":98},[],{"trials":5285,"activeCount":98},[5286],{"nctId":5287,"briefTitle":5288,"status":154,"phases":5289,"primaryCompletion":1436,"completion":1436,"start":5020,"enrollment":5290,"conditions":5291,"interventions":5294},"NCT02397343","The Effect of Hyperbaric Oxygen Therapy on Inflammatory Parameters Induced by a Heat Injury Model",[87],26,[5292,5293],"Secondary Hyperalgesia","Inflammation",[5278],{"trials":5296,"activeCount":98},[],{"trials":5298,"activeCount":98},[],{"trials":5300,"activeCount":98},[],{"intervention":5302,"totalTrials":181,"cells":5303},"Erythropoietin",{"EARLY_PHASE1":5304,"PHASE1":5306,"PHASE2":5308,"PHASE3":5319,"PHASE4":5321,"NA":5323},{"trials":5305,"activeCount":98},[],{"trials":5307,"activeCount":98},[],{"trials":5309,"activeCount":98},[5310],{"nctId":5311,"briefTitle":5312,"status":967,"phases":5313,"primaryCompletion":949,"completion":3026,"start":5314,"enrollment":5315,"conditions":5316,"interventions":5318},"NCT01144117","The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis",[87],"2009-11",56,[5317],"Multiple Sclerosis (Primary or Secondary Progressive Phase).",[5302],{"trials":5320,"activeCount":98},[],{"trials":5322,"activeCount":98},[],{"trials":5324,"activeCount":98},[],{"intervention":5326,"totalTrials":181,"cells":5327},"6-mercaptopurine",{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5332,"PHASE3":5343,"PHASE4":5345,"NA":5347},{"trials":5329,"activeCount":98},[],{"trials":5331,"activeCount":98},[],{"trials":5333,"activeCount":98},[5334],{"nctId":5335,"briefTitle":5336,"status":154,"phases":5337,"primaryCompletion":1437,"completion":5338,"start":5339,"enrollment":2491,"conditions":5340,"interventions":5342},"NCT00548431","NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia",[87],"2009-05","2007-12",[5341],"Leukemia, Lymphocytic, Acute",[5326],{"trials":5344,"activeCount":98},[],{"trials":5346,"activeCount":98},[],{"trials":5348,"activeCount":98},[],{"intervention":5350,"totalTrials":181,"cells":5351},"Omalizumab",{"EARLY_PHASE1":5352,"PHASE1":5354,"PHASE2":5356,"PHASE3":5368,"PHASE4":5370,"NA":5372},{"trials":5353,"activeCount":98},[],{"trials":5355,"activeCount":98},[],{"trials":5357,"activeCount":98},[5358],{"nctId":5359,"briefTitle":5360,"status":154,"phases":5361,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":603,"conditions":5364,"interventions":5366},"NCT03727971","Treatment With the Anti-IgE Monoclonal Antibody Omalizumab in Women With Asthma Undergoing Fertility Treatment. - A Proof of Concept Study.",[87],"2024-12-31","2019-01-01",[5365,3249],"Asthma",[5350,5367],"NaCl",{"trials":5369,"activeCount":98},[],{"trials":5371,"activeCount":98},[],{"trials":5373,"activeCount":98},[],{"intervention":5367,"totalTrials":181,"cells":5375},{"EARLY_PHASE1":5376,"PHASE1":5378,"PHASE2":5380,"PHASE3":5386,"PHASE4":5388,"NA":5390},{"trials":5377,"activeCount":98},[],{"trials":5379,"activeCount":98},[],{"trials":5381,"activeCount":98},[5382],{"nctId":5359,"briefTitle":5360,"status":154,"phases":5383,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":603,"conditions":5384,"interventions":5385},[87],[5365,3249],[5350,5367],{"trials":5387,"activeCount":98},[],{"trials":5389,"activeCount":98},[],{"trials":5391,"activeCount":98},[],{"intervention":1413,"totalTrials":181,"cells":5393},{"EARLY_PHASE1":5394,"PHASE1":5396,"PHASE2":5398,"PHASE3":5404,"PHASE4":5406,"NA":5408},{"trials":5395,"activeCount":98},[],{"trials":5397,"activeCount":98},[],{"trials":5399,"activeCount":98},[5400],{"nctId":1405,"briefTitle":1406,"status":154,"phases":5401,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":1410,"conditions":5402,"interventions":5403},[86,87],[695],[1413,975],{"trials":5405,"activeCount":98},[],{"trials":5407,"activeCount":98},[],{"trials":5409,"activeCount":98},[],{"intervention":4596,"totalTrials":181,"cells":5411},{"EARLY_PHASE1":5412,"PHASE1":5414,"PHASE2":5416,"PHASE3":5422,"PHASE4":5424,"NA":5426},{"trials":5413,"activeCount":98},[],{"trials":5415,"activeCount":98},[],{"trials":5417,"activeCount":98},[5418],{"nctId":4588,"briefTitle":4589,"status":936,"phases":5419,"completion":4591,"start":4592,"enrollment":2739,"conditions":5420,"interventions":5421},[87],[4594],[4596,1215,1213],{"trials":5423,"activeCount":98},[],{"trials":5425,"activeCount":98},[],{"trials":5427,"activeCount":98},[],{"intervention":5429,"totalTrials":181,"cells":5430},"Granulocyte Colony Stimulating Factor G-CSF",{"EARLY_PHASE1":5431,"PHASE1":5433,"PHASE2":5435,"PHASE3":5444,"PHASE4":5446,"NA":5448},{"trials":5432,"activeCount":98},[],{"trials":5434,"activeCount":98},[],{"trials":5436,"activeCount":98},[5437],{"nctId":5438,"briefTitle":5439,"status":154,"phases":5440,"primaryCompletion":4592,"completion":4592,"start":5441,"enrollment":2479,"conditions":5442,"interventions":5443},"NCT00135928","Stem Cells in Myocardial Infarction",[87],"2003-05",[1326],[5429],{"trials":5445,"activeCount":98},[],{"trials":5447,"activeCount":98},[],{"trials":5449,"activeCount":98},[],{"intervention":5451,"totalTrials":181,"cells":5452},"Bupivacaine",{"EARLY_PHASE1":5453,"PHASE1":5455,"PHASE2":5457,"PHASE3":5467,"PHASE4":5469,"NA":5471},{"trials":5454,"activeCount":98},[],{"trials":5456,"activeCount":98},[],{"trials":5458,"activeCount":98},[5459],{"nctId":5460,"briefTitle":5461,"status":967,"phases":5462,"primaryCompletion":1436,"start":2391,"enrollment":5463,"conditions":5464,"interventions":5466},"NCT02349581","Ultrasound Guided Pectoral Nerves Blockade for Persistent Pain After Breast Cancer Surgery",[87],6,[5465],"Persistent Pain After Breast Cancer Surgery",[5451],{"trials":5468,"activeCount":98},[],{"trials":5470,"activeCount":98},[],{"trials":5472,"activeCount":98},[],{"intervention":5474,"totalTrials":181,"cells":5475},"Bleomycin",{"EARLY_PHASE1":5476,"PHASE1":5478,"PHASE2":5480,"PHASE3":5490,"PHASE4":5492,"NA":5494},{"trials":5477,"activeCount":98},[],{"trials":5479,"activeCount":98},[],{"trials":5481,"activeCount":98},[5482],{"nctId":5483,"briefTitle":5484,"status":967,"phases":5485,"primaryCompletion":5486,"completion":5486,"start":2282,"enrollment":1498,"conditions":5487,"interventions":5489},"NCT02549742","Electrochemotherapy on Head and Neck Cancer",[87],"2019-09",[5488],"Head Neck Cancer",[5474],{"trials":5491,"activeCount":98},[],{"trials":5493,"activeCount":98},[],{"trials":5495,"activeCount":98},[],{"intervention":5497,"totalTrials":181,"cells":5498},"cisplatin, taxotere",{"EARLY_PHASE1":5499,"PHASE1":5501,"PHASE2":5503,"PHASE3":5514,"PHASE4":5516,"NA":5518},{"trials":5500,"activeCount":98},[],{"trials":5502,"activeCount":98},[],{"trials":5504,"activeCount":98},[5505],{"nctId":5506,"briefTitle":5507,"status":154,"phases":5508,"primaryCompletion":4461,"completion":4461,"start":5509,"enrollment":5510,"conditions":5511,"interventions":5513},"NCT00324012","Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma",[87],"2006-04",19,[5512],"Adrenocortical Carcinoma",[5497],{"trials":5515,"activeCount":98},[],{"trials":5517,"activeCount":98},[],{"trials":5519,"activeCount":98},[],{"intervention":5521,"totalTrials":181,"cells":5522},"Injection of PET tracer 68Ga-NOTA-AE105",{"EARLY_PHASE1":5523,"PHASE1":5525,"PHASE2":5527,"PHASE3":5537,"PHASE4":5539,"NA":5541},{"trials":5524,"activeCount":98},[],{"trials":5526,"activeCount":98},[],{"trials":5528,"activeCount":98},[5529],{"nctId":5530,"briefTitle":5531,"status":936,"phases":5532,"primaryCompletion":765,"completion":765,"start":815,"enrollment":16,"conditions":5533,"interventions":5536},"NCT02964988","uPAR PET\u002FCT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer",[87],[5534,5535],"Prostate Cancer Metastatic","Bone Metastases",[5521],{"trials":5538,"activeCount":98},[],{"trials":5540,"activeCount":98},[],{"trials":5542,"activeCount":98},[],{"intervention":5544,"totalTrials":181,"cells":5545},"Target-controlled naloxone-infusion",{"EARLY_PHASE1":5546,"PHASE1":5548,"PHASE2":5550,"PHASE3":5562,"PHASE4":5564,"NA":5566},{"trials":5547,"activeCount":98},[],{"trials":5549,"activeCount":98},[],{"trials":5551,"activeCount":98},[5552],{"nctId":5553,"briefTitle":5554,"status":154,"phases":5555,"primaryCompletion":5556,"completion":5557,"start":5558,"enrollment":777,"conditions":5559,"interventions":5561},"NCT01992146","Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Patients Following Groin-Hernia Repair.",[87],"2015-12-14","2018-05-11","2015-11-11",[5560,23,2274],"Central Nervous System Sensitization",[5544],{"trials":5563,"activeCount":98},[],{"trials":5565,"activeCount":98},[],{"trials":5567,"activeCount":98},[],{"intervention":1423,"totalTrials":181,"cells":5569},{"EARLY_PHASE1":5570,"PHASE1":5572,"PHASE2":5574,"PHASE3":5580,"PHASE4":5582,"NA":5584},{"trials":5571,"activeCount":98},[],{"trials":5573,"activeCount":98},[],{"trials":5575,"activeCount":98},[5576],{"nctId":1415,"briefTitle":1416,"status":967,"phases":5577,"primaryCompletion":1418,"completion":1140,"start":1419,"enrollment":791,"conditions":5578,"interventions":5579},[86,87],[1421],[1423,975],{"trials":5581,"activeCount":98},[],{"trials":5583,"activeCount":98},[],{"trials":5585,"activeCount":98},[],{"intervention":5587,"totalTrials":181,"cells":5588},"erlotinib",{"EARLY_PHASE1":5589,"PHASE1":5591,"PHASE2":5593,"PHASE3":5603,"PHASE4":5605,"NA":5607},{"trials":5590,"activeCount":98},[],{"trials":5592,"activeCount":98},[],{"trials":5594,"activeCount":98},[5595],{"nctId":5596,"briefTitle":5597,"status":936,"phases":5598,"primaryCompletion":4540,"completion":5599,"start":1001,"enrollment":3442,"conditions":5600,"interventions":5602},"NCT00452075","Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy",[87],"2010-08",[5601],"Non Small Cell Lung Cancer",[5587],{"trials":5604,"activeCount":98},[],{"trials":5606,"activeCount":98},[],{"trials":5608,"activeCount":98},[],{"intervention":5610,"totalTrials":181,"cells":5611},"Dimethyl fumarate",{"EARLY_PHASE1":5612,"PHASE1":5614,"PHASE2":5616,"PHASE3":5626,"PHASE4":5628,"NA":5630},{"trials":5613,"activeCount":98},[],{"trials":5615,"activeCount":98},[],{"trials":5617,"activeCount":98},[5618],{"nctId":5619,"briefTitle":5620,"status":154,"phases":5621,"primaryCompletion":5622,"completion":5623,"start":2390,"enrollment":4550,"conditions":5624,"interventions":5625},"NCT02959658","Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis",[87],"2019-12-21","2020-12-09",[806],[5610],{"trials":5627,"activeCount":98},[],{"trials":5629,"activeCount":98},[],{"trials":5631,"activeCount":98},[],{"intervention":4564,"totalTrials":181,"cells":5633},{"EARLY_PHASE1":5634,"PHASE1":5636,"PHASE2":5638,"PHASE3":5644,"PHASE4":5646,"NA":5648},{"trials":5635,"activeCount":98},[],{"trials":5637,"activeCount":98},[],{"trials":5639,"activeCount":98},[5640],{"nctId":4556,"briefTitle":4557,"status":154,"phases":5641,"primaryCompletion":4559,"completion":4559,"start":4560,"enrollment":3619,"conditions":5642,"interventions":5643},[87],[4562],[4564,4528,4554],{"trials":5645,"activeCount":98},[],{"trials":5647,"activeCount":98},[],{"trials":5649,"activeCount":98},[],{"intervention":5651,"totalTrials":181,"cells":5652},"Carboplatin and Vinorelbine",{"EARLY_PHASE1":5653,"PHASE1":5655,"PHASE2":5657,"PHASE3":5667,"PHASE4":5669,"NA":5671},{"trials":5654,"activeCount":98},[],{"trials":5656,"activeCount":98},[],{"trials":5658,"activeCount":98},[5659],{"nctId":5660,"briefTitle":5661,"status":154,"phases":5662,"primaryCompletion":2478,"completion":2478,"start":5663,"enrollment":1232,"conditions":5664,"interventions":5666},"NCT00272558","Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma",[87],"2004-09",[5665],"Malignant Pleural Mesothelioma",[5651],{"trials":5668,"activeCount":98},[],{"trials":5670,"activeCount":98},[],{"trials":5672,"activeCount":98},[],{"intervention":4489,"totalTrials":181,"cells":5674},{"EARLY_PHASE1":5675,"PHASE1":5677,"PHASE2":5679,"PHASE3":5685,"PHASE4":5687,"NA":5689},{"trials":5676,"activeCount":98},[],{"trials":5678,"activeCount":98},[],{"trials":5680,"activeCount":98},[5681],{"nctId":4479,"briefTitle":4480,"status":154,"phases":5682,"completion":4482,"start":4483,"enrollment":905,"conditions":5683,"interventions":5684},[87],[4485],[4487,4488,4489],{"trials":5686,"activeCount":98},[],{"trials":5688,"activeCount":98},[],{"trials":5690,"activeCount":98},[],{"intervention":1620,"totalTrials":181,"cells":5692},{"EARLY_PHASE1":5693,"PHASE1":5695,"PHASE2":5697,"PHASE3":5703,"PHASE4":5705,"NA":5707},{"trials":5694,"activeCount":98},[],{"trials":5696,"activeCount":98},[],{"trials":5698,"activeCount":98},[5699],{"nctId":1610,"briefTitle":1611,"status":967,"phases":5700,"primaryCompletion":1613,"completion":1614,"start":1615,"enrollment":21,"conditions":5701,"interventions":5702},[87],[15,1604,1605,1606,1617,1618],[1586,1620],{"trials":5704,"activeCount":98},[],{"trials":5706,"activeCount":98},[],{"trials":5708,"activeCount":98},[],{"intervention":5710,"totalTrials":181,"cells":5711},"VEGF-A165 plasmid",{"EARLY_PHASE1":5712,"PHASE1":5714,"PHASE2":5716,"PHASE3":5727,"PHASE4":5729,"NA":5731},{"trials":5713,"activeCount":98},[],{"trials":5715,"activeCount":98},[],{"trials":5717,"activeCount":98},[5718],{"nctId":5719,"briefTitle":5720,"status":154,"phases":5721,"primaryCompletion":5722,"completion":5722,"start":5723,"enrollment":2271,"conditions":5724,"interventions":5726},"NCT00135850","The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris",[86,87],"2005-02","2003-03",[5725],"Ischemic Heart Disease",[5710],{"trials":5728,"activeCount":98},[],{"trials":5730,"activeCount":98},[],{"trials":5732,"activeCount":98},[],{"intervention":5734,"totalTrials":181,"cells":5735},"Ropivacaine + dexamethasone",{"EARLY_PHASE1":5736,"PHASE1":5738,"PHASE2":5740,"PHASE3":5750,"PHASE4":5752,"NA":5754},{"trials":5737,"activeCount":98},[],{"trials":5739,"activeCount":98},[],{"trials":5741,"activeCount":98},[5742],{"nctId":5743,"briefTitle":5744,"status":154,"phases":5745,"primaryCompletion":1408,"completion":1408,"start":5020,"enrollment":1455,"conditions":5746,"interventions":5748},"NCT02351804","Does Perineural Dexamethasone Prolong Duration of a Nerve Block?",[87],[5747],"Healthy Volunteers",[5734,5749],"Ropivacaine + placebo",{"trials":5751,"activeCount":98},[],{"trials":5753,"activeCount":98},[],{"trials":5755,"activeCount":98},[],{"intervention":5749,"totalTrials":181,"cells":5757},{"EARLY_PHASE1":5758,"PHASE1":5760,"PHASE2":5762,"PHASE3":5768,"PHASE4":5770,"NA":5772},{"trials":5759,"activeCount":98},[],{"trials":5761,"activeCount":98},[],{"trials":5763,"activeCount":98},[5764],{"nctId":5743,"briefTitle":5744,"status":154,"phases":5765,"primaryCompletion":1408,"completion":1408,"start":5020,"enrollment":1455,"conditions":5766,"interventions":5767},[87],[5747],[5734,5749],{"trials":5769,"activeCount":98},[],{"trials":5771,"activeCount":98},[],{"trials":5773,"activeCount":98},[],{"intervention":5775,"totalTrials":181,"cells":5776},"OctaplasLG",{"EARLY_PHASE1":5777,"PHASE1":5779,"PHASE2":5781,"PHASE3":5792,"PHASE4":5794,"NA":5796},{"trials":5778,"activeCount":98},[],{"trials":5780,"activeCount":98},[],{"trials":5782,"activeCount":98},[5783],{"nctId":5784,"briefTitle":5785,"status":154,"phases":5786,"primaryCompletion":5787,"completion":5787,"start":5788,"enrollment":2392,"conditions":5789,"interventions":5790},"NCT03092245","Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial",[87],"2019-04-17","2017-04-18",[2406],[5775,5791],"Ringer-Acetate",{"trials":5793,"activeCount":98},[],{"trials":5795,"activeCount":98},[],{"trials":5797,"activeCount":98},[],{"intervention":5791,"totalTrials":181,"cells":5799},{"EARLY_PHASE1":5800,"PHASE1":5802,"PHASE2":5804,"PHASE3":5810,"PHASE4":5812,"NA":5814},{"trials":5801,"activeCount":98},[],{"trials":5803,"activeCount":98},[],{"trials":5805,"activeCount":98},[5806],{"nctId":5784,"briefTitle":5785,"status":154,"phases":5807,"primaryCompletion":5787,"completion":5787,"start":5788,"enrollment":2392,"conditions":5808,"interventions":5809},[87],[2406],[5775,5791],{"trials":5811,"activeCount":98},[],{"trials":5813,"activeCount":98},[],{"trials":5815,"activeCount":98},[],{"intervention":5817,"totalTrials":181,"cells":5818},"Fibrinogen",{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5834,"PHASE4":5836,"NA":5838},{"trials":5820,"activeCount":98},[],{"trials":5822,"activeCount":98},[],{"trials":5824,"activeCount":98},[5825],{"nctId":5826,"briefTitle":5827,"status":154,"phases":5828,"primaryCompletion":5829,"completion":5830,"start":5020,"enrollment":1232,"conditions":5831,"interventions":5833},"NCT02344069","Pilot Randomized Trial of Fibrinogen in Trauma Haemorrhage",[87],"2017-03","2017-04",[2354,5832],"Haemorrhage",[5817],{"trials":5835,"activeCount":98},[],{"trials":5837,"activeCount":98},[],{"trials":5839,"activeCount":98},[],{"intervention":5841,"totalTrials":181,"cells":5842},"Sildenafil",{"EARLY_PHASE1":5843,"PHASE1":5845,"PHASE2":5847,"PHASE3":5857,"PHASE4":5859,"NA":5861},{"trials":5844,"activeCount":98},[],{"trials":5846,"activeCount":98},[],{"trials":5848,"activeCount":98},[5849],{"nctId":5850,"briefTitle":5851,"status":154,"phases":5852,"primaryCompletion":3026,"completion":3026,"start":5853,"enrollment":16,"conditions":5854,"interventions":5856},"NCT01350154","Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients",[87],"2011-11",[5855],"Becker Muscular Dystrophy",[5841],{"trials":5858,"activeCount":98},[],{"trials":5860,"activeCount":98},[],{"trials":5862,"activeCount":98},[],{"intervention":5864,"totalTrials":181,"cells":5865},"Bosentan",{"EARLY_PHASE1":5866,"PHASE1":5868,"PHASE2":5870,"PHASE3":5881,"PHASE4":5883,"NA":5885},{"trials":5867,"activeCount":98},[],{"trials":5869,"activeCount":98},[],{"trials":5871,"activeCount":98},[5872],{"nctId":5873,"briefTitle":5874,"status":154,"phases":5875,"primaryCompletion":1730,"completion":1730,"start":3134,"enrollment":3028,"conditions":5876,"interventions":5880},"NCT01292551","Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.",[87],[5877,5878,5879],"Hypoplastic Left Heart Syndrome","Tricuspid Atresia","Other Specified Congenital Anomalies of Heart",[5864],{"trials":5882,"activeCount":98},[],{"trials":5884,"activeCount":98},[],{"trials":5886,"activeCount":98},[],{"intervention":5888,"totalTrials":181,"cells":5889},"Erlotinib and bevacizumab",{"EARLY_PHASE1":5890,"PHASE1":5892,"PHASE2":5894,"PHASE3":5905,"PHASE4":5907,"NA":5909},{"trials":5891,"activeCount":98},[],{"trials":5893,"activeCount":98},[],{"trials":5895,"activeCount":98},[5896],{"nctId":5897,"briefTitle":5898,"status":154,"phases":5899,"primaryCompletion":5900,"completion":5900,"start":5241,"enrollment":5901,"conditions":5902,"interventions":5904},"NCT00350753","Avastin and Tarceva for Upper Gastrointestinal Cancers",[87],"2009-06",126,[4519,5903],"Gallbladder Cancer",[5888],{"trials":5906,"activeCount":98},[],{"trials":5908,"activeCount":98},[],{"trials":5910,"activeCount":98},[],{"intervention":5912,"totalTrials":181,"cells":5913},"Natalizumab",{"EARLY_PHASE1":5914,"PHASE1":5916,"PHASE2":5918,"PHASE3":5927,"PHASE4":5929,"NA":5931},{"trials":5915,"activeCount":98},[],{"trials":5917,"activeCount":98},[],{"trials":5919,"activeCount":98},[5920],{"nctId":5921,"briefTitle":5922,"status":154,"phases":5923,"primaryCompletion":5924,"completion":5924,"start":2477,"enrollment":3442,"conditions":5925,"interventions":5926},"NCT01077466","Natalizumab Treatment of Progressive Multiple Sclerosis",[87],"2012-01",[806,805],[5912],{"trials":5928,"activeCount":98},[],{"trials":5930,"activeCount":98},[],{"trials":5932,"activeCount":98},[],{"intervention":5934,"totalTrials":181,"cells":5935},"Injection of 18F-ASIS",{"EARLY_PHASE1":5936,"PHASE1":5938,"PHASE2":5951,"PHASE3":5953,"PHASE4":5955,"NA":5957},{"trials":5937,"activeCount":98},[],{"trials":5939,"activeCount":98},[5940],{"nctId":5941,"briefTitle":5942,"status":154,"phases":5943,"primaryCompletion":5944,"completion":5944,"start":5945,"enrollment":34,"conditions":5946,"interventions":5950},"NCT03790423","18F-ASIS PET\u002FCT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer",[86],"2019-11-18","2019-01-03",[15,5947,5948,4485,5949],"Lung Cancer","Pancreatic Cancer","Cervix Cancer",[5934],{"trials":5952,"activeCount":98},[],{"trials":5954,"activeCount":98},[],{"trials":5956,"activeCount":98},[],{"trials":5958,"activeCount":98},[],{"intervention":5960,"totalTrials":181,"cells":5961},"Allogeneic adipose derived stem\u002Fstromal cells",{"EARLY_PHASE1":5962,"PHASE1":5964,"PHASE2":5978,"PHASE3":5980,"PHASE4":5982,"NA":5984},{"trials":5963,"activeCount":98},[],{"trials":5965,"activeCount":98},[5966],{"nctId":5967,"briefTitle":5968,"status":967,"phases":5969,"primaryCompletion":5970,"completion":5971,"start":5972,"enrollment":34,"conditions":5973,"interventions":5977},"NCT03874572","Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia\u002FDry Mouth",[86],"2020-06-22","2025-12-01","2019-03-18",[4971,4973,4927,5974,5975,4972,4974,4975,5976],"Oropharynx Cancer","Salivary Gland Diseases","Stem Cells",[5960],{"trials":5979,"activeCount":98},[],{"trials":5981,"activeCount":98},[],{"trials":5983,"activeCount":98},[],{"trials":5985,"activeCount":98},[],{"intervention":5987,"totalTrials":181,"cells":5988},"Clarithromycin",{"EARLY_PHASE1":5989,"PHASE1":5991,"PHASE2":6000,"PHASE3":6002,"PHASE4":6004,"NA":6006},{"trials":5990,"activeCount":98},[],{"trials":5992,"activeCount":98},[5993],{"nctId":5994,"briefTitle":5995,"status":154,"phases":5996,"primaryCompletion":5997,"completion":5997,"start":3770,"enrollment":5290,"conditions":5998,"interventions":5999},"NCT00707330","Study of the Ability of Clarithromycin to Induce Oxidative Stress",[86],"2008-07",[5022],[5987],{"trials":6001,"activeCount":98},[],{"trials":6003,"activeCount":98},[],{"trials":6005,"activeCount":98},[],{"trials":6007,"activeCount":98},[],{"intervention":1734,"totalTrials":181,"cells":6009},{"EARLY_PHASE1":6010,"PHASE1":6012,"PHASE2":6018,"PHASE3":6020,"PHASE4":6022,"NA":6024},{"trials":6011,"activeCount":98},[],{"trials":6013,"activeCount":98},[6014],{"nctId":1727,"briefTitle":1728,"status":154,"phases":6015,"primaryCompletion":1730,"completion":1241,"start":1731,"enrollment":1232,"conditions":6016,"interventions":6017},[86],[25],[1734,1720],{"trials":6019,"activeCount":98},[],{"trials":6021,"activeCount":98},[],{"trials":6023,"activeCount":98},[],{"trials":6025,"activeCount":98},[],{"intervention":6027,"totalTrials":181,"cells":6028},"Calcium chloride",{"EARLY_PHASE1":6029,"PHASE1":6031,"PHASE2":6040,"PHASE3":6042,"PHASE4":6044,"NA":6046},{"trials":6030,"activeCount":98},[],{"trials":6032,"activeCount":98},[6033],{"nctId":6034,"briefTitle":6035,"status":967,"phases":6036,"primaryCompletion":6037,"completion":4642,"start":4061,"enrollment":5463,"conditions":6038,"interventions":6039},"NCT03051269","Calcium Electroporation for Head and Neck Cancer",[86],"2018-12",[5488],[6027],{"trials":6041,"activeCount":98},[],{"trials":6043,"activeCount":98},[],{"trials":6045,"activeCount":98},[],{"trials":6047,"activeCount":98},[],{"intervention":162,"totalTrials":181,"cells":6049},{"EARLY_PHASE1":6050,"PHASE1":6052,"PHASE2":6058,"PHASE3":6060,"PHASE4":6062,"NA":6064},{"trials":6051,"activeCount":98},[],{"trials":6053,"activeCount":98},[6054],{"nctId":152,"briefTitle":153,"status":154,"phases":6055,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":6056,"interventions":6057},[86],[160],[145,162],{"trials":6059,"activeCount":98},[],{"trials":6061,"activeCount":98},[],{"trials":6063,"activeCount":98},[],{"trials":6065,"activeCount":98},[],{"intervention":6067,"totalTrials":181,"cells":6068},"Injection of 68Ga-NODAGA-E(c[RGDyK])2",{"EARLY_PHASE1":6069,"PHASE1":6071,"PHASE2":6080,"PHASE3":6082,"PHASE4":6084,"NA":6086},{"trials":6070,"activeCount":98},[],{"trials":6072,"activeCount":98},[6073],{"nctId":6074,"briefTitle":6075,"status":967,"phases":6076,"primaryCompletion":6077,"start":4678,"enrollment":34,"conditions":6078,"interventions":6079},"NCT02970786","Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans",[86],"2017-06",[1605,15,4485],[6067],{"trials":6081,"activeCount":98},[],{"trials":6083,"activeCount":98},[],{"trials":6085,"activeCount":98},[],{"trials":6087,"activeCount":98},[],{"intervention":6089,"totalTrials":181,"cells":6090},"Naloxone",{"EARLY_PHASE1":6091,"PHASE1":6093,"PHASE2":6103,"PHASE3":6105,"PHASE4":6107,"NA":6109},{"trials":6092,"activeCount":98},[],{"trials":6094,"activeCount":98},[6095],{"nctId":6096,"briefTitle":6097,"status":154,"phases":6098,"primaryCompletion":3702,"completion":3702,"start":6099,"enrollment":21,"conditions":6100,"interventions":6102},"NCT01935206","Effect of High Dose Naloxone on Secondary Hyperalgesia",[86],"2013-06",[2274,23,6089,6101],"Opioid Antagonist",[6089],{"trials":6104,"activeCount":98},[],{"trials":6106,"activeCount":98},[],{"trials":6108,"activeCount":98},[],{"trials":6110,"activeCount":98},[],{"intervention":6112,"totalTrials":181,"cells":6113},"USPIO labeled MSC",{"EARLY_PHASE1":6114,"PHASE1":6116,"PHASE2":6126,"PHASE3":6128,"PHASE4":6130,"NA":6132},{"trials":6115,"activeCount":98},[],{"trials":6117,"activeCount":98},[6118],{"nctId":6119,"briefTitle":6120,"status":154,"phases":6121,"primaryCompletion":1206,"completion":6122,"start":6123,"enrollment":2404,"conditions":6124,"interventions":6125},"NCT03651791","In Vivo Tracking of USPIO Labeled MSC in the Heart",[86],"2017-10","2013-05",[5725],[6112],{"trials":6127,"activeCount":98},[],{"trials":6129,"activeCount":98},[],{"trials":6131,"activeCount":98},[],{"trials":6133,"activeCount":98},[],{"intervention":1395,"totalTrials":181,"cells":6135},{"EARLY_PHASE1":6136,"PHASE1":6142,"PHASE2":6144,"PHASE3":6146,"PHASE4":6148,"NA":6150},{"trials":6137,"activeCount":98},[6138],{"nctId":1385,"briefTitle":1386,"status":154,"phases":6139,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":6140,"interventions":6141},[85],[1392,1393],[1395,975],{"trials":6143,"activeCount":98},[],{"trials":6145,"activeCount":98},[],{"trials":6147,"activeCount":98},[],{"trials":6149,"activeCount":98},[],{"trials":6151,"activeCount":98},[],{"intervention":6153,"totalTrials":181,"cells":6154},"Adipose tissue-derived mesenchymal stem cells",{"EARLY_PHASE1":6155,"PHASE1":6169,"PHASE2":6171,"PHASE3":6173,"PHASE4":6175,"NA":6177},{"trials":6156,"activeCount":98},[6157],{"nctId":6158,"briefTitle":6159,"status":154,"phases":6160,"primaryCompletion":6161,"completion":6162,"start":6163,"enrollment":1535,"conditions":6164,"interventions":6168},"NCT03878628","Treatment With Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Aqueous Deficient Dry Eye Disease",[85],"2020-06-30","2023-02-20","2019-10-16",[6165,6166,6167],"Dry Eye","Kerato Conjunctivitis Sicca","Aqueous Tear Deficiency",[6153],{"trials":6170,"activeCount":98},[],{"trials":6172,"activeCount":98},[],{"trials":6174,"activeCount":98},[],{"trials":6176,"activeCount":98},[],{"trials":6178,"activeCount":98},[],{"intervention":1491,"totalTrials":1463,"cells":6180},{"EARLY_PHASE1":6181,"PHASE1":6183,"PHASE2":6185,"PHASE3":6187,"PHASE4":6193,"NA":6195},{"trials":6182,"activeCount":98},[],{"trials":6184,"activeCount":98},[],{"trials":6186,"activeCount":98},[],{"trials":6188,"activeCount":98},[6189],{"nctId":3972,"briefTitle":3973,"status":154,"phases":6190,"primaryCompletion":3975,"completion":3975,"start":3976,"enrollment":1390,"conditions":6191,"interventions":6192},[88],[891],[3961,3979,3980,1491],{"trials":6194,"activeCount":98},[],{"trials":6196,"activeCount":98},[6197,6208,6212],{"nctId":6198,"briefTitle":6199,"status":154,"phases":6200,"primaryCompletion":6201,"completion":6201,"start":6202,"enrollment":34,"conditions":6203,"interventions":6205},"NCT04337268","Acute Effects of GLP-1 on Renal Hemodynamics",[90],"2020-03-01","2019-04-01",[6204],"The GLP-1-mediated Gut-kidney Axis",[6206,6207],"Glucagon-Like Peptide 1","saline 0.9%",{"nctId":1482,"briefTitle":1483,"status":154,"phases":6209,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":1487,"conditions":6210,"interventions":6211},[90],[1489,18],[60,1491],{"nctId":1493,"briefTitle":1494,"status":154,"phases":6213,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":1498,"conditions":6214,"interventions":6215},[90],[1489,18],[60,1491],{"intervention":6217,"totalTrials":979,"cells":6218},"68Ga-NODAGA-E[c(RGDyK)]2",{"EARLY_PHASE1":6219,"PHASE1":6221,"PHASE2":6223,"PHASE3":6238,"PHASE4":6240,"NA":6242},{"trials":6220,"activeCount":98},[],{"trials":6222,"activeCount":98},[],{"trials":6224,"activeCount":98},[6225,6231],{"nctId":6226,"briefTitle":6227,"status":967,"phases":6228,"primaryCompletion":5971,"completion":5971,"start":2801,"enrollment":3595,"conditions":6229,"interventions":6230},"NCT03505346","68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease",[87],[1244],[6217],{"nctId":6232,"briefTitle":6233,"status":154,"phases":6234,"primaryCompletion":1389,"completion":1389,"start":6235,"enrollment":3595,"conditions":6236,"interventions":6237},"NCT03445884","68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis",[87],"2018-02-20",[1326],[6217],{"trials":6239,"activeCount":98},[],{"trials":6241,"activeCount":98},[],{"trials":6243,"activeCount":98},[6244],{"nctId":6245,"briefTitle":6246,"status":967,"phases":6247,"primaryCompletion":254,"completion":254,"start":6248,"enrollment":1498,"conditions":6249,"interventions":6251},"NCT03655977","Radiation Therapy Planning by Multi-parametric PET\u002FMRI Imaging in Patients With Cervical Cancer",[90],"2018-09-01",[6250],"Cervical Cancer",[6217,6217],{"intervention":6253,"totalTrials":94,"cells":6254},"Faricimab Injection [Vabysmo]",{"EARLY_PHASE1":6255,"PHASE1":6257,"PHASE2":6259,"PHASE3":6261,"PHASE4":6263,"NA":6265},{"trials":6256,"activeCount":98},[],{"trials":6258,"activeCount":98},[],{"trials":6260,"activeCount":98},[],{"trials":6262,"activeCount":98},[],{"trials":6264,"activeCount":98},[],{"trials":6266,"activeCount":98},[6267,6278],{"nctId":6268,"briefTitle":6269,"status":154,"phases":6270,"primaryCompletion":6271,"completion":6272,"start":6273,"enrollment":6274,"conditions":6275,"interventions":6277},"NCT06902207","Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy",[],"2025-01-26","2025-03-01","2024-11-10",6053,[6276],"Intraocular Inflammation",[6253],{"nctId":6279,"briefTitle":6280,"status":154,"phases":6281,"primaryCompletion":6282,"completion":6282,"start":1919,"enrollment":6283,"conditions":6284,"interventions":6287},"NCT06890026","Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration",[],"2026-03-01",742,[6285,6286],"Neovascular Age-Related Macular Degeneration (nAMD)","Treatment-naïve",[6253],{"intervention":6289,"totalTrials":94,"cells":6290},"Blood samples",{"EARLY_PHASE1":6291,"PHASE1":6293,"PHASE2":6295,"PHASE3":6297,"PHASE4":6299,"NA":6301},{"trials":6292,"activeCount":98},[],{"trials":6294,"activeCount":98},[],{"trials":6296,"activeCount":98},[],{"trials":6298,"activeCount":98},[],{"trials":6300,"activeCount":98},[],{"trials":6302,"activeCount":98},[6303,6314],{"nctId":6304,"briefTitle":6305,"status":154,"phases":6306,"primaryCompletion":6307,"completion":6307,"start":6308,"enrollment":158,"conditions":6309,"interventions":6313},"NCT03826381","NAFLD Among Patients With Type 2 Diabetes and CKD",[],"2021-06-23","2019-05-06",[6310,6311,6312],"Non-Alcoholic Fatty Liver Disease","Chronic Kidney Diseases","Type2 Diabetes",[6289],{"nctId":6315,"briefTitle":6316,"status":936,"phases":6317,"primaryCompletion":6318,"completion":6319,"start":6320,"enrollment":979,"conditions":6321,"interventions":6324},"NCT03866421","NAFLD Among Patients With Chronic Kidney Disease and the Effect of Kidney Transplantation",[],"2021-02-25","2022-03-31","2019-05-29",[6310,6311,6322,6323],"PreDiabetes","Kidney Transplant",[6289],{"intervention":6326,"totalTrials":94,"cells":6327},"Oxygen",{"EARLY_PHASE1":6328,"PHASE1":6330,"PHASE2":6332,"PHASE3":6334,"PHASE4":6336,"NA":6346},{"trials":6329,"activeCount":98},[],{"trials":6331,"activeCount":98},[],{"trials":6333,"activeCount":98},[],{"trials":6335,"activeCount":98},[],{"trials":6337,"activeCount":98},[6338],{"nctId":6339,"briefTitle":6340,"status":154,"phases":6341,"primaryCompletion":3177,"completion":1834,"start":6342,"enrollment":1966,"conditions":6343,"interventions":6345},"NCT00364741","Supplemental Oxygen and Complications After Abdominal Surgery (The PROXI-trial)",[89],"2006-10",[6344],"Laparotomy",[6326],{"trials":6347,"activeCount":98},[6348],{"nctId":6349,"briefTitle":6350,"status":936,"phases":6351,"primaryCompletion":6352,"completion":6352,"start":6353,"enrollment":979,"conditions":6354,"interventions":6355},"NCT05686265","Cerebral Nitrosative\u002FOxidative Stress in Aneurysmal Subarachnoid Haemorrhage",[],"2024-03-15","2023-05-11",[578],[6326],{"intervention":6357,"totalTrials":94,"cells":6358},"Escherichia Coli Endotoxin",{"EARLY_PHASE1":6359,"PHASE1":6361,"PHASE2":6363,"PHASE3":6365,"PHASE4":6367,"NA":6369},{"trials":6360,"activeCount":98},[],{"trials":6362,"activeCount":98},[],{"trials":6364,"activeCount":98},[],{"trials":6366,"activeCount":98},[],{"trials":6368,"activeCount":98},[],{"trials":6370,"activeCount":98},[6371,6380],{"nctId":6372,"briefTitle":6373,"status":154,"phases":6374,"primaryCompletion":6375,"completion":6375,"start":6376,"enrollment":2271,"conditions":6377,"interventions":6379},"NCT00412906","Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls",[90],"2008-04","2006-11",[18,30,6378],"Endotoxemia",[6357],{"nctId":6381,"briefTitle":6382,"status":967,"phases":6383,"completion":5339,"start":6376,"enrollment":3619,"conditions":6384,"interventions":6385},"NCT00413465","Study of Renal Blood Flow During Human Endotoxemia",[90],[18,30,6378],[6357],{"intervention":6387,"totalTrials":94,"cells":6388},"Rocuronium",{"EARLY_PHASE1":6389,"PHASE1":6391,"PHASE2":6393,"PHASE3":6395,"PHASE4":6397,"NA":6408},{"trials":6390,"activeCount":98},[],{"trials":6392,"activeCount":98},[],{"trials":6394,"activeCount":98},[],{"trials":6396,"activeCount":98},[],{"trials":6398,"activeCount":98},[6399],{"nctId":6400,"briefTitle":6401,"status":154,"phases":6402,"primaryCompletion":4516,"completion":4516,"start":6403,"enrollment":6404,"conditions":6405,"interventions":6407},"NCT00540085","Pharmacodynamic Trial on Rocuronium in Obese Patients",[89],"2007-10",51,[6406],"Bariatric Surgery",[6387],{"trials":6409,"activeCount":98},[6410],{"nctId":6411,"briefTitle":6412,"status":154,"phases":6413,"primaryCompletion":6414,"completion":6414,"start":6415,"enrollment":3619,"conditions":6416,"interventions":6418},"NCT03857750","Neuromuscular Blocking Agents in the Elderly",[],"2019-10-08","2019-03-27",[6417],"Elective Surgery",[6387],{"intervention":6420,"totalTrials":94,"cells":6421},"Faricimab",{"EARLY_PHASE1":6422,"PHASE1":6424,"PHASE2":6426,"PHASE3":6428,"PHASE4":6430,"NA":6432},{"trials":6423,"activeCount":98},[],{"trials":6425,"activeCount":98},[],{"trials":6427,"activeCount":98},[],{"trials":6429,"activeCount":98},[],{"trials":6431,"activeCount":98},[],{"trials":6433,"activeCount":98},[6434,6443],{"nctId":6435,"briefTitle":6436,"status":154,"phases":6437,"primaryCompletion":6438,"completion":6439,"start":4967,"enrollment":26,"conditions":6440,"interventions":6442},"NCT06231121","Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab",[],"2024-01-15","2024-01-19",[6441],"Neovascular Age-related Macular Degeneration",[6420],{"nctId":6444,"briefTitle":6445,"status":154,"phases":6446,"primaryCompletion":6447,"completion":4967,"start":6448,"enrollment":176,"conditions":6449,"interventions":6450},"NCT06124677","Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments",[],"2023-11-15","2023-11-01",[6441],[6420],{"intervention":6452,"totalTrials":181,"cells":6453},"Corticosteroid",{"EARLY_PHASE1":6454,"PHASE1":6456,"PHASE2":6458,"PHASE3":6460,"PHASE4":6462,"NA":6464},{"trials":6455,"activeCount":98},[],{"trials":6457,"activeCount":98},[],{"trials":6459,"activeCount":98},[],{"trials":6461,"activeCount":98},[],{"trials":6463,"activeCount":98},[],{"trials":6465,"activeCount":98},[6466],{"nctId":6467,"briefTitle":6468,"status":936,"phases":6469,"primaryCompletion":6470,"completion":6471,"start":6472,"enrollment":979,"conditions":6473,"interventions":6476},"NCT05698563","Intermetatarsal Bursitis in Patients With Rheumatoid Arthritis",[90],"2023-02-14","2024-12-12","2023-01-18",[6474,6475],"Intermetatarsal Bursitis","Rheumatoid Arthritis",[6452],{"intervention":6478,"totalTrials":181,"cells":6479},"Temozolomide",{"EARLY_PHASE1":6480,"PHASE1":6482,"PHASE2":6484,"PHASE3":6486,"PHASE4":6488,"NA":6490},{"trials":6481,"activeCount":98},[],{"trials":6483,"activeCount":98},[],{"trials":6485,"activeCount":98},[],{"trials":6487,"activeCount":98},[],{"trials":6489,"activeCount":98},[],{"trials":6491,"activeCount":98},[6492],{"nctId":6493,"briefTitle":6494,"status":936,"phases":6495,"primaryCompletion":3553,"completion":3553,"start":2270,"enrollment":1390,"conditions":6496,"interventions":6498},"NCT02329795","Image-derived Prediction of Response to Chemo-radiation in Glioblastoma",[],[6497],"Glioblastoma",[6478],{"intervention":6500,"totalTrials":181,"cells":6501},"Sirolimus based immunosuppression",{"EARLY_PHASE1":6502,"PHASE1":6504,"PHASE2":6506,"PHASE3":6508,"PHASE4":6510,"NA":6512},{"trials":6503,"activeCount":98},[],{"trials":6505,"activeCount":98},[],{"trials":6507,"activeCount":98},[],{"trials":6509,"activeCount":98},[],{"trials":6511,"activeCount":98},[],{"trials":6513,"activeCount":98},[6514],{"nctId":6515,"briefTitle":6516,"status":154,"phases":6517,"primaryCompletion":6518,"completion":6519,"start":6520,"enrollment":6521,"conditions":6522,"interventions":6524},"NCT02995096","Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma",[],"2018-10","2019-03","2016-01",23124,[6523],"Liver Transplantation",[6500],{"intervention":6206,"totalTrials":181,"cells":6526},{"EARLY_PHASE1":6527,"PHASE1":6529,"PHASE2":6531,"PHASE3":6533,"PHASE4":6535,"NA":6537},{"trials":6528,"activeCount":98},[],{"trials":6530,"activeCount":98},[],{"trials":6532,"activeCount":98},[],{"trials":6534,"activeCount":98},[],{"trials":6536,"activeCount":98},[],{"trials":6538,"activeCount":98},[6539],{"nctId":6198,"briefTitle":6199,"status":154,"phases":6540,"primaryCompletion":6201,"completion":6201,"start":6202,"enrollment":34,"conditions":6541,"interventions":6542},[90],[6204],[6206,6207],{"intervention":6544,"totalTrials":181,"cells":6545},"Antihypertensiva, mainly Metyldopa",{"EARLY_PHASE1":6546,"PHASE1":6548,"PHASE2":6550,"PHASE3":6552,"PHASE4":6554,"NA":6556},{"trials":6547,"activeCount":98},[],{"trials":6549,"activeCount":98},[],{"trials":6551,"activeCount":98},[],{"trials":6553,"activeCount":98},[],{"trials":6555,"activeCount":98},[],{"trials":6557,"activeCount":98},[6558],{"nctId":6559,"briefTitle":6560,"status":154,"phases":6561,"primaryCompletion":3552,"completion":6562,"start":1965,"enrollment":6563,"conditions":6564,"interventions":6566},"NCT02890836","Blood Pressure, Antihypertensive Treatment and Preeclampsia in Pregnant Wom-en With Pre-existing Diabetes",[],"2021-02",513,[6565],"Pregnancy in Diabetics",[6544],{"intervention":6568,"totalTrials":181,"cells":6569},"Amiodarone",{"EARLY_PHASE1":6570,"PHASE1":6572,"PHASE2":6574,"PHASE3":6576,"PHASE4":6578,"NA":6580},{"trials":6571,"activeCount":98},[],{"trials":6573,"activeCount":98},[],{"trials":6575,"activeCount":98},[],{"trials":6577,"activeCount":98},[],{"trials":6579,"activeCount":98},[],{"trials":6581,"activeCount":98},[6582],{"nctId":6583,"briefTitle":6584,"status":154,"phases":6585,"primaryCompletion":1241,"completion":1241,"start":1437,"enrollment":766,"conditions":6586,"interventions":6587},"NCT00826826","The Effect of Short Term Amiodarone Treatment After Catheter Ablation for Atrial Fibrillation",[90],[232],[6568],{"intervention":6589,"totalTrials":181,"cells":6590},"ultrasound contrast",{"EARLY_PHASE1":6591,"PHASE1":6593,"PHASE2":6595,"PHASE3":6597,"PHASE4":6599,"NA":6601},{"trials":6592,"activeCount":98},[],{"trials":6594,"activeCount":98},[],{"trials":6596,"activeCount":98},[],{"trials":6598,"activeCount":98},[],{"trials":6600,"activeCount":98},[],{"trials":6602,"activeCount":98},[6603],{"nctId":6604,"briefTitle":6605,"status":154,"phases":6606,"primaryCompletion":6607,"completion":6375,"start":4560,"enrollment":1455,"conditions":6608,"interventions":6610},"NCT00370136","Sentinel Node With Ultrasound Contrast in Melanoma",[90],"2008-03",[6609],"Malignant Melanoma",[6589],{"intervention":6612,"totalTrials":181,"cells":6613},"Infusion of sodium nitroprusside",{"EARLY_PHASE1":6614,"PHASE1":6616,"PHASE2":6618,"PHASE3":6620,"PHASE4":6622,"NA":6624},{"trials":6615,"activeCount":98},[],{"trials":6617,"activeCount":98},[],{"trials":6619,"activeCount":98},[],{"trials":6621,"activeCount":98},[],{"trials":6623,"activeCount":98},[],{"trials":6625,"activeCount":98},[6626],{"nctId":6627,"briefTitle":6628,"status":154,"phases":6629,"primaryCompletion":4851,"completion":4851,"start":6630,"enrollment":1455,"conditions":6631,"interventions":6633},"NCT03317652","Effect of Sodium Nitroprusside on Cerebral Blood Flow",[90],"2017-11-03",[6632],"Healthy Male Subjects",[6612],{"intervention":926,"totalTrials":181,"cells":6635},{"EARLY_PHASE1":6636,"PHASE1":6638,"PHASE2":6640,"PHASE3":6642,"PHASE4":6644,"NA":6646},{"trials":6637,"activeCount":98},[],{"trials":6639,"activeCount":98},[],{"trials":6641,"activeCount":98},[],{"trials":6643,"activeCount":98},[],{"trials":6645,"activeCount":98},[],{"trials":6647,"activeCount":98},[6648],{"nctId":6649,"briefTitle":6650,"status":936,"phases":6651,"primaryCompletion":2389,"completion":2389,"start":3528,"enrollment":34,"conditions":6652,"interventions":6655},"NCT02167633","Stereotactic Radiosurgery in Metastatic Spinal Cord Compression",[90],[6653,6654],"Spinal Cord Compression","Neoplasm Metastasis",[926,6656],"Pantoprazole",{"intervention":6656,"totalTrials":181,"cells":6658},{"EARLY_PHASE1":6659,"PHASE1":6661,"PHASE2":6663,"PHASE3":6665,"PHASE4":6667,"NA":6669},{"trials":6660,"activeCount":98},[],{"trials":6662,"activeCount":98},[],{"trials":6664,"activeCount":98},[],{"trials":6666,"activeCount":98},[],{"trials":6668,"activeCount":98},[],{"trials":6670,"activeCount":98},[6671],{"nctId":6649,"briefTitle":6650,"status":936,"phases":6672,"primaryCompletion":2389,"completion":2389,"start":3528,"enrollment":34,"conditions":6673,"interventions":6674},[90],[6653,6654],[926,6656],{"intervention":6676,"totalTrials":181,"cells":6677},"Estrogen",{"EARLY_PHASE1":6678,"PHASE1":6680,"PHASE2":6682,"PHASE3":6684,"PHASE4":6686,"NA":6688},{"trials":6679,"activeCount":98},[],{"trials":6681,"activeCount":98},[],{"trials":6683,"activeCount":98},[],{"trials":6685,"activeCount":98},[],{"trials":6687,"activeCount":98},[],{"trials":6689,"activeCount":98},[6690],{"nctId":6691,"briefTitle":6692,"status":967,"phases":6693,"primaryCompletion":6694,"completion":970,"start":6695,"enrollment":1455,"conditions":6696,"interventions":6699},"NCT05302726","Impact of Exogenous Estrogens on Cotisol Levels During Synacthen Stimulation",[90],"2022-12-31","2022-01-01",[6697,6698],"Adrenal Insufficiency","Hypogonadism Female",[6676],{"intervention":6701,"totalTrials":181,"cells":6702},"Botulinum toxin type A",{"EARLY_PHASE1":6703,"PHASE1":6705,"PHASE2":6707,"PHASE3":6709,"PHASE4":6711,"NA":6713},{"trials":6704,"activeCount":98},[],{"trials":6706,"activeCount":98},[],{"trials":6708,"activeCount":98},[],{"trials":6710,"activeCount":98},[],{"trials":6712,"activeCount":98},[],{"trials":6714,"activeCount":98},[6715],{"nctId":6716,"briefTitle":6717,"status":967,"phases":6718,"primaryCompletion":6719,"completion":6720,"start":175,"enrollment":2404,"conditions":6721,"interventions":6727},"NCT04207632","Quantifying Muscle Tone in Patients With Brain Injury - a Feasibility Study",[],"2021-01-15","2021-04-01",[1894,6722,6723,6724,6725,6726],"Muscle Dystonia","Spasticity, Muscle","Muscle Tightness","Acquired Brain Injury","Muscle Tone Abnormalities",[6701],{"intervention":6729,"totalTrials":181,"cells":6730},"Cu-64 DOTATATE",{"EARLY_PHASE1":6731,"PHASE1":6733,"PHASE2":6735,"PHASE3":6737,"PHASE4":6739,"NA":6741},{"trials":6732,"activeCount":98},[],{"trials":6734,"activeCount":98},[],{"trials":6736,"activeCount":98},[],{"trials":6738,"activeCount":98},[],{"trials":6740,"activeCount":98},[],{"trials":6742,"activeCount":98},[6743],{"nctId":6744,"briefTitle":6745,"status":3550,"phases":6746,"primaryCompletion":1205,"completion":6747,"start":3839,"enrollment":98,"conditions":6748,"interventions":6750},"NCT02812849","Somatostatin Receptor Imaging in Cardiac Sarcoidosis",[],"2020-02-27",[6749],"Cardiac Sarcoidosis",[6729],{"intervention":6752,"totalTrials":181,"cells":6753},"Tocilizumab Injectable Product",{"EARLY_PHASE1":6754,"PHASE1":6756,"PHASE2":6758,"PHASE3":6760,"PHASE4":6762,"NA":6764},{"trials":6755,"activeCount":98},[],{"trials":6757,"activeCount":98},[],{"trials":6759,"activeCount":98},[],{"trials":6761,"activeCount":98},[],{"trials":6763,"activeCount":98},[],{"trials":6765,"activeCount":98},[6766],{"nctId":6767,"briefTitle":6768,"status":154,"phases":6769,"primaryCompletion":6770,"completion":6770,"start":6771,"enrollment":791,"conditions":6772,"interventions":6776},"NCT04616235","Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade",[90],"2021-10-04","2021-03-15",[6773,6774,6775],"Interleukin-6 Inhibition","Physical Stress","Appetitive Behavior",[6752],{"intervention":6778,"totalTrials":181,"cells":6779},"Voluven",{"EARLY_PHASE1":6780,"PHASE1":6782,"PHASE2":6784,"PHASE3":6786,"PHASE4":6788,"NA":6790},{"trials":6781,"activeCount":98},[],{"trials":6783,"activeCount":98},[],{"trials":6785,"activeCount":98},[],{"trials":6787,"activeCount":98},[],{"trials":6789,"activeCount":98},[],{"trials":6791,"activeCount":98},[6792],{"nctId":6793,"briefTitle":6794,"status":936,"phases":6795,"primaryCompletion":1454,"completion":1454,"start":6796,"enrollment":2404,"conditions":6797,"interventions":6799},"NCT01452581","Liberal Versus Restrictive Transfusion During Symptomatic Moderate Anemia After Hip Arthroplasty",[90],"2011-10",[6798],"Arthroplasty, Hip",[6778],{"intervention":6801,"totalTrials":181,"cells":6802},"Cocaine Nasal",{"EARLY_PHASE1":6803,"PHASE1":6805,"PHASE2":6807,"PHASE3":6809,"PHASE4":6811,"NA":6813},{"trials":6804,"activeCount":98},[],{"trials":6806,"activeCount":98},[],{"trials":6808,"activeCount":98},[],{"trials":6810,"activeCount":98},[],{"trials":6812,"activeCount":98},[],{"trials":6814,"activeCount":98},[6815],{"nctId":6816,"briefTitle":6817,"status":154,"phases":6818,"primaryCompletion":6819,"completion":6819,"start":3362,"enrollment":6820,"conditions":6821,"interventions":6823},"NCT05334056","Drug Test Detection of Cocaine for Nasal Intubation",[],"2023-05-27",27,[6822],"Cocaine Adverse Reaction",[6801],{"intervention":6825,"totalTrials":181,"cells":6826},"Hydrochloric Acid",{"EARLY_PHASE1":6827,"PHASE1":6829,"PHASE2":6831,"PHASE3":6833,"PHASE4":6835,"NA":6837},{"trials":6828,"activeCount":98},[],{"trials":6830,"activeCount":98},[],{"trials":6832,"activeCount":98},[],{"trials":6834,"activeCount":98},[],{"trials":6836,"activeCount":98},[],{"trials":6838,"activeCount":98},[6839],{"nctId":6840,"briefTitle":6841,"status":154,"phases":6842,"primaryCompletion":6282,"completion":6282,"start":6843,"enrollment":766,"conditions":6844,"interventions":6846},"NCT05376566","Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections",[90],"2022-06-01",[6845],"Central Line-associated Bloodstream Infection (CLABSI)",[6825,6847],"Normal saline",{"intervention":6847,"totalTrials":181,"cells":6849},{"EARLY_PHASE1":6850,"PHASE1":6852,"PHASE2":6854,"PHASE3":6856,"PHASE4":6858,"NA":6860},{"trials":6851,"activeCount":98},[],{"trials":6853,"activeCount":98},[],{"trials":6855,"activeCount":98},[],{"trials":6857,"activeCount":98},[],{"trials":6859,"activeCount":98},[],{"trials":6861,"activeCount":98},[6862],{"nctId":6840,"briefTitle":6841,"status":154,"phases":6863,"primaryCompletion":6282,"completion":6282,"start":6843,"enrollment":766,"conditions":6864,"interventions":6865},[90],[6845],[6825,6847],{"intervention":6867,"totalTrials":181,"cells":6868},"Probiotic",{"EARLY_PHASE1":6869,"PHASE1":6871,"PHASE2":6873,"PHASE3":6875,"PHASE4":6877,"NA":6879},{"trials":6870,"activeCount":98},[],{"trials":6872,"activeCount":98},[],{"trials":6874,"activeCount":98},[],{"trials":6876,"activeCount":98},[],{"trials":6878,"activeCount":98},[],{"trials":6880,"activeCount":98},[6881],{"nctId":6882,"briefTitle":6883,"status":154,"phases":6884,"primaryCompletion":3594,"completion":2389,"start":816,"enrollment":940,"conditions":6885,"interventions":6887},"NCT02764684","The Effect of Probiotics on Microbial Translocation and Inflammation in HIV-infected Patients",[90],[6886],"HIV",[6867],{"intervention":6889,"totalTrials":181,"cells":6890},"Hormone treatment",{"EARLY_PHASE1":6891,"PHASE1":6893,"PHASE2":6895,"PHASE3":6897,"PHASE4":6899,"NA":6901},{"trials":6892,"activeCount":98},[],{"trials":6894,"activeCount":98},[],{"trials":6896,"activeCount":98},[],{"trials":6898,"activeCount":98},[],{"trials":6900,"activeCount":98},[],{"trials":6902,"activeCount":98},[6903],{"nctId":6904,"briefTitle":6905,"status":967,"phases":6906,"primaryCompletion":6907,"completion":6907,"start":2320,"enrollment":2271,"conditions":6908,"interventions":6910},"NCT02525276","Female Sex Hormones, Insulin Resistance and Effects of Exercise in a Human Experimental Model of Menopause",[90],"2018-08",[6909],"Metabolic Syndrome",[6889],{"intervention":6912,"totalTrials":181,"cells":6913},"Mepivacaine with epinephrine",{"EARLY_PHASE1":6914,"PHASE1":6916,"PHASE2":6918,"PHASE3":6920,"PHASE4":6922,"NA":6924},{"trials":6915,"activeCount":98},[],{"trials":6917,"activeCount":98},[],{"trials":6919,"activeCount":98},[],{"trials":6921,"activeCount":98},[],{"trials":6923,"activeCount":98},[],{"trials":6925,"activeCount":98},[6926],{"nctId":6927,"briefTitle":6928,"status":936,"phases":6929,"primaryCompletion":1709,"completion":1709,"start":1454,"enrollment":1390,"conditions":6930,"interventions":6932},"NCT01533545","Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients",[90],[6931],"Renal Insufficiency, Chronic",[6912,6933],"Plain mepivacaine",{"intervention":6933,"totalTrials":181,"cells":6935},{"EARLY_PHASE1":6936,"PHASE1":6938,"PHASE2":6940,"PHASE3":6942,"PHASE4":6944,"NA":6946},{"trials":6937,"activeCount":98},[],{"trials":6939,"activeCount":98},[],{"trials":6941,"activeCount":98},[],{"trials":6943,"activeCount":98},[],{"trials":6945,"activeCount":98},[],{"trials":6947,"activeCount":98},[6948],{"nctId":6927,"briefTitle":6928,"status":936,"phases":6949,"primaryCompletion":1709,"completion":1709,"start":1454,"enrollment":1390,"conditions":6950,"interventions":6951},[90],[6931],[6912,6933],{"intervention":6953,"totalTrials":181,"cells":6954},"Iron-III Isomaltoside 1000",{"EARLY_PHASE1":6955,"PHASE1":6957,"PHASE2":6959,"PHASE3":6961,"PHASE4":6963,"NA":6965},{"trials":6956,"activeCount":98},[],{"trials":6958,"activeCount":98},[],{"trials":6960,"activeCount":98},[],{"trials":6962,"activeCount":98},[],{"trials":6964,"activeCount":98},[],{"trials":6966,"activeCount":98},[6967],{"nctId":6968,"briefTitle":6969,"status":967,"phases":6970,"primaryCompletion":3553,"completion":6971,"start":2270,"enrollment":6972,"conditions":6973,"interventions":6977},"NCT02385383","An Intravenous Iron Based Protocol for Preoperative Anaemia in Hip and Knee Surgery - An Observational Study",[],"2017-02",300,[6974,6975,6976],"Anemia","Arthroplasty, Replacement, Hip","Arthroplasty, Replacement, Knee",[6953],{"intervention":6979,"totalTrials":181,"cells":6980},"Lactobacillus acidophilus NCFM",{"EARLY_PHASE1":6981,"PHASE1":6983,"PHASE2":6985,"PHASE3":6987,"PHASE4":6989,"NA":6991},{"trials":6982,"activeCount":98},[],{"trials":6984,"activeCount":98},[],{"trials":6986,"activeCount":98},[],{"trials":6988,"activeCount":98},[],{"trials":6990,"activeCount":98},[],{"trials":6992,"activeCount":98},[6993],{"nctId":6994,"briefTitle":6995,"status":967,"phases":6996,"completion":5339,"start":6376,"enrollment":2271,"conditions":6997,"interventions":6998},"NCT00413348","Type 2 Diabetes and the Effect of Probiotics",[90],[30,18,6378],[6979],{"intervention":7000,"totalTrials":181,"cells":7001},"Propofol Thiopental",{"EARLY_PHASE1":7002,"PHASE1":7004,"PHASE2":7006,"PHASE3":7008,"PHASE4":7010,"NA":7012},{"trials":7003,"activeCount":98},[],{"trials":7005,"activeCount":98},[],{"trials":7007,"activeCount":98},[],{"trials":7009,"activeCount":98},[],{"trials":7011,"activeCount":98},[],{"trials":7013,"activeCount":98},[7014],{"nctId":7015,"briefTitle":7016,"status":967,"phases":7017,"completion":5339,"start":7018,"enrollment":158,"conditions":7019,"interventions":7021},"NCT00379886","Comparison of Thiopental and Propofol as Anaesteticum During ECT",[90],"2003-01",[7020],"Depression",[7000],{"intervention":7023,"totalTrials":181,"cells":7024},"Capsaicin",{"EARLY_PHASE1":7025,"PHASE1":7027,"PHASE2":7029,"PHASE3":7031,"PHASE4":7033,"NA":7035},{"trials":7026,"activeCount":98},[],{"trials":7028,"activeCount":98},[],{"trials":7030,"activeCount":98},[],{"trials":7032,"activeCount":98},[],{"trials":7034,"activeCount":98},[],{"trials":7036,"activeCount":98},[7037],{"nctId":7038,"briefTitle":7039,"status":154,"phases":7040,"completion":3884,"start":3884,"enrollment":3595,"conditions":7041,"interventions":7043},"NCT00583180","Sensory Function After Wound Instillation of Capsaicin",[],[7042],"Primary Hyperalgesia",[7023],{"intervention":7045,"totalTrials":181,"cells":7046},"Estradiol",{"EARLY_PHASE1":7047,"PHASE1":7049,"PHASE2":7051,"PHASE3":7053,"PHASE4":7055,"NA":7057},{"trials":7048,"activeCount":98},[],{"trials":7050,"activeCount":98},[],{"trials":7052,"activeCount":98},[],{"trials":7054,"activeCount":98},[],{"trials":7056,"activeCount":98},[],{"trials":7058,"activeCount":98},[7059],{"nctId":7060,"briefTitle":7061,"status":967,"phases":7062,"primaryCompletion":7063,"completion":7063,"start":1241,"enrollment":7064,"conditions":7065,"interventions":7067},"NCT02638922","Evaluation and Treatment of Tall Statured Girls",[],"2017-12",304,[7066],"Constitutional Tall Stature",[7045],{"intervention":7069,"totalTrials":181,"cells":7070},"Zolpidem",{"EARLY_PHASE1":7071,"PHASE1":7073,"PHASE2":7075,"PHASE3":7077,"PHASE4":7079,"NA":7081},{"trials":7072,"activeCount":98},[],{"trials":7074,"activeCount":98},[],{"trials":7076,"activeCount":98},[],{"trials":7078,"activeCount":98},[],{"trials":7080,"activeCount":98},[],{"trials":7082,"activeCount":98},[7083],{"nctId":7084,"briefTitle":7085,"status":967,"phases":7086,"primaryCompletion":4036,"completion":4397,"start":4461,"enrollment":1455,"conditions":7087,"interventions":7089},"NCT01551485","Postoperative Sleep Disturbances After Zolpidem Treatment in Fast-track Hip and Knee Replacement",[90],[7088],"Sleep Duration on the First Night After Surgery",[7069],{"intervention":7091,"totalTrials":181,"cells":7092},"Metformin",{"EARLY_PHASE1":7093,"PHASE1":7095,"PHASE2":7097,"PHASE3":7099,"PHASE4":7101,"NA":7103},{"trials":7094,"activeCount":98},[],{"trials":7096,"activeCount":98},[],{"trials":7098,"activeCount":98},[],{"trials":7100,"activeCount":98},[],{"trials":7102,"activeCount":98},[],{"trials":7104,"activeCount":98},[7105],{"nctId":7106,"briefTitle":7107,"status":154,"phases":7108,"primaryCompletion":5830,"completion":7109,"start":3553,"enrollment":21,"conditions":7110,"interventions":7112},"NCT02951260","The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation",[90],"2017-07",[7111],"Diabetes Mellitus, Type 2",[7091],{"intervention":7114,"totalTrials":181,"cells":7115},"Pfizer-BioNTech mRNA COVID-19 vaccination",{"EARLY_PHASE1":7116,"PHASE1":7118,"PHASE2":7120,"PHASE3":7122,"PHASE4":7124,"NA":7126},{"trials":7117,"activeCount":98},[],{"trials":7119,"activeCount":98},[],{"trials":7121,"activeCount":98},[],{"trials":7123,"activeCount":98},[],{"trials":7125,"activeCount":98},[],{"trials":7127,"activeCount":98},[7128],{"nctId":7129,"briefTitle":7130,"status":967,"phases":7131,"primaryCompletion":7132,"completion":7133,"start":7134,"enrollment":7135,"conditions":7136,"interventions":7142},"NCT05186571","Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old",[],"2022-03-01","2022-04-28","2021-12-01",350000,[7137,7138,7139,7140,7141],"Myopericarditis","Myocarditis","Vaccination; Complications","COVID-19 Pandemic","SARS-CoV2 Infection",[7114],{"intervention":7144,"totalTrials":181,"cells":7145},"Zidovudine and Lamivudine",{"EARLY_PHASE1":7146,"PHASE1":7148,"PHASE2":7150,"PHASE3":7152,"PHASE4":7154,"NA":7156},{"trials":7147,"activeCount":98},[],{"trials":7149,"activeCount":98},[],{"trials":7151,"activeCount":98},[],{"trials":7153,"activeCount":98},[],{"trials":7155,"activeCount":98},[],{"trials":7157,"activeCount":98},[7158],{"nctId":7159,"briefTitle":7160,"status":154,"phases":7161,"primaryCompletion":7162,"completion":790,"start":5241,"enrollment":7163,"conditions":7164,"interventions":7166},"NCT00346567","Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)",[90],"2010-10",566,[7165],"HIV Infections",[7144,7167],"Emtricitabine and Tenofovir",{"intervention":7167,"totalTrials":181,"cells":7169},{"EARLY_PHASE1":7170,"PHASE1":7172,"PHASE2":7174,"PHASE3":7176,"PHASE4":7178,"NA":7180},{"trials":7171,"activeCount":98},[],{"trials":7173,"activeCount":98},[],{"trials":7175,"activeCount":98},[],{"trials":7177,"activeCount":98},[],{"trials":7179,"activeCount":98},[],{"trials":7181,"activeCount":98},[7182],{"nctId":7159,"briefTitle":7160,"status":154,"phases":7183,"primaryCompletion":7162,"completion":790,"start":5241,"enrollment":7163,"conditions":7184,"interventions":7185},[90],[7165],[7144,7167],{"intervention":7187,"totalTrials":181,"cells":7188},"Recombinant human Erythropoietin",{"EARLY_PHASE1":7189,"PHASE1":7191,"PHASE2":7193,"PHASE3":7195,"PHASE4":7197,"NA":7199},{"trials":7190,"activeCount":98},[],{"trials":7192,"activeCount":98},[],{"trials":7194,"activeCount":98},[],{"trials":7196,"activeCount":98},[],{"trials":7198,"activeCount":98},[],{"trials":7200,"activeCount":98},[7201],{"nctId":7202,"briefTitle":7203,"status":967,"phases":7204,"primaryCompletion":4151,"completion":3703,"start":7205,"enrollment":31,"conditions":7206,"interventions":7207},"NCT00265486","Can Erythropoietin Protect the Cerebral Blood Flow and Oxygenation During Simulated Dive?",[],"2005-08",[18],[7187],{"intervention":1714,"totalTrials":181,"cells":7209},{"EARLY_PHASE1":7210,"PHASE1":7212,"PHASE2":7214,"PHASE3":7216,"PHASE4":7218,"NA":7220},{"trials":7211,"activeCount":98},[],{"trials":7213,"activeCount":98},[],{"trials":7215,"activeCount":98},[],{"trials":7217,"activeCount":98},[],{"trials":7219,"activeCount":98},[],{"trials":7221,"activeCount":98},[7222],{"nctId":1706,"briefTitle":1707,"status":154,"phases":7223,"primaryCompletion":1709,"completion":1709,"start":1710,"enrollment":1232,"conditions":7224,"interventions":7225},[90],[1712],[1461,1714],{"intervention":7227,"totalTrials":181,"cells":7228},"Rocuronium 0,3mg\u002Fkg",{"EARLY_PHASE1":7229,"PHASE1":7231,"PHASE2":7233,"PHASE3":7235,"PHASE4":7237,"NA":7239},{"trials":7230,"activeCount":98},[],{"trials":7232,"activeCount":98},[],{"trials":7234,"activeCount":98},[],{"trials":7236,"activeCount":98},[],{"trials":7238,"activeCount":98},[],{"trials":7240,"activeCount":98},[7241],{"nctId":7242,"briefTitle":7243,"status":154,"phases":7244,"primaryCompletion":7245,"completion":7246,"start":7247,"enrollment":7248,"conditions":7249,"interventions":7251},"NCT04512313","A Comparison of Rocuronium 0.3 mg\u002Fkg, and 0.9 mg\u002Fkg for Induction of Anesthesia in Elderly Patients.",[90],"2021-05-18","2021-05-25","2020-12-17",34,[3301,7250,3303,3302],"Neuromuscular Blockade, Residual",[7227,7252],"Rocuronium 0,9mg\u002Fkg",{"intervention":7252,"totalTrials":181,"cells":7254},{"EARLY_PHASE1":7255,"PHASE1":7257,"PHASE2":7259,"PHASE3":7261,"PHASE4":7263,"NA":7265},{"trials":7256,"activeCount":98},[],{"trials":7258,"activeCount":98},[],{"trials":7260,"activeCount":98},[],{"trials":7262,"activeCount":98},[],{"trials":7264,"activeCount":98},[],{"trials":7266,"activeCount":98},[7267],{"nctId":7242,"briefTitle":7243,"status":154,"phases":7268,"primaryCompletion":7245,"completion":7246,"start":7247,"enrollment":7248,"conditions":7269,"interventions":7270},[90],[3301,7250,3303,3302],[7227,7252],{"intervention":7272,"totalTrials":181,"cells":7273},"Immunoglobulins",{"EARLY_PHASE1":7274,"PHASE1":7276,"PHASE2":7278,"PHASE3":7280,"PHASE4":7282,"NA":7284},{"trials":7275,"activeCount":98},[],{"trials":7277,"activeCount":98},[],{"trials":7279,"activeCount":98},[],{"trials":7281,"activeCount":98},[],{"trials":7283,"activeCount":98},[],{"trials":7285,"activeCount":98},[7286],{"nctId":7287,"briefTitle":7288,"status":154,"phases":7289,"primaryCompletion":7290,"completion":7290,"start":1241,"enrollment":1633,"conditions":7291,"interventions":7295},"NCT02111590","Immunoglobulin Dosage and Administration Form in CIDP and MMN",[],"2015-07",[7292,7293,7294],"Chronic Inflammatory Demyelinating Polyneuropathy","Multifocal Motor Neuropathy","Hemolytic Anemia",[7272],{"intervention":7297,"totalTrials":181,"cells":7298},"Naropine",{"EARLY_PHASE1":7299,"PHASE1":7301,"PHASE2":7303,"PHASE3":7305,"PHASE4":7307,"NA":7309},{"trials":7300,"activeCount":98},[],{"trials":7302,"activeCount":98},[],{"trials":7304,"activeCount":98},[],{"trials":7306,"activeCount":98},[],{"trials":7308,"activeCount":98},[],{"trials":7310,"activeCount":98},[7311],{"nctId":7312,"briefTitle":7313,"status":154,"phases":7314,"primaryCompletion":4461,"completion":4461,"start":1710,"enrollment":3028,"conditions":7315,"interventions":7316},"NCT01317368","The Analgesic Effect of Transversus Abdominis Plane (TAP) Block Following Radical Prostatectomy",[90],[896],[7297,7297],{"intervention":7318,"totalTrials":181,"cells":7319},"Femicept",{"EARLY_PHASE1":7320,"PHASE1":7322,"PHASE2":7324,"PHASE3":7326,"PHASE4":7328,"NA":7330},{"trials":7321,"activeCount":98},[],{"trials":7323,"activeCount":98},[],{"trials":7325,"activeCount":98},[],{"trials":7327,"activeCount":98},[],{"trials":7329,"activeCount":98},[],{"trials":7331,"activeCount":98},[7332],{"nctId":7333,"briefTitle":7334,"status":967,"phases":7335,"primaryCompletion":7336,"completion":7337,"start":7338,"enrollment":1232,"conditions":7339,"interventions":7346},"NCT05212389","The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling",[90],"2024-08-31","2025-08-31","2021-12-22",[160,7340,7341,7342,7343,7344,7345],"Sexual Behavior","Mood Disturbance","Mood Change","Affect Altered","Affect Blunted","Drug Mechanism",[7318],{"intervention":7348,"totalTrials":181,"cells":7349},"Anakinra",{"EARLY_PHASE1":7350,"PHASE1":7352,"PHASE2":7354,"PHASE3":7356,"PHASE4":7358,"NA":7360},{"trials":7351,"activeCount":98},[],{"trials":7353,"activeCount":98},[],{"trials":7355,"activeCount":98},[],{"trials":7357,"activeCount":98},[],{"trials":7359,"activeCount":98},[],{"trials":7361,"activeCount":98},[7362],{"nctId":7363,"briefTitle":7364,"status":3550,"phases":7365,"primaryCompletion":7366,"completion":7367,"start":4060,"enrollment":98,"conditions":7368,"interventions":7370},"NCT02310009","IL-1RA, Acute Exercise, and Beta-cell Function",[90],"2015-06","2015-07-30",[7369],"Type 2 Diabetes Mellitus",[7348]]